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1. Editorial
Welcome to DANMAP 2015, a 20-year anniversary edition of 
the Danish surveillance programme of antimicrobial resistance 
and consumption in humans and animals. The report includes 
the annual surveillance and a jubilee chapter presenting the 
main milestones and experiences from the last 20 years. The 
jubilee chapter also outlines suggestions on monitoring of 
antimicrobial resistance (AMR) in the future. The layout of 
the report has changed slightly compared to previous years: 
Each chapter commences with a short introduction to most 
important findings and highlights of 2015. Most chapters also 
include the most significant findings in their area from the last 
20 years. This has made the main summary obsolete.
DANMAP was developed making the most of a collaborative 
spirit between stakeholders and with a common understand-
ing of AMR as a serious health threat requiring a One Health 
approach to counter - because humans, foods and animals 
constitute overlapping reservoirs of antimicrobial resistance. 
The driver for DANMAP was the concern that use of the an-
timicrobial growth promoter avoparcin posed a risk for occur-
rence of vancomycin resistant enterococci (VRE) in hospitals. 
These concerns led to intensive research and the Danish ban 
on avoparcin in 1995, eventually followed by termination of 
the use of all antimicrobial agents for growth promotion in the 
entire EU from 2006.  You can read more about the collabora-
tion and its´ impacts on the Danish and international animal 
and human welfare in the jubilee chapter on page 9.
A circle closes, a new one begins. VRE has re-appeared on the 
health agenda, since 2013 in the form of hospital outbreaks in 
the Capital Region of Denmark and in the Region of Zealand. 
This report describes whole-genome sequencing of VREs, 
which points towards a niche in the hospital environment, 
where certain subtypes of these bacteria thrive (textbox 8.3).
The biggest emerging threat we are facing is the occurrence of 
carbapenemase-producing Enterobacteriacea (CPE) and other 
carbapenemase-producing organisms (CPO) in Danish hospitals 
(textbox 8.2). Spread is not only restricted to specific species 
but also includes their resistance genes, which move between 
the different bacterial species with ease. As for the VRE there 
is no known or suspected animal or food reservoir of the 
CPE and CPO in Denmark. Although only sporadic cases and 
outbreaks have been reported, the numbers are increasing at a 
frightening speed, and spread not only within departments but 
between hospitals has been observed. This demands an inten-
sification of all efforts, if we are to control the situation. While 
some departments have begun screening, others have not yet 
encountered CPE in their patients.  Thus a new surveillance 
programme for these resistance genes is needed, if we want 
to stop the spread in time. The questions are: How do we both 
extend and restrict the screening to cover all relevant patients 
and departments in a timely national surveillance programme? 
And should screening procedures, for the first time, include 
hospital staff at exposed departments? – A decision to carry 
out such screening would be in conflict with the protection of 
the individual worker and will demand ethical discussions as 
well. 
Once again, we need to draw on our experience and knowl-
edge from 20 years of collaboration and research. Here we 
benefit from our experience with methicillin-resistant Staphy-
lococcus aureus (MRSA). During the last eight years, livestock-
associated MRSA (LA-MRSA) has been DANMAPs biggest One 
Health encounter. The knowledge gained from an extensive 
surveillance and research programme on MRSA has enabled 
definition and control of some of the health problems that 
arise from transmissible resistant bacteria. It also supports 
development of targeted efforts for protection of the vulner-
able population at hospitals. An example is the newest version 
of “The National Guidelines on Prevention of Transmission of 
MRSA” published by the Danish Health Authority.
Characterization of possible zoonotic transmission links 
of Escherichia coli and their many resistance mechanisms 
has proven more difficult and challenging than for MRSA. In 
Denmark, no specific direct transmission route from food to 
humans has been identified and we suspect a complex link 
to exist between animals and humans. This link might only 
consist of transmission of the resistance genes and not neces-
sarily the bacterial strains. Several attempts have been made 
to establish these possible transmission routes and the latest 
attempt is described in textbox 7.3. 
It is important to remember that most surveillance pro-
grammes have gaps and primarily find what they are designed 
to look for. The task is to discover new or unknown resistances 
in a timely manner, which requires special surveillance designs. 
One of the newest examples is the discovery of the mcr-1 
gene conferring resistance to colistin. Historically, DANMAP 
has not had focus on colistin consumption and resistance in 
animals as the drug was rarely used in humans, though it had 
been reintroduced due to the occurrence of CPE. The finding of 
the mcr-1 genes in Chinese meat and humans in August 2015, 
with a possible high rate of transfer even between different 
species, was alarming (Liu et al, 2015). Using the existing 
ESBL-surveillance data from DANMAP, Denmark was the first 
country outside of China to identify mcr-1 among sequences 
from human blood and animal indicator E.coli isolates in No-
vember 2015 [Hasman et al, 2015].  Since then, it has been 
described by most European countries in human and animal 
isolates, some of which date back as early as the 1980s.
In the last 20 years, technology, methodology and interpreta-
tion of antimicrobial resistance identification have developed 
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massively. Today, fast track systems such as whole-genome 
sequencing present a wide variety of opportunities for the 
future. Interpretation and standardization of these massive 
data files will be the challenge over the next decade. It is 
important to keep in mind that the discovery of a resistance 
gene not necessarily renders that specific strain resistant to 
the antimicrobial. We therefore need to keep qualified resis-
tance testing methods like broth dilution for determination of 
phenotypic colistin resistance in bacteria and ensure robust 
and representative comparative studies, before we choose to 
abandon classic and standardized methods.
There are several lessons to be learned from the emerged 
mobile colistin resistance:
Firstly, surveillance has never been more important - and no 
national surveillance and control system, no matter how good, 
is adequate in the face of a global AMR threat.  We need global 
interactions and interventions, also in the fight for a more pru-
dent use of antimicrobial agents in both veterinary and human 
medicine.
Secondly, it is clear that minor antimicrobials may suddenly 
rise to prominence. This applies to colistin but may apply to 
other antimicrobial classes as well.  An example is the use of 
coccidiostats, which is monitored by VetStat, but has not been 
reported since 2004 as we have focused on prescription anti-
microbials. In DANMAP 2015, data on the use of coccidiostats 
are shown in textbox 4.1. 
We believe that AMR levels in Denmark would have been sig-
nificantly higher without the detailed research and monitoring 
of antimicrobial consumption in food animals and in humans. 
This has provided significant tools for timely decision-making 
for authorities and other stakeholders. In other words, DAN-
MAP provides data for action.
Today we acknowledge the need for new and better surveil-
lance tools and especially the need for a more timely dissemi-
nation of the results to medical and veterinary professionals. 
In this respect, other countries with younger models and 
systems might be of inspiration to us. As we face a pandemic 
and extremely costly threat from AMR [O’Neill, 2016] we need 
to reinvent our model of “data for action”. 
We are thankful for all the collaboration, formal and informal, 
that has developed and stabilised through the years, in Den-
mark and around the world. We would like to thank all con-
tributors to this edition of DANMAP without whom, the report 
would not exist.
On the threshold to the next twenty years, we would like to 
ask: The times they are a-changing - are we able to keep up?
Flemming Bager, DTU National Food Institute 
Ute Wolff Sönksen, Statens Serum Institut
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Introduction
DANMAP – the Danish Antimicrobial Resistance Monitoring and 
Research Programme – was a reaction to concerns about how 
antimicrobials were used in food animal production in Denmark 
in the mid-1990s and what the consequences might be for 
human and animal health. It came in the wake of a national 
food crisis caused by a steep increase in human salmonellosis 
incidence that could be traced back to domestic food animal 
production. At the same time Europe was struggling with the 
BSE crisis that originated in the UK.
Based on an idea of a One Health perspective – the purpose of 
which is to unite methods and knowledge and share surveil-
lance data between sectors for a better health for humans and 
animals - the first samples for DANMAP were collected in 1995 
and published in an interim report in 1996. The One Health 
paradigm was a pioneer concept and the specific design used 
in the DANMAP programme was state-of-the art at the time. 
The design has only changed slightly over the past 20 years. It 
is, however, becoming quite clear that antimicrobial resistance 
is no longer an issue that can be handled adequately at the 
local regional or national level. Today, the world faces a global 
antimicrobial resistance pandemic that might exert devastat-
ing effects on both human and animal health. A British report 
on antimicrobial resistance estimates that the costs due to 
increased illness and deaths and a subsequent fall in produc-
tivity amount to 100 trillion dollars by 2050 (O’Neill, 2016). 
So, while local measures to control antimicrobial resistance are 
indispensable, they are not sufficient in the face of a pan-
demic.
As DANMAP celebrates 20 years of existence, we describe 
some highlights and key elements from the programme and 
present a perspective on where to go from here.
Antimicrobial growth promoters
Antimicrobial agents were included in feed for food animals 
as early as the late 1940s in order to improve growth and 
reduce production costs. In these early days the positive ef-
fects observed – initially when feeding waste from production 
of tetracyclines to chickens - may partly have been due to the 
improvement of low quality feed in general, but the procedure 
of including sub-therapeutic concentrations of antimicrobials in 
animal feed was soon integrated as an established practice in 
several countries [Moore, 1946; Dibner, 2005]. 
Following the introduction of the first antimicrobial agents 
for human clinical treatment, resistance very rapidly emerged. 
However, as several new antimicrobial classes were discovered 
in the late 1940s and early 1950s, this was not considered a 
major problem. During the 1960s, bacteria resistant to several 
antimicrobial classes were discovered, while emerging treat-
ment failures in humans gave the first warnings that resis-
tance might outrace the discovery of new antimicrobials. 
In food animals high levels of resistance were observed, to 
some extent related to the use of antimicrobial growth promot-
ers (AGPs). In 1969, the Swann Committee in the United King-
dom considered the available evidence and clearly concluded 
that the use of AGPs selected for resistance that was transfer-
able between bacterial species and could cause problems for 
human health [Swann et al, 1969]. The report recommended 
that antimicrobial agents used for therapy should not be used 
for growth promotion. Following this, a number of antimicrobial 
agents were banned for use as AGPs in the UK. After the UK 
entered the European Union (EU) the ban was implemented in 
the other European Union member states. In other countries, 
including the USA, similar recommendations were issued by 
the authorities, but restrictions were never implemented. 
One important thing, however, appears to have been over-
looked, namely that different antimicrobial agents belonging 
to the same drug class will select for the same antimicrobial 
resistance mechanisms. Furthermore, it was not considered 
that other antimicrobial classes already being used as AGPs 
might become important for human treatment as new resis-
tance mechanisms emerge. Consequently, a number of new 
antimicrobial agents were approved and used as AGPs in the 
EU and other countries in the 1970s and 1980s.
Discussions of potential problems associated with this contin-
ued use surfaced from time to time, but it was not until the 
mid-1990s, when new studies found new evidence, that larger 
scale interventions occurred.
2. DANMAP – a 20 year perspective
Frank Møller Aarestrup, professor, National Food Institute, Technical University of Denmark, Kgs. Lyngby
Niels Frimodt-Møller, professor, DMSc, Rigshospitalet, Copenhagen
Kåre Mølbak, state epidemiologist, DMSc, Statens Serum Institut, Copenhagen
Maja Laursen, midwife, PhD, The Register of Medicinal Product Statistics, The Danish Health Data Authority; Copenhagen
Flemming Bager, Head of Division, DVM PhD, National Food Institute, Technical University of Denmark, Kgs. Lyngby
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Resistance to glycopeptides
In 1993 enterococci resistant to the glycopeptide antimicrobial 
vancomycin were isolated from food animals in England and 
soon after in 1994 in Germany [Bates et al]. This was surpris-
ing because no vancomycin or other glycopeptides was ap-
proved for therapy in food animals. However, the glycopeptide 
avoparcin had been used for several years as an AGP.
In Denmark, we first became aware of this in December 1994 
and, based on a small survey of organic and conventional 
broiler flocks, it was in January 1995 suggested that occur-
rence of vancomycin resistant enterococci (VRE) was associ-
ated with the use of avoparcin [Aarestrup, 1995]. The use of 
antimicrobial agents for food animals – including therapeutic 
use - had been an issue of increasing concern in Denmark since 
the early 1990s. The new findings resulted in much scientific 
and public attention and already in April the Danish agricultural 
organizations decided to voluntarily stop the use of avoparcin. 
This move was followed by a ban imposed by the Minister of 
Agriculture in May 1995.
Within the European Union AGPs were approved centrally by 
the European Commission’s Scientific Committee on Animal 
Nutrition (SCAN). Denmark was allowed to ban avoparcin only 
if new information was able to show the danger to human 
health. Initial research, conducted within a short time-frame in 
Denmark, had clearly demonstrated that the use of avoparcin 
selected for occurrence of VRE, that these bacteria were found 
in and were transferable through food, and that the respon-
sible gene was transferable. However, the direct consequences 
for human health were difficult to prove definitely.
The Danish ban was highly controversial and not supported by 
the European Commission’s Scientific Committee on Animal 
Nutrition. However, the ban was upheld by the European Coun-
cil of Ministers and as additional scientific evidence accumu-
lated, similar restrictions were implemented by other countries, 
e.g. by Germany in January 1996. In 1997 a general EU ban 
was implemented.
These initial findings prompted a number of initiatives in 
Denmark and elsewhere. Research into the potential conse-
quences of other AGPs was initiated and all use of AGPs has 
been banned by EU member states since 2006. In addition, it 
was realized that one of the reasons that these problems had 
passed undiscovered for so many years was the complete lack 
of any monitoring programmes. Thus, the DANMAP programme 
was established, first including samples from food animals 
only in 1995 and extended to food and humans in 1996. 
Escherichia coli - the ideal sentinel organism
Escherichia coli is a common member of the intestinal and 
faecal flora of most vertebrates including humans, although 
outnumbered 1000 - 100 : 1 by many Gram-positives and 
anaerobes in the gut flora. Usually E. coli lives in happy col-
laboration with the other bacteria in the gut, without causing 
harm to its host. However, if it gains access to the urinary 
tract or other organ systems or worse, to the blood stream, 
E. coli can be a deadly encounter for the host. This opportu-
nistic pathogen is the most commonly found bacterial agent 
in bacteraemia or septicaemia, as it is present in around 30% 
of all positive blood cultures in human patients in most of 
the world. It is also by far the most common pathogen found 
in urinary tract infections (UTI), one of the most frequent 
occurring bacterial infections in humans both in primary care 
and in hospitals. In addition, diarrhoeagenic E. coli dominates 
among aetiologies for bacterial diarrhoeal diseases, not least 
traveller´s diarrhoea. The bacterium is very versatile and can 
carry a broad range of virulence factors on its chromosome or 
on several different plasmids in the same cell. The virulence 
factors help the bacterium adhere to, penetrate and survive in 
epithelial cells, spread in tissues, gain access to blood vessels, 
escape the immune system, etc.  
E. coli is a potential zoonotic pathogen, although not in the 
same strict sense as non-typhoid Salmonella enterica, which 
within certain limits is an obligatory pathogen for humans, 
causing infections via intake of food. Being ubiquitous in most 
production animals and their environment including waste-
water and vegetable products, E. coli is commonly introduced 
into the human gut on a daily basis and often in vast amounts. 
Most humans carry between 1 – 6 different clones of E. coli in 
the gut at all times [Nielsen et al, 2014], meaning that there 
is a constant flow and replacement of these bacteria. Fur-
thermore, these E. coli may interact with other Gram-negative 
bacteria in the gut and exchange genetic information.
From the viewpoint of antimicrobial susceptibility, the naïve E. 
coli strain is susceptible to most antimicrobials with anti-Gram-
negative activity. It is therefore relatively easy to treat when 
infections occur, even with sulfonamide, the first chemothera-
peutic antibiotic drug introduced in the 1930´s. On the other 
hand, E. coli can easily mutate or take up foreign DNA by all 
mechanisms, i.e. transformation, transduction and conjugation, 
the latter being by far the most common.
E. coli is an ideal bacterial organism to study because of the 
relationship between antimicrobial use and the development 
of antimicrobial resistance. This is due to E.coli’s uptake and 
presence in the heavily populated gut flora with availability of 
millions of resistance genes, its ease in developing resistance 
towards the most important antimicrobial classes, and the fact 
that all antimicrobials administered systemically will reach the 
gut either directly from the stomach or indirectly via blood to 
the intestines and their lumen. 
E. coli in DANMAP
When planning DANMAP, the aim was to encompass antimi-
crobial resistance in important pathogenic bacteria that were 
present in production animals, meat and in humans. It was 
therefore obvious that E. coli would have a pivotal role. Since 
the first DANMAP report in 1996, antimicrobial resistance 
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has been monitored in E. coli both as commensals sampled 
from poultry, pigs and cattle, and meat products from these 
animals (so-called indicator strains), as well as pathogens 
from diagnostic samples from production animals (diagnostic 
animal strains) and from blood and urine from infected humans 
(diagnostic human strains). Furthermore, within the frame of 
the DANMAP programme E. coli has been followed as com-
mensal in gut flora from various cohorts of healthy humans 
(military recruits, nurses, random healthy volunteers etc.) and 
from environmental samples from wastewater and sludge. 
(See chapter 8.1. for more information on the E. coli from clini-
cal submissions and textbox 7.2 for sampling from healthy 
humans during the years).
Collections of preserved E. coli isolates from all of the above 
origins have since been used in numerous research projects. 
Various aspects of the bacterium have been studied: viru-
lence genes, antimicrobial resistance genes, resistance fit-
ness-cost, E. coli clonal types and their possible spread from 
animals directly or via food to humans, in most cases taking 
into account antimicrobial use in animals and in humans. 
As one example, for the purpose of determining the role of 
animal derived E. coli strains in urinary tract infections in hu-
mans, a large DANMAP collection of E. coli strains from cattle, 
pigs, poultry and meat products from these animals was used 
and compared to a collection of E. coli isolates from healthy 
humans and human urinary tract infections. Comparison of 
virulence genes, phylotypes, pulse-field gel electrophoresis 
and antimicrobial susceptibility demonstrated complete over-
lap between animal or meat and humans for some isolates 
and, in general, antimicrobial resistance markers correspond-
ed among all groups, which lead to the conclusion that E. coli 
UTI in humans can be a zoonosis [Jakobsen et al, 2012]. 
Antimicrobial resistance monitoring - caveats
With respect to using monitoring of antimicrobial resistance 
levels in E. coli as a basis for understanding the relationship to 
antimicrobial consumption, for use in policies, intervention pur-
poses or for treatment guidelines, respectively, it is extremely 
important to take into account the origin of isolates, i.e. the 
sampling strategy.
In animals and food, antimicrobial resistance in E. coli has been 
evaluated in isolates from samples obtained using randomized 
sampling strategies – collecting samples from healthy animals 
at slaughter or fresh meat at wholesale and retail outlets. In 
contrast, the treating veterinarian or physician mostly obtains 
clinical samples of E. coli from infected animals or humans. This 
results in a tendency towards a skewed prevalence of antimi-
crobial resistance, since GPs may tend to submit samples from 
problematic patients only and not from those who respond to 
first-hand empiric antimicrobial treatment. This was shown 
in a study, where general practitioners were asked to submit 
all E. coli samples from patients with urinary tract infections 
irrespective of whether these were uncomplicated or compli-
cated, i.e. recurrent infections or infections not responding to 
first-line antimicrobials [Kerrn et al, 2002].
The study demonstrated that E. coli from the urine of patients 
with uncomplicated urinary tract infections showed resistance 
levels about 50% lower than isolates from complicated cases 
e.g. resistance towards ampicillin 20% versus 40%, sulfon-
amide 20% versus 40%, and trimethoprim 10% versus 20%, 
respectively [Kerrn et al]. The higher resistance levels cor-
respond to those levels usually reported in DANMAP reports 
in E. coli from urinary tract infections from primary care and 
hospitals as well as from bacteraemia cases (See all DANMAP 
reports from 1996 – 2015, chapter 8 on clinical resistance in 
humans). Several investigations from Danish clinical microbiol-
ogy laboratories also showed, that the first E. coli isolate from 
a patient usually is more susceptible than later isolates from 
the same patient (Thøger Gorm Jensen, Henrik Schønheyder, 
Jens Kjølseth Møller, personal communication). All the above 
adds a cautionary note for the use of antimicrobial resistance 
monitoring data for research and policy purposes.
Relationship between antimicrobial use and 
resistance
Even so, DANMAP has amply demonstrated a relationship 
between antimicrobial use and antimicrobial resistance levels 
with E. coli as the indicator bacterium both in production 
animals and in humans. Figure 1 illustrates in rough terms the 
relationship between antimicrobial consumption by species 
and the resistance levels in E. coli from poultry, cattle and pigs 
when taking into account the size of the biomass treated. 
Diagnostic samples show the highest resistance levels. Among 
indicator E. coli, resistance levels are clearly highest in pigs, 
which have the highest antimicrobial use both for treatment 
and meta-prophylaxis.
An example from humans is illustrated in Figure 2, which 
shows ciprofloxacin use in primary health care and ciprofloxa-
cin resistance in E. coli from urine samples in primary care. 
Both sets of data are from 2000 - 2015 (modified from this 
year’s report). There is a clear correlation association between 
the increase in use and concomitant increase in resistance 
from 2000 - 2009, after which a levelling off in the resistance 
level reflects a levelling off in the consumption from 2009 and 
onwards. One of the reasons for the rapid increase in cipro-
floxacin use during the `00´s was a significant reduction in 
price of ciprofloxacin after the market was opened to generic 
ciprofloxacin in 2002 (DANMAP report 2003).
These examples of a relationship between antimicrobial use 
and resistance led to policy changes both in the veterinarian 
and the human field, e.g. a general warning against wide-
spread use of ciprofloxacin in primary care in Denmark was 
issued by the Danish Health Authority (Sundhedsstyrelsen) in 
2012. 
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Novel antimicrobial resistance mechanisms
As new resistance mechanisms have emerged in the world, 
DANMAP has been used to evaluate the impact of these re-
sistance determinants in all fields in Denmark. The occurrence 
of extended spectrum beta-lactamase (ESBL) in E. coli was 
reported from Europe already in the 1980s, but did not reach 
Denmark on a larger scale until around 2005.
The first ESBL-positive Klebsiella isolates from humans were 
reported in 1998 [Hansen et al, 1998]. A prospective study of 
isolates from blood cultures at Herlev Hospital in 2003 found 
three isolates (0.8%) of 380 consecutive E. coli and Klebsiella 
spp. [Kjerulf et al, 2008]. The first ESBL-positive isolates in 
food animals was a Salmonella Heidelberg isolate from a boar 
in 2003 imported from Canada [Aarestrup et al, 2004]. Since 
then, several studies have been conducted to evaluate the 
importance of ESBL-producing E. coli in animals and humans. 
Resistance to 3rd generation cephalosporins in E. coli as a 
marker for ESBL-production was introduced in DANMAP 2009. 
While CTX-M-15 has been the dominating genotype among E. 
coli and Klebsiella spp. in humans (around 50-70% of all ESBLs) 
this type has rarely been found in Danish production animals, 
indicating that little transfer of these types occur from Danish 
husbandry to humans. Resistance towards 3rd generation 
cephalosporins has been around 5-6% in E. coli from urine 
cultures from 2010 – 2015 although there is a slight increas-
ing tendency in resistance in urines from primary health care. 
The lack of steep increases in resistance seems to indicate 
that policy changes in response to surveillance and research, 
e.g. recommendations on reduced use of cephalosporins and 
other broadspectrum antibiotics in antimicrobial guidelines, 
have had an impact, probably associated with implementation 
of measures on infectious disease control.
The new fluoroquinolone resistance gene, qnr, was reported 
for the first time in Denmark in a collaborative veterinary and 
human research project under DANMAP in 2007 [Cavaco et al, 
2007].
The new global threat from carbapenemase-producing Entero-
bacteriaceae (CPE) has also been recognised in the Danish 
community since 2008. This is now under intense scrutiny at 
Statens Serum Institut (SSI), which offers whole-genome se-
quencing on all submitted carbapenemase-producing bacteria 
from clinical laboratories. Until 2014, most of the cases were 
related to travel abroad, but from 2014 for many cases no 
Figure 1. Resistance (%) in indicator and diagnostic Escherichia coli from pigs, cattle and broilers, Denmark
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relation to travel could be established [DANMAP report 2014 
and Textbox 8.2 in DANMAP 2015]. A long-term outbreak 
(more than 4 years) with NDM-1 producing Citrobacter freundii 
and further spread to other Enterobacteriaceae has been 
reported (Hammerum et al, 2016). The cooperation between 
the clinical microbiology departments and SSI via the so-called 
DANRES-network seems to assure that all laboratories screen 
for meropenem-resistance in Enterobacteriaceae and other 
selected Gram-negative pathogens in all clinical samples and 
submit suspected isolates to SSI for epidemiological surveil-
lance. Carbapenem use in hospitals has also been restricted via 
the Danish Health Authority’s 2012 warning.
In 2015, a transferable colistin resistance, encoded by the mcr-
1 gene, was reported from China. Also in Denmark the mcr-1 
gene was detected from the DANMAP 2014 ESBL-producing 
E. coli collections from both veterinary and human origins 
[Hasman et al, 2015]  and phenotypical resistance testing for 
colistin is now offered at the reference laboratory at Statens 
Serum Institut. So far no phenotypically resistant strains have 
been found. 
Monitoring antimicrobial consumption
For many years Denmark has had a restrictive approach to the 
use of antimicrobials. In human medicine there were never any 
over-the-counter sales of antimicrobials. Rather, they are avail-
able only through licensed pharmacies on prescription from a 
medical doctor or dentist. Pharmaceutical companies are free 
to set any price for their products. However, in Denmark there 
is a high degree of transparency in price structures, with the 
mark-up by pharmacies defined through regulation. Particu-
larly, medical professionals do not derive any significant part 
of their income from the sale of antimicrobials, i.e. there is no 
financial incentive to overprescribe.
The supply infrastructure for antimicrobials in the agricul-
tural sector closely reflects this. Since 1995 veterinarians in 
Denmark have earned their income from offering specialized 
diagnostic services, and treatment, not from the sale of medi-
cines. The mark-up for veterinarians dispensing antimicrobials 
directly to the animal owner, is by regulation non-profit.
Veterinary use of antimicrobials
The legal infrastructure underpinning the supply chain is of 
key importance for the implementation of VetStat, the Danish 
system for monitoring the use of antimicrobials in food animals 
at species and herd level. Monitoring of antimicrobial usage 
was part of the original DANMAP brief from 1995.
In 1995, data on the use of antimicrobials in the veterinary 
field were available from the Danish Medical Statistics and - for 
extemporaneous mixtures (magistral formulas) – from produc-
tion pharmacies and wholesalers. It was clear, however, that 
consumption of therapeutics had increased sharply during 
the second half of the 1980s and the early 1990s to the 
extent that the National Pig Producers’ Association became 
concerned. They formed a stakeholder committee to analyse 
the situation and in a report from November 1995 [N.E. Rønn, 
ed., 1995] concluded that use of antimicrobials in pigs had 
increased by 91% between 1986 and 1994, in particular as 
oral medication, mainly tetracycline. The committee was of the 
opinion that the increased consumption largely represented 
overuse and was not justified by disease patterns or increased 
production. The report describes a number of drivers contribut-
ing to the increase, among them the difficulty of monitoring 
by the authorities the compliance of farmers and veterinarians 
with existing legislation.
The intention to implement VetStat was announced in Sep-
tember 1998 and the system went live on 1 August 2000. 
The system was designed as an add-on to the national farm 
register (CHR) which contains data on all farms in Denmark, 
including animal species present on the farm and their num-
bers (or a surrogate measure, eg. the number of pen places). 
This provides denominator information for reporting of use. 
The objective of VetStat was to provide close to real-time data 
on all use of prescription medicines in production animals, at 
farm and species level (cattle, small ruminants, pigs, poultry, 
aquaculture, fur animals and other). Also, the target age group 
is recorded as is the reason for prescribing.
The collection of data for VetStat is shown in Figure 3. In 
2015, approximately 95% of consumption was represented by 
prescriptions that were processed at pharmacies. At the phar-
macy, the prescription is processed electronically and relevant 
data extracted and sent to The Danish Health Data Authority. 
Data are forwarded to VetStat on a daily basis for production 
animals. Use by veterinary practitioners account for about 
3% of the total use. Data on this are harvested automatically 
when veterinarians invoice their clients. The data are sent 
to VetStat via the Dairy Associations database (for historic 
reasons). Finally, about 2% of the antimicrobial consumption is 
in the form of medicated feed. Medicated feed is produced by 
Figure 2. Resistance (%) in Escherichia coli from urine samples 
and fluoroquinolone consumption, data from primary health 
care, Denmark
0,0
0,1
0,2
0,3
0,4
0,5
0,6
0
2
4
6
8
10
12
14
16
00 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
D
D
D
/1
00
0 
in
ha
bi
ta
nt
 d
ay
s
%
 r
es
is
ta
nt
 i
so
la
te
s
Fluoroquinolone consumption Ciprofloxacin resistant E. coli
0,0
0,1
0,2
0,3
0,4
0,5
0,6
0
2
4
6
8
10
12
14
16
00 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
D
D
D
/1
00
0 
in
ha
bi
ta
nt
 d
ay
s
%
 r
es
is
ta
nt
 i
so
la
te
s
Fluoroquinolone consumption Ciprofloxacin resistant E. coli
15DANMAP 2015
2.DANMAP - 20 YEARS
feed mills on the basis of a veterinary prescription and data are 
reported directly to VetStat. Medicated feed is used mainly in 
aquaculture.
The only exception to the rule that antimicrobials are pre-
scription-only is the use of coccidiostats. The consumption of 
coccidiostats is reported by feed mills to VetStat.
Combining information contained within CHR about herd size 
and type with data on the antimicrobial prescribed, including 
recommended dosages, allows VetStat to monitor total usage 
as Animal Defined Dosages [Jensen et al, 2004]. This metric is 
highly attractive in terms of permitting comparison of usage 
over time, even when patterns of use of antimicrobials with 
different potency vary over time. It also makes it possible to 
show which part of production is associated with a particularly 
high use of antimicrobials, eg. use in weaner pigs is much 
higher than in older age groups. In addition, relevant changes 
in dispensation form (eg. parenteral vs. oral) can be extracted 
from the database.
Interventions in the animal sector
Data on the use of antimicrobials have been reported annually 
in the DANMAP reports (www.DANMAP.org) and have formed 
the basis for a number of interventions by stakeholders – 
primarily the relevant authorities, but also the animal industry 
associations.
Figure 4 shows a timeline on interventions to reduce antimi-
crobial consumption. Among the most notable in the veterinary 
field are
• Implementation of Veterinary Advisory Service 
Contracts (VASC)
The first statutory order on VASC in herds of cattle and 
pigs came into force in 1995. Since then, the concept has 
been improved and extended several times. In 2010, VASC 
became mandatory for large herds of cattle and pigs as 
well as mink farms. The VASC results in frequent veterinary 
advisory visits and provides the farmer with extended 
treatment possibilities. The most important aims of the 
VASC are to focus on advice and prevention of illness rather 
than treatment, to optimize the use of antimicrobials in 
order to minimize antimicrobial resistance and to improve 
animal welfare.
• Stop for use of antimicrobial growth promoters
Since 2006, use of AGPs has been illegal within the EU. 
DANMAP has helped document the effect of the ban on 
antimicrobial resistance.
• Prudent use guidelines in pigs and cattle
Official guidelines on the use of antimicrobials in pigs and 
cattle have been available since 1996. They were initially 
developed by the National Veterinary Laboratory (now DTU 
Danish Health Data 
Authority
VetStat
Medicated feed
Coccidiostats
Pharmacies
Feed mills
Figure 3. Harvesting data on antimicrobial consumption in animals for VetStat
Illustration: Erik Jacobsen
Note: All antimicrobials used for animals must be prescribed by veterinarians and most prescriptions are processed at pharmacies (98% of the 
total use), Of the  antimicrobials processed at pharmacies, 3% are administered directly by the veterinarians and 95% are distributed via  the 
pharmacies. In addition, 2% of the total use, are distributed via medicated feed.
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Figure 4. Timeline illustration activities concerning antimicrobial use in humans and animals, Denmark
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National Veterinary Institute). Since 2005 the guidelines 
have been updated by the veterinary authorities, in collabo-
ration with university experts and stakeholders.
• Benchmarking herds according to use of antimicrobials 
– the Yellow Card initiative
VetStat data are used to rank pig herds in a standardized 
way according to their use of antimicrobials, calculated as 
Animal Daily Doses (ADDs). In 2010, the veterinary authori-
ties launched the Yellow Card initiative. The initiative was 
a response to an increase in use of antimicrobials in pig 
production since 2001. In brief, the authorities set thresh-
old limits for use of antimicrobials in weaners, grower pigs 
and adult pigs. If over a 9-month period a farm exceeds a 
threshold, the veterinary authorities may issue an injunction, 
requiring the animal owner to bring down consumption. More 
details about the Yellow Card system may be found in the 
DANMAP 2010 report (www.DANMAP.org).
• Industry initiatives to stop use of 3rd and 4th 
generation cephalosporins
In 2009, the Danish pig industry, in response to concerns 
about extended spectrum cephalosporin resistance raised by 
DANMAP, decided to stop using 3rd and 4th cephalosporins 
in pigs, except as last resort antimicrobials. Since 2011, Vet-
Stat has been able to document that the industry interven-
tion has been effective, with a total use of cephalosporins in 
pig production close to zero. In 2014, the Danish dairy cattle 
association made a similar decision, which it also showing 
some effect.
Human consumption of antimicrobials 
Until 1991 the use of antimicrobials among humans was 
reported once a year through the Association of Medicine 
Importers (Medicinimportørforeningen, MEDIF) and the As-
sociation of Danish Medicinal Factories (Foreningen af danske 
Medicinfabrikker, MEFA) and was based on the whole sales 
to the pharmacies. From the end of the 1980´s sales data 
became more and more unreliable since there was an increas-
ing amount of parallel imported drugs which were not covered 
by this registration. Since 1994, one year before the establish-
ment of the DANMAP programme, sales have been recorded 
in the Register of Medicinal Product Statistics at the Danish 
Health Data Authority based on the information delivered by 
all pharmacies.  Because drug sales is mandatory to report the 
total sales in Denmark is covered. For the primary sector data 
have through all DANMAP years been detailed and covered 
the number of prescriptions, the size and number of pack-
ages as well as age and gender of the patient. These data are 
reported from each pharmacy and thus make it possible also 
to follow the sales of antimicrobials in different regions. For 
hospitals the sales have covered the amount of antimicrobi-
als delivered to the different departments, but no information 
on the patient level has been available. Also, in the beginning 
the consumption of antimicrobials at hospitals was difficult to 
establish, since multipackages and magistral formulas were 
not clearly marked, which made it impossible to get informa-
tion on the precise drug, ATC group, strength, package size and 
dosages. 
Today surveillance of consumption is possible through several 
publically available sources:
WWW.MEDSTAT.dk provides aggregate statistics on medicine 
sales in the Danish primary health care sector since 1996 and 
the hospital sector since 1997. Data are available as total 
sales for all antimicrobial substances by Region. Prescription 
sales are additionally aggregated by sex and age. Sales at 
package-level are available for both sectors. 
Other statistics on primary sector sales (www.esundhed.dk) 
show indications and specialty of the prescriber (e.g. dermatol-
ogist or dentist) as well as the patient’s age and gender. The 
number of prescriptions (indicating the number of treatment 
courses) as well as number of Defined Daily Doses (DDD) per 
prescription is shown among other variables.
The website www.Ordiprax.dk is a closed online system with 
user access that provides general practitioners with feedback 
on their prescribing practice by enabling comparison with other 
practices. One measure is number of DDDs per 1000 patients.
Improved surveillance will shortly be implemented on hospital 
antimicrobial use related to the individual patient. This will 
make it possible to establish the total use per patient indepen-
dent of sector. Access to data from the shared medicine card 
will provide higher data quality on indications and the dosage 
and duration of treatment described. The shared medicine card 
also makes available information on prescriptions that have not 
been redeemed. 
Important milestones in the human consumption
As mentioned above Denmark has always had a restrictive 
policy on the consumption of antimicrobials. In human medi-
cine this becomes manifest through a general agreement on 
using penicillins whenever appropriate 
Focus on the appropriateness of antimicrobial use might have 
arisen due to an outbreak with methicillinresistant Staphylo-
coccus aureus in Danish hospitals in the 1960´s, also de-
scribed from other European hospitals [Rosdahl and Knudsen, 
1991]. Measures against their spread included treatment of 
carriers, isolation of patients and restraint in the use of antibi-
otics. The prevalence of MRSA declined again in the beginning 
of the 1970´s, but in Denmark the surveillance of Staphyloc-
cal strains continued and over the years the surveillance was 
broadened to also include streptococcus pneumoniae, gono-
cocci and other important human pathogen bacteria.
This might have become the cornerstone not only of the Dan-
ish surveillance programme but also to a restrictive antibiotic 
policy and demands among many other things the availability 
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of microbiological diagnostics combined with a close collabo-
ration between the clinical microbiologist and the treating 
clinician.  
Microbiological diagnosis is also performed in the primary 
sector, where most GP´s perform microscopy and culturing 
of urines for an identification and resistance testing of the 
infectious agent in their UTI patients. The system is surveilled 
through mikap (www.mikap.dk), a system developed for quality 
assurance of microbiology on regional level. Again, this also 
includes close collaboration with the local clinical microbiologi-
cal laboratory and includes advice on how diagnostics are to be 
performed.  
National guidelines on the use of medicine have existed for 
many years, published through the Danish Medicinal Informa-
tion A/S, a daughter company of the Danish Pharmaceutical 
Industry. Information on the use of the different drugs is 
written by Danish experts and includes a chapter on the use of 
antibiotics for the different organ systems and infection types 
that is restrictive and follows the mentioned rule on using 
penicillins whenever possible. 
Also regional and local guidelines on the consumption of 
antibiotics have been developed over the years, often in 
collaboration between the clinical microbiologist and special-
ists in infectious diseases and in some situations in response 
to the occurrence of new resistant mechanisms and strains. 
An example of this is the antibiotic intervention group from 
Bispebjerg Hospital, where the occurrence of ESBL-producing 
Klebsiella pneumoniae was worrisome and resulted in an 
antibiotic programme abandoning the use of cephalosporins in 
all acutely ill patients combined with reduction of all fluoroqui-
nolones and encouragement to the use of penicillins if possible 
(see Textbox 8, Danmap 2010). 
As mentioned earlier the Council of Antibiotics was established 
in 2010 and a national action plan on the use of antimicrobials 
was issued the same year. 
This plan has been supported by the National Health Authori-
ties who on a regular basis publish guidelines for the rational 
use of medicine (www.irf.dk) which also covers the use of 
antimicrobials for specific infectious diseases. 
New guidelines on prescribing antibiotics in primary health 
care and hospitals from the Danish Health and Medicines 
Authority were issued in 2012. These recommend the reduced 
use of cephalosporins and define rules for the consumption 
of fluoroquinolones in the Primary health sector as well as re-
stricted use of these and the carbapenems at Danish Hospitals 
(see Textbox 3, DANMAP 2012).
In addition the Danish Council of Ethics published a recom-
mendation on the ethical use of antibiotics in Danish context 
in January 2014.
Initiatives directed towards the education of the Danish popu-
lation on a more rational use of antibiotics cover the participa-
tion in the yearly European Antibiotic Awareness Day and the 
establishment of a homepage containing the material of the 
campaign as well as more information on the subject of bacte-
rial infections and how and when to treat them. Denmark has 
also participated in developing a Danish model of the e-Bug 
system, where school material for teachers and students is 
developed, aiming at the education of future generations. The 
e-Bug system is funded by the Directorate-General for Health 
and Consumers of the European Commission (see Textbox 2, 
DANMAP 2011).
Current initiatives include the development of National 
guidelines on a more rational use of antimicrobials devel-
oped in collaboration between the five Danish Regions and 
medical specialists covering the different disease topics. Also 
most hospitals are working on developing local guidelines on 
the implementation of antibiotic stewardship based on local 
resistances and pathogenic strains (see textbox 5.1 DANMAP 
2014)
Visions for the surveillance of antimicrobial drug 
resistance
From a One Health perspective the DANMAP monitoring 
programme has been innovative in setting up the first pro-
gramme in the world to monitor antimicrobial consumption and 
resistance in farm animals, meat products and humans. The 
annual report has been a model for many other monitoring 
programmes internationally. The foundation DANMAP provides 
for research within the field of antimicrobial resistance is ex-
emplary. Furthermore, DANMAP is more than data and a report: 
It is a network and collaboration between various groups from 
different disciplines and institutions, all striving towards the 
common goal of fighting the threat to humankind posed by 
antimicrobial resistance.
The design of DANMAP in 2016 largely remains a solution to 
the challenges that were identified 20 years ago. With the 
realization that the occurrence of antimicrobial resistance 
in one country is affected by the global antimicrobial resis-
tance pandemic, and with the technological breakthroughs in 
recent years, there is considerable potential for improvement. 
DANMAP was not designed as a rapid monitoring and report-
ing system. Thus, the annual reports present data that are a 
snapshot in time and may not reflect the most recent trends, 
new emerging types of resistance or current outbreaks. Fur-
thermore, economic considerations dictate that the number of 
samples that can be included in the monitoring programme is 
limited, and accordingly the sensitivity, in terms of detecting 
new types of resistance, is limited.
Real-time monitoring of AMR in human health care – 
the MiBa system
Hence, in order to create data that the industry, researchers, 
clinicians and decision makers can act on, there is a need to 
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complement DANMAP with a timely system for surveillance of 
antimicrobial drug resistance. This can be done in the form of 
automated and electronic surveillance where users can access 
data on the internet and create tables and graphs. With current 
information and communication technology, such a system is in 
principle not difficult to build. It has many advantages, including 
the possibility of adding algorithms for outbreak detection, set-
ting flags for emergence of certain drug-bug combinations, and 
many other tools for decision support and quality assurance.
Challenges emerging from limitations of the Linnean 
taxonomy
Bacteria are prokaryotic microorganisms that traditionally are 
classified in a Linnean hierarchical family tree (species, genus, 
family, tribe, order), as described by Carl von Linné. In many 
respects, this hierarchical system is insufficient in modern 
microbiology. In the context of antimicrobial resistance, the 
fact that drug resistance often is carried by mobile genetic 
elements constitutes a challenge, because these elements can 
be exchanged between different species and thereby do not 
obey hierarchical rules.
For example, the same or very closely related extended spec-
trum beta-lactamase genes can be found in many different 
gram negative species due to genetic exchange. Furthermore, 
some of these species may have other characteristics, for 
example virulence traits that are also distributed across spe-
cies or subtypes. Moreover, with the current development in 
typing and classification, including the use of whole genome 
sequencing and a focus on a dynamic bacterial evolution with 
exchange of genetic elements, a data model based solely on 
the Linnean system is outdated for the purpose of surveillance 
and reporting of test results. 
In real life, in the medical sector different departments of 
clinical microbiology manage this situation differently. In 
test reports to the requesting clinicians, some departments 
will give the result of an “MRSA” in the species-field in the IT 
system, almost as if MRSA was a bacterial species in its own 
right. In contrast, others prefer to answer “growth of Staphy-
lococcus aureus” as the result and then make a text remark 
that it is an MRSA. These text remarks are rarely standardized. 
Furthermore, the antimicrobial resistance pattern included in 
clinical microbiology reports is often restricted to include drugs 
relevant for treatment.
The lack of a common data model for exchanging digital 
information about specific resistance mechanisms is one of 
the bottlenecks for implementing electronic surveillance for 
antimicrobial resistance. To develop electronic surveillance, we 
need to extend the currently used data model based on the 
Linnean classification.
The implementation of flexible property tables in MiBa 
Broadly speaking, we define properties as characteristics of 
bacteria that can be measured by various methods (e.g. by de-
fined genotypic and phenotypic methods) and at various levels 
of detail (e.g. a Minimum inhibitory concentration (MIC) value or 
an overall interpretation as “resistant” against a drug). These 
can be expressed in various ways (from a gene sequence to an 
overall conclusion, e.g. an ESBL producing organism or a Multi-
locus sequence typing (MLST) type). Bacteria can have a very 
large number of properties, and the same properties can be 
found across the Linnean family tree. Joining flexible property 
tables to the traditional tables of microbiological findings is a 
solution to the limitations of the current data model. The new 
data model for microbiological reporting in Denmark will also 
provide opportunities for sending other types of information 
along with the result produced by the clinical microbiology 
department, e.g. patient data or exposure information.
From 2010, all reports from Danish clinical microbiology de-
partments have been stored in a national database called MiBa. 
At present, only limited and unstructured data on antimicrobial 
resistance are stored in the database, for the reasons men-
tioned above. Currently, MiBa is suitable for general microbial 
surveillance, but not for detailed surveillance of antimicro-
bial resistance. However, flexible property tables have been 
developed and are currently being implemented [Voldstedlund 
et al, 2014]. With a consensus about the use and content of 
these tables, the vision of electronic and timely antimicrobial 
resistance is getting within reach.
The eRES and MiBALert projects
In anticipation of the implementation and use of property 
tables, the next steps include the development of a system 
for AMR surveillance. In the beginning, priority will be given 
to the major indicators and bacteria including MRSA, VRE, 
ESBL and CROs. However, other types of resistance will also 
be included in a stepwise manner. Thereby, it will be possible 
to describe and analyse trends and distributions of resistance 
in an interactive and timely manner, and develop tools for risk 
assessment and action.
One example of a very specific tool for action is the MiBAlert 
project. MiBAlert is a tool directed toward healthcare person-
nel who access a patient’s electronic health record as well 
as those further involved in the care and treatment of the 
patient. It is based on a web service using data from MiBa. The 
alert is generated automatically whenever the health record 
of a patient is accessed and can thus provide timely informa-
tion about for example previous positive cultures for eg. VRE, 
MRSA, CPE and multi-drug-resistant enterobacteriae. This will 
enable hospital staff to implement timely measures such as 
isolation of patients and will also assist in the selection of 
antimicrobial treatment.
MiBAlert is currently implemented in the Capital Region of 
Denmark and is expected to be implemented in other re-
gions as well. Experiences from the Capital Region show 
that MiBAlert was one of the helpful components in a bundle 
approach to control a VRE outbreak in Copenhagen. MiBAlert 
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is an example of how the same data that are used for national 
surveillance can be applied in the encounter between a patient 
and the hospital where they are being treated. 
Real-time sampling of populations for AMR
Current surveillance of antimicrobial resistance (AMR) is mainly 
based on passive reporting of clinical diagnoses and phenotyp-
ic laboratory results for specific pathogens. Even utilizing the 
potential of whole genome sequencing, this procedure leads to 
significant time-delays and a narrow pathogen spectrum that 
does not capture all relevant AMR genes, where the bulk may 
be present in the commensal bacterial flora.
Although Denmark was the first country in the world to 
establish integrated – One Health – surveillance in 1995, the 
coverage of bacterial species is extremely limited and does not 
include a screening programme for healthy humans. Among 
food animals sentinel bacteria (E. coli and enterococci) are 
monitored, but again only an extremely narrow spectrum and 
the current programme with a single isolate per farm has very 
low sensitivity.
From a surveillance point of view, sewage is an attractive 
matrix because it combines material from a large and mostly 
healthy population, which would otherwise not be feasible to 
monitor. In addition, sampling this matrix requires no informed 
consent from providers of samples, consequently avoiding 
most ethical concerns. For food animals, combined slaughter-
house samples could also be used to obtain samples from a 
large number of farms simultaneously. 
Next generation sequencing (NGS) based diagnostics provide 
both cost-efficient sample analysis and rapid turnaround. NGS 
generates millions of DNA reads from a sample, where each 
target is sequenced according to the abundance within the 
sample. Metagenomics benefit from the ability to quantify 
thousands of targets in a single sample without requiring a 
priori knowledge of which genes are present, including addi-
tional features of interest, such as presence of pathogens and 
virulence genes.
Through a number of recent projects [www.genomicepide-
miology.org, [www.compare-europe.eu], we have developed 
an online method for identifying all known resistance genes, 
which has been intensively accessed from more than 70 coun-
tries [Zankari et al, 2012]. We have also shown that NGS is su-
perior to phenotypic testing for susceptibility testing [Zankari 
et al, 2014]. Genotyping using whole genome sequencing is a 
realistic alternative to surveillance based on phenotypic anti-
microbial susceptibility testing [Hasman et al, 2014] and it is 
feasible to identify resistance through metagenomic sequenc-
ing of clinical samples. We have recently shown that metage-
nomic read mapping can be used to quantify AMR genes 
from airplane septic tanks from international flights [Nordahl 
Petersen et al,2015], which demonstrates the potential of 
enabling real-time monitoring of the AMR load in a country. In 
addition, we have demonstrated that metagenomics is superior 
to conventional methods for resistance surveillance at the 
pig herd level [Munk et al, 2016] and proven the feasibility of 
rapidly sharing data with the global research community.
Through further development and use of the technology, it is 
the expectation that in the future it will be possible to estab-
lish a novel supplement to the current DANMAP programme, 
where data on AMR genes are also collected from sewage 
and slaughterhouses and analysed in real-time, and the data 
shared by researchers and the general public.
Such surveillance will provide an important sentinel function and 
provide a concurrent baseline, informing decision makers about 
needs for adaptation of reservoir specific monitoring efforts.
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3. Introduction to DANMAP
3.1 About DANMAP
DANMAP was established at the initiative of the Danish 
Ministry of Health and the Danish Ministry of Food, Agriculture 
and Fisheries. The programme participants are the National 
Food Institute and the National Veterinary Institute, both at 
the Technical University of Denmark (DTU), as well as Statens 
Serum Institut (SSI). The DANMAP programme is funded jointly 
by the Ministry of Health, the Ministry of Higher Education and 
Science, and the Ministry of Environment and Food.
The Danish Integrated Antimicrobial Resistance Monitoring 
and Research Programme, DANMAP, has implemented the One 
Health approach, comprising the entire chain from farm to 
fork to sickbed, since 1995. The organisation and collection of 
DANMAP data is presented in Figure 3.1.
The objectives of DANMAP are:
• to monitor the consumption of antimicrobial agents in food 
animals and humans;
• to monitor the occurrence of antimicrobial resistance in bac-
teria isolated from food animals, food of animal origin (e.g. 
meat) and humans;
• to study associations between antimicrobial consumption 
and antimicrobial resistance; and
• to identify routes of transmission and areas for further 
research studies.
The monitoring of antimicrobial resistance is based on three 
categories of bacteria:
Human and animal pathogens that cause infections and are 
thought to reflect resistance caused by the use of antimicro-
bial agents in the respective reservoirs;
Zoonotic bacteria that can develop resistance in the animal 
reservoir, which may subsequently compromise treatment 
outcome when causing infection in humans;
Indicator bacteria (enterococci and E. coli) due to their ubiqui-
tous nature in animals, food and humans, and their ability to 
readily develop or transfer antimicrobial resistance in response 
to selective pressure in both reservoirs.
All pathogens may be considered reservoirs of resistance de-
terminants – genes – that may be disseminated independently 
of the bacterial hosts.
A web annex presenting Minimum inhibitory concentration 
(MIC) distributions, detailed tables of antimicrobial consump-
tion and other additional data are available for download at 
www.danmap.org. Current and previous DANMAP reports are 
also available at the website (PDF versions).
Public health risks
Bacteria become resistant either by spontaneous mutation or by transfer of resistance genes from other bacteria. Resistant 
strains are favoured when use of antimicrobial agents provide a selective pressure. This occurs in humans as well as in animals 
undergoing antimicrobial treatment. Resistant bacteria can spread between humans in the community, at healthcare centres 
and at hospitals. Furthermore, resistant bacteria from animals can be transmitted to humans either through direct contact with 
animals and their environment or through ingestion of contaminated food or other contaminated vehicles.
Antimicrobial treatment failure may occur if the ingested resistant bacteria are a direct cause of disease, or if resistance 
determinants are transferred to pathogenic bacteria causing the disease. Bacteria may be resistant to several – sometimes all – 
antimicrobial agents available for treatment, leading to life-threatening illness.
Currently, there is only a limited number of antimicrobial agents, with novel modes of actions, under development by the phar-
maceutical industry. Therefore, it is vital for public health organisations to ensure the continued effectiveness of compounds 
considered critically important to human treatment by ensuring prudent use for both humans and animals.
Prudent use should include the restriction of critical antimicrobial agents for use in humans only, as well as the elimination of 
overuse, i.e. only humans and animals suffering from an infection responsive to antimicrobial treatment should be exposed to 
antimicrobial agents.
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3.2 General information
The following sections present some general information 
about the human population in Denmark in 2015, as well 
as the production of food animals and the amount of meat 
available for human consumption in Denmark over the past 
decade. It also provides an overview of the antimicrobial 
agents for systemic and intramammary therapeutic use in 
humans and animals in 2015.
3.2.1 Populations
Over the past two decades the human population in Denmark 
has increased from approximately 5.2 million inhabitants in 
1995 to 5.7 million in 2015 (www.dst.dk).The distribution of 
the population, which could potentially have received antimi-
crobial treatment in 2015, is shown in Figure 3.2, together 
with the five healthcare regions and the 11 Departments of 
Clinical Microbiology (DCM) in Denmark.
The production of food animals and the production of meat and 
milk are presented in Table 3.1. From 1995 to 2015, there has 
been an overall decrease in the number of turkeys, cattle and 
dairy cows produced pr. year. In contrast, the number of pigs 
produced has increased remarkably over the same period of 
time. Also, the production of milk and marine fish has incre-
ased over the past two decades.
In 2015, the number of pigs produced was approximately 3% 
higher than in 2014 and the number of fattening pigs (15–50 
kg) exported increased by 17% from 2014 to 2015. Since 
2004, the total exports of fattening pigs have increased 
by   more than six-fold.
From 2014 to 2015, the number of cattle slaughtered decre-
ased by 6%, while the number of dairy cows remained almost 
unchanged and the amount of milk produced continued to 
increase (up 3%).
The number of broilers produced decreased by approximately 
1% from 2014 to 2015, and approximately 16% of the broi-
lers produced in 2015 were exported for slaughter. The pro-
duction of turkeys has fluctuated considerably over the past 
decade but remained at almost the same level in 2014 and 
2015. Since 2006, more than 99% of the turkeys produced 
have been exported for slaughter, thus the majority of turkey 
meat available for sale in Denmark is listed as imported.
Figure 3.1. Organisation of DANMAP
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3.2.2 Registered antimicrobial agents
Table 3.2 shows the antimicrobial agents that are registered 
to treat bacterial infections in humans and animals. Some of 
these are considered to be critically important for treating 
bacterial infections in humans. An antimicrobial agent is consi-
dered critically important if it is the only compound, or one of 
a limited number compounds, available to treat serious human 
disease. Fluoroquinolones, 3rd and 4th generation cephalo-
sporins, macrolides and glycopeptides are among these criti-
cally important antimicrobial agents [AGISAR, 3.revision, WHO 
2011]. Critically important antimicrobial agents are also used 
to treat diseases in food animals and pets, and bacteria that 
are resistant to critically important agents may be transmitted 
to humans. Also, bacteria that cause human disease may 
acquire resistance genes from bacteria of animal origin.
Growth promoters, which are no longer used for animals in 
Denmark, are shown in parentheses in Table 3.2. Most of 
these had effects on Gram-positive bacteria. Since 1995, the 
indicator enterococci from animals and meat (and in some 
years from healthy humans) have been used as a measure of 
resistance to growth promoters.
Figure 3.2 The five health care regions and 11 Departments of Clinical Microbiology (DCM) in Denmark DANMAP 2015
North Denmark Region
No. of inhabitants 584,918
No. of inhabitants/km2 74
No. of inhabitants/GP 1881
Central Denmark Region
No. of inhabitants 1,291,643
No. of inhabitants/km2 98
No. of inhabitants/GP 1589
Capital Region of Denmark
No. of inhabitants 1,786,469
No. of inhabitants/km2 697
No. of inhabitants/GP 1681
Region Zealand:
No. of inhabitants 825,893
No. of inhabitants/km2 114
No. of inhabitants/GP 1706
Region of Southern Denmark
No. of inhabitants 1,210,297
No. of inhabitants/km2 99
No. of inhabitants/GP 1503
Source: Statistics Denmark (www.dst.dk)  
and the Danish Medical Association  
(www.laeger.dk) GP=general practitioner.
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Year Broilers Turkeys Cattle 
(slaughtered)
Dairy cows Pigs  Farmed fish(a) 
Fresh 
water
Marine
1,000 
heads 
mill. 
kg(b)
1,000 
heads
mill. kg 1,000 
heads
mill. kg 1,000 
heads
mill. kg 1,000 
heads
Export 
1,000 
heads(c)
mill. kg
1990 94560 116 571 2.5 789 219 753 4542 16425 - 1260 - -
1992 107188 137 761 5.4 862 236 712 4405 18442 - 1442 35 7
1994 116036 152 1091 8.6 813 210 700 4442 20651 - 1604 35 7
1996 107895 149 961 9.3 789 198 701 4494 20424 - 1592 32 8
1998 126063 168 1124 11.6 732 179 669 4468 22738 - 1770 32 7
2000 133987 181 1042 10.3 691 171 636 4520 22414 - 1748 32 7
2001 136603 192 1086 13.2 653 169 623 4418 23199 - 1836 31 8
2002 136350 190 1073 12.8 668 169 611 4455 24203 - 1892 32 8
2003 129861 197 777 11.2 625 161 596 4540 24434 - 1898 34 8
2004 130674 198 1086 19.6 632 165 569 4434 25141 1712 1967 34 9
2005 122179 183 1237 17.4 549 145 559 4449 25758 2720 1988 31 8
2006 106182 161 785 11.3 509 140 556 4492 25763 3204 1957 29 8
2007 107952 163 1009 14.4 512 141 545 4515 26311 3522 2046 31 10
2008 107595 163 1068 12.3 509 138 559 4585 27078 4943 1985 30 10
2009 108851 165 1175 11.1 507 137 569 4734 27603 6642 1898 29 11
2010 117653 178 1184 14 519 142 574 4830 28505 7074 1974 28 10
2011 115454 175 960 9.4 551 145 575 4801 29399 7632 2008 28 11
2012 111080 168 1103 12.4 539 138 580 4928 29047 8794 1902 28 13
2013 117315 177 692 8.3 551 140 574 5025 28996 9318 1896 28 12
2014 115497 174 595 8.8 556 143 563 5113 29926 10517 1924 30 11
2015 114238 172 598 8.8 522 135 561 5270 30874 12314 1954 30 11
Diff.(d) -1% -1% 1% 0 -6% -6% <1% 3% 3% 17% 2% 0 0
Table 3.1. Production of food animals and the production of meat and milk, Denmark
Source: Statistics Denmark (www.dst.dk) and The Danish AgriFish Agency. Production data for farmed fish was not available for 2015. Live 
animals exported prior to slaughter are included in number of animals and amount of meat produced. Export data for poultry from Statistics 
Denmark (personal communication) and export of 15-50 kg live pigs from the Danish Agriculture and Food Council
a) The numbers for 2015 are not final. The production of farmed fish includes fish transferred from one production facility to another. 
b) Assume a final slaughtered weight of 1.51 kg per broiler produced (Danish Agriculture and Food, 2013)
c) Export of 15-50 kg live pigs. These are included in total number of heads, but antimicrobial use after export until slaughter is not registered as 
it takes place outside of Denmark
d) Difference from 2014 to 2015
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Table 3.2.  Antimicrobial agents registered for systemic and veterinary intramammary therapeutic use  
in animals and humans, Denmark 2015
ATC / ATCvet codes (a) Therapeutic group Antimicrobial agents within the therapeutic groups
Animals Humans
S01AA / J01AA / QJ01AA,QJ51AA Tetracyclines Chlortetracycline, doxycycline, 
oxytetracycline
Doxycycline, lymecycline, 
oxytetracycline, tetracycline, 
tigecycline
S01AA01 / QJ01BA Amphenicols Florfenicol Chloramphenicol
J01CA / QJ01CA Penicillins with extended 
spectrum
Ampicillin, amoxicillin Ampicillin, pivampicillin, amoxicillin, 
pivmecillinam, mecillinam
J01CE / QJ01CE Beta-lactamase sensitive 
penicillins
Benzylpenicillin, 
phenoxymethylpenicillin, 
procaine penicillin, 
penethamate hydroiodide
Benzylpenicillin, 
phenoxymethylpenicillin
J01CF / QJ51CF Beta-lactamase resistant 
penicillins
Cloxacillin, nafcillin Dicloxacillin, flucloxacillin
J01CR / QJ01CR Comb. of penicillins, incl. beta-
lactamase inhibitors
Amoxicillin/clavulanate Amoxicillin/clavulanic acid, 
piperacillin/tazobactam
J01DB / QJ01DB,QJ51DB First-generation cephalosporins Cefalexin, cefadroxil, cefapirin Cefalexin, cefazolin
J01DC Second-generation cephalosporins Cefuroxime
J01DD / QJ01DD,QJ51DD Third-generation cephalosporins Cefoperazone, ceftiofur, 
cefovecin
Cefotaxime, ceftazidime, 
ceftriaxone
J01DE / QJ51DE Fourth-generation cephalosporins Cefquinome Cefepime
J01DF Monobactams Aztreonam
J01DH Carbapenems Meropenem, ertapenem
J01DI Fifth-generation cephalosporins Ceftaroline, ceftobiprol, ceftolozan/
tazobactam
J01EA Trimethoprim and derivatives Trimethoprim
J01EB / QJ01EQ Short-acting sulfonamides Sulfadimidine Sulfamethizole
J01EE / QJ01EW Comb.of sulfonamides and 
trimethoprim, incl. derivatives 
sulfamethoxasol/trimethoprim  
Sulfadiazine/trimethoprim, 
sulfadoxine/trimethoprim, 
Sulfamethoxazole/trimethoprim
J01FA / QJ01FA Macrolides Spiramycin, tylosin, tilmicosin, 
tylvalosintartrat, tulathromycin, 
gamithromycin, tildiprocin
Erythromycine, roxithromycine, 
clarithromycine, azithromycine, 
telithromycine
J01FF / QJ01FF Lincosamides Clindamycin, lincomycin Clindamycin
J01FG / QJ01XX (b) Streptogramins (Virginiamycin)
J01GB / QJ01RA,QA07AA Aminoglycosides Streptomycin, 
dihydrostreptomycin, 
gentamicin, neomycin, 
apramycin
Tobramycin, gentamicin
J01MA / QJ01MA Fluoroquinolones Enrofloxacin, marbofloxacin, 
difloxacin, ibafloxacin, 
pradofloxacin
Ciprofloxacin, levofloxacin, 
moxifloxacin
QJ01MB Other quinolones Oxolinic acid
QJ01MQ (b) Quinoxalines (Carbadox, olaquindox)
J01XA,A07AA / Not in ATCvet (b,c) Glycopeptides (Avoparcin) Vancomycin, teicoplanin, telavancin, 
dalbavancin, oritavancin
J01XB / QA07AA (b) Polypeptides (incl. polymyxins) Colistin, bacitracin Colistin
J01XC Steroid antibacterials Fusidic acid 
J01XD,P01AB (c) Imidazole derivatives Metronidazole
J01XE Nitrofurane derivatives Nitrofurantoin 
J01XX / QJ01FF Other antibacterials Spectinomycin Methenamine, linezolid, daptomycin, 
tedizolide, fosfomycin
QJ01XQ Pleuromutilins Tiamulin, valnemulin
QP51AG04 Antiprotozoals, sulfonamides Sulfaclozine
Not in ATCvet (b) Oligosaccharides (Avilamycin)
Not in ATCvet (b) Flavofosfolipols (Flavomycin)
a) ATCvet codes start with a Q   
b) Animal growth promoters used before 1999 are listed in parentheses   
c) Intestinal antiinfectives (A07AA) and imidazole derivatives for protozoal diseases (P01AB) were, for the first time, included in DANMAP 2014, 
since their widespread use in the treatment of Clostridium difficile infections makes them belong to the most used antibiotics in human infections 
in Denmark.   
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4. Antimicrobial consumption in animals
4.1 Introduction
The use of antimicrobial agents in humans and animals has   
been monitored by the DANMAP programme since 1995. Since 
the early 1990s, there has been both political and public focus 
on the use of antimicrobial agents in the Danish animal produc-
tion. This resulted in discontinued use of several antimicrobial 
agents used for growth promotion from 1994-1999, and more 
recently, in a voluntary ban of use of cephalosporins in the pig  
and dairy cattle production, as well as in regulatory legislation  
regarding therapeutic use [DANMAP 2010].
Overall, the antimicrobial consumption for both humans and 
animals has increased since the late 1990s. Figure 4.1 shows 
the total antimicrobial consumption in animals and humans 
since 1994 and 1997, respectively. Increases in antimicro-
bial consumption for animals can partly be explained by the 
increase in pork production, which constitutes approximately 
86% of the meat production in Denmark (Table 3.1), however, 
risk management measures to reduce consumption have also 
played a role.
The prescription patterns were clearly influenced by imple-
mented legislation (Figure 4, chapter 2). For example, the 
decrease in antimicrobial consumption after 1994 was likely 
the result of the following important actions: 1) limitation of 
veterinarians profit from sales of medicine 2) implementation 
of preventive veterinary strategies with Veterinary Advisory 
Service contracts (VASCs) and regular monthly visits from the 
veterinarian in order to promote preventive veterinary strate-
gies and optimize antimicrobial use, and 3) enforcement of the 
so called “cascade rule” [Order (DK) 142/1993], which limits 
the use of (cheaper) extemporaneously produced medicines. 
The latter particularly affected the use of tetracyclines from 
1994. Another important intervention was the restriction on 
the use of fluoroquinolones in production animals through 
legislation implemented in 2002 and 2003. Furthermore, in 
July 2010, the pig industry imposed a voluntary ban on the use 
of cephalosporins. This was followed by a similar initiative by 
dairy cattle farmers in July 2014.
From 2010 to 2011, consumption decreased following the 
introduction of threshold values for antimicrobial consumption  
adopted within the “yellow card initiative”. This enforces legal 
actions on pig farmers with high antimicrobial agent use per 
pig [DANMAP 2010]. Effects from other parts of the legislation 
may be less obvious, must also be considered, when interpret-
ing the veterinary prescription patterns.
Official veterinary guidelines regarding the selection of an-
timicrobial agents for pigs and cattle, have existed available 
since 1996. The guidelines provide specific recommendations 
for selection of the appropriate antimicrobial treatment of all 
common indications in the major production animal species. 
Initially, guidelines were developed by the National Veterinary 
Laboratory (presently, National Veterinary Institute, DTU). 
Since 2005, the guidelines have been updated by the Danish 
    Highlights: In 2015, the overall use of antimicrobials for animals decreased by 5%. This 
was mainly caused by a 5% decrease in antimicrobial usage in the pig industry, which is the 
dominant user of antimicrobials for animals in Denmark. The use of tetracycline, aminogly-
cosides and pleuromutilins for pigs has decreased consistently over the last three years.  In 
the poultry production (other than turkeys), the use of antimicrobials increased by 184% 
in 2015, due to several serious disease outbreaks in the broiler production. In contrast, the 
use for turkeys decreased by 41%. The fur animal industry also experienced serious disease 
outbreaks in 2015, which is reflected in a 23% increase antimicrobial usage.
  The use of critically important antimicrobials remained low in the pig production, and other 
food production animals. In companion animals, however, the use of critically important anti-
microbials remained relatively high compared with other species, but has decreased over the 
last three years. It is, however, of some concern that the use of colistin in pigs has increased, 
especially from 2014 to 2015. Colistin is of increasing importance as a last resort antimicro-
bial in human medicine.
  For the first time since DANMAP 2004, the use of coccidiostats is also presented in this 
report; the total use of coccidiostats in Denmark has increased steadily from 2008 to 2015.
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Veterinary and Food Administration (DVFA) in collaboration 
with National Veterinary Institute DTU, National Food Institute 
DTU, the Practicing Veterinarians Organization, university 
experts, the Danish Association of the Veterinary Pharmaceu-
tical Industry and the Danish Agriculture and Food Council. 
The latest update was in 2010, when new dynamic evidence-
based treatment guidelines for pigs were launched [DANMAP 
2010, www.fvst.dk]. In 2012, the Danish Veterinary Associa-
tion published treatment guidelines to promote prudent use of 
antimicrobials in dogs and cats, prepared by clinical specialists 
and expert scientists from the Faculty of Health and Medical 
Sciences at the University of Copenhagen and National Food 
Institute DTU.
4.1.1 Data sources
Data on antimicrobial use at the product level have been col-
lected in Denmark since 1996, including historical data back to 
1990. In Denmark, all therapeutic medicine is available by pre-
scription only, and since 2001, data on all medicine prescribed 
for use in animals, including vaccines, have been collected in 
a national database (VetStat). Data on consumption of coc-
cidiostatic agents (non-prescription) and antimicrobial growth 
promoters (no longer permitted), are also collected in VetStat.
Consumption data used in DANMAP 2015 were extracted from 
VetStat by the Danish Veterinary and Food Administration (DVFA) 
in March (zinc oxide) and October 2016. National Food Institute 
DTU carried out no further validation of the received data. Fur-
thermore, data concerning use of coccidiostats were also obtained 
from VetStat (July 2016) and these are presented in Textbox 4.1
4.1.2 Methods
Metrics of antimicrobial consumption are numerous, each with 
its own advantages and limitations. Therefore, the selection 
of measures to monitor must depend on the purpose and the 
available information.
The overall amount of antimicrobial agents is measured in kg 
active  compound and is used in Section 4.2 for the purpose of 
an overall crude comparison of antimicrobial use in the veteri-
nary and human sectors and to enable international compari-
sons (Figure 4.1).
In DANMAP 2012, we introduced two new metrics to monitor 
trends in antimicrobial consumption to ensure the robust-
ness of the analyses over time and to facilitate comparisons 
between animal species, as well as comparisons between the 
Figure 4.1. Prescribed antimicrobial agents for humans, and for all animal species, including the number of pigs produced, Denmark
Sources: Human therapeutics: The Danish Medicines Agency. Antimicrobials for animals: Until 2001, data are based on reports from the 
pharmaceutical industry of total annual sales from the Federation of Danish pig producers and slaughterhouses (1994-1995) and Danish 
Medicines Agency and Danish Plant Directorate (1996–2000). Data from 2004–2015 are based on data extracted from VetStat.
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veterinary and human sectors. The new metrics are defined 
below, and for additional information on methodology, please 
refer to Chapter 9 and the web annex [www.Danmap.org]. 
DADD (Defined animal daily dose). 
DADD is the average maintenance dose per day for the main 
indication of a drug in the appropriate animal species. The 
DADD is not defined at product level but for each antimicrobial 
agent, administration route and animal species; and when 
appropriate, also age group. The DADDs have been specifically 
defined for use in DANMAP based on current knowledge and 
may vary from the prescribed daily dose or the recommended 
dosage in the Summaries of Product Characteristics (SPC) or in 
the VetStat database.
DAPD - proportion of population in treatment per day
Trends in veterinary consumption, both within and across spe-
cies, are presented in DAPD, because this measure allows for 
comparison between sectors. DAPD=DADD per 1000 animals 
per day, where ‘animals’ are represented by their live biomass 
and adjusted for life-span. The estimated live biomass is ex-
pressed as the number of standard animals with an estimated 
average weight on a given day. This may also be referred to as 
the ‘standard-animals-at-risk’, and allows comparison between 
species with large differences in body-mass and life-span e.g. 
cattle and chicken.
DAPD, or estimated treatment proportion, is a statistical 
measure that provides a rough estimate of the proportion of 
Table 4.1. Antimicrobial agents sold (kg active compound) by animal species and age group, Denmark
Note: Only the ATCvet group contributing mostly to the antimicrobial group is mentioned. Combination drugs are divided into active compounds 
a) Penicillins with extended spectrum, cloxacillin and amoxicillin/clavulanic acid 
b) Antimicrobials used for companion animals: DVFA has allocated kg active compound to the appropriate target species (horses/pets) based on 
knowlegde of which products are used for the particular species         
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Pigs, total 338 4435 1 0 0 1987 10157 7878 16744 8059 7172 23902 825 86020 81499
-Sows and piglets 251 1806 0 0 0 448 516 802 8619 3648 5226 1955 97 24140 23366
-Weaners 72 2444 1 0 0 725 6675 3065 1872 3538 1749 14142 710 36131 34992
-Finishers 15 186 1 0 0 815 2966 4012 6253 874 197 7805 18 25749 23141
Cattle, total 563 647 70 0 3 4 228 0 7919 918 1062 1720 16 13048 13151
-Intramammaries 32 59 2 245 158 7 1 497 503
-Cows and bulls (excl 
intramammaries)
9 286 10 0 3 1 113 0 7207 567 893 1155 1 10377 10245
-Calves < 12 mdr 549 308 1 0 0 1 113 0 388 183 152 531 15 2008 2241
-Heifers and steers 5 21 0 0 2 79 10 10 34 0 166 162
Poultry, total 4 258 0 1 0 129 114 0 184 500 445 796 7 1548 2440
Poultry incl. broilers,  
layers and other poultry
3 251 0 1 0 125 37 0 119 387 444 561 2 679 1931
Turkeys 1 8 4 77 65 113 1 235 5 869 509
Other production  
animal species
311 375 0 0 1005 188 645 0 1 2221 2705 681 14 9318 8147
Fur animals 0 375 0 0 0 188 645 0 1 2216 1056 681 14 4202 5177
Aquaculture 311 0 0 0 1005 0 0 0 0 5 1650 1 0 5116 2970
Companion animals 0 190 102 10 0 67 47 1 792 655 1281 172 22 4088 3339
Horses 0 13 4 4 0 0 0 0 723 109 755 13 0 2071 1621
Pets(b) 0 177 98 6 0 67 47 1 69 546 526 159 22 2017 1718
Total 1217 5906 173 11 1008 2376 11190 7880 25641 12352 12666 27272 885 114023 108576
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animals treated daily with a particular antimicrobial agent. For 
example, 10 DAPDs indicate that an estimated 1% of the pig 
population, on average, receives a certain treatment on a given 
day (Section 4.3 and Chapter 9, Materials and Methods). DAPD 
also allows comparisons with the antimicrobial consumption in 
the human sector, which is measured in defined daily dose per 
1,000 inhabitants per day (DID), see Chapter 10, Terminology, 
for a description of DID.
4.2 Total antimicrobial consumption in animals
In 2015, the total veterinary consumption of antimicrobial 
agents, including agents used for companion animals, amount-
ed to 108.6 tonnes active compound (Table 4.1), representing 
a 5% decrease compared with 2014.
In 2015, the antimicrobial use for pigs, cattle and poultry com-
prised 75%, ~12%, and ~2% of the total antimicrobial consump-
tion for animals, respectively (Figure 4.2). The decrease in anti-
microbial use for animals was mainly attributed to a 5% decrease 
in the amount used in the pig industry, which is the main driver 
of antimicrobial consumption in animals in Denmark, due to the 
size of the industry. Cattle and pigs are the two major production 
species in Denmark and they comprise almost equal proportions 
of live biomass. However, the vast proportion of cattle biomass 
consists of dairy cows, which have  very low consumption of 
antimicrobial agents compared with growing animals. 
Historically, the overall consumption, measured as kg active 
compound, was 47% lower in 2015 compared with 1994. In 
contrast, the total meat production increased by 15% dur-
ing this period (Table 3.1 and Figure 4.1). A major part of the 
decrease in consumption can be explained by the discontinued 
use of growth promoters from 1994 to 1999.
Between 2000, when antimicrobial consumption was first 
registered in VetStat, and 2009, when it was at its highest, 
the amount of kg active compound increased by 62% (Figure 
4.1). This increase was also driven mainly by an increase in 
consumption in pigs and should be seen in the context that 
the number of pigs produced increased by 23% (Table 3.1). At 
the same time, the proportion of exported live pigs (approx. 
30 kg) increased and thus resulted in a decrease in the overall 
biomass of the pig population. Since then, the antimicrobial 
consumption for animals has gradually decreased and in 2015 
it was 16% lower than in 2009.  
Pigs, 75%
Cattle, 12%
Horses and pets, 3%
Poultry, 2%
Fur Animals , 5%
Aquaculture, 3%
Kg active compound
Pigs, 43%
Cattle >1 yr., 40%
Cattle<1 yr., 7%
Pets, 1%
Horses , 5%
Poultry, 1%
Fur Animals , 1%
Aquaculture, 2%
Live biomass 
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Figure 4.2. Live biomass (mill. kg) and antimicrobial consumption (kg) in main animal species, Denmark
Note: The live biomass is estimated from census data (pigs, cattle and pet animals) and production data (poultry, fur animals, aquaculture). For 
poultry: the figures comprise only the biomass for the main production types (turkey and broiler production). The live biomass estimates for cattle, 
broiler, turkey, fur animals, aquaculture and pet animals based on 2012 data. The estimation procedures are described in Chapter 9.
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4.3 Antimicrobial consumption by animal species
4.3.1 Antimicrobial consumption in pigs
For this issue of DANMAP, updated data from 2004-2015 were 
extracted from VetStat and all measures for the antimicrobial 
usage in pigs were recalculated for all years, using the updated 
dataset. 
In 2015, the total antimicrobial consumption in pigs was 81.5 
tonnes active compound (Table 4.1), a decrease of 4.5 tonnes 
(5%) compared with 2014. 
The treatment proportions (DAPD) in the pig population overall 
and by age group are presented in Figure 4.3 and in the web 
annex (Table A4.1).
The DAPD of the total population should reflect the trends in 
selection pressure in the population. Due to the differences in 
treatment proportion between age groups, the DAPD of the 
total population is therefore affected by changes in population 
structure. For example, an increased export of live pigs at 30 
kg would, in itself, cause an increase in DAPD for the remaining 
population, since the DAPD for finishers is relatively low. Any 
changes in export and productivity must therefore be taken 
into account to get a true impression of the antimicrobial con-
sumption pattern and selection pressure in the pig production.
Also, the treatment proportion (DAPD) is much higher in the 
weaning pigs, compared with finishers and sows (Figure 4.3). 
However, the biomass of the weaning pigs is very small (7.5-
30 kg, 4 weeks), compared with the finishers (31-107 kg, 12 
weeks) and the sows.
In 2015, the antimicrobial consumption in pigs, measured in 
DAPD decreased by 4% to approximately 27 DAPD (Figure 4.3) 
when adjusted for changes in export. Overall the number of 
pigs produced in 2015 increased by 3%, and the number of 
pigs exported increased by 17% (Table 3.1).
Historically, the treatment proportion (DAPD) increased from 
2004 to 2009, followed by a decrease in 2010 and 2011, 
which is considered a result of the “yellow card initiative” (See 
DANMAP 2010). The reductions in antimicrobial usage were 
also associated with increasing use of vaccines (DANMAP 
2014) and a slight temporary decrease in productivity in some 
herds. However, disease outbreaks did not increase [Danish 
Veterinary Bulletin no. 6, 2012]. Measured in DAPD, the anti-
microbial consumption in pigs in 2015 was 22% lower than in 
2009, when adjusted for changes in export (Figure 4.3).
Within the different age groups, the DAPD decreased in wean-
ers and finishers, but remained at approximately the same 
level for sows and piglets. The decrease was primarily in the 
use of tetracyclines and macrolides (Figure 4.4). Tetracycline 
has been one of the most commonly used antimicrobials in 
the Danish pig production for a decade (Figure 4.4). They are 
almost entirely administered orally, and particularly used for 
treatment of gastrointestinal disease in weaning pigs and 
finishers. The overall use of tetracyclines in the pig production 
has fluctuated since 2009, but 2015 saw the lowest DAPD 
levels since 2006. Measured in DAPD the use of tetracyclines 
has been reduced by 9% since 2014 and by 24% since 2009. 
In 2014 the Danish pig producers committed themselves to 
reduce the consumption of tetracyclines by 50% by the end of 
2015. However, this goal has yet to be achieved. 
While the overall consumption of antimicrobials for pigs has 
decreased consistently since 2009, the use of colistin for 
pigs has increased markedly from 409 kg in 2009 to 825 kg 
in 2015, mainly in weaners. The consumption of colistin in 
the different age groups of pigs, measured in DAPD, is shown 
in Figure 4.5. Although the use of colistin constitutes a very 
small fraction of the overall antimicrobial consumption in pigs 
(1% in 2015), the increase is concerning due to One Health im-
plications, as polymyxins, to which colistin belongs, have found 
a role for treatment of carbapenemase resistant infections in 
human medicine. 
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Figure 4.3.  Antimicrobial consumption in the pig production, and 
the distribution on age groups, Denmark
Note: The” adjusted total” is adjusted for the increasing export of pigs 
at 30 kg (see text). “Sows” includes treatment in boars and piglets 
pre-weaning.
The DAPD is calculated as the number of standard doses for one kg 
animal divided by the estimated live biomass in the age group at the   
total population (in tonnes).
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Figure 4.4. Antimicrobial consumption(a) in the total pig production(b), and in finishers, weaners, sows and piglets, Denmark
Note: Amphenicols, colistin, fluoroquinolones, intramammaries, gynecologicals and topical drugs are not included in the figure. 
a) The DAPD is calculated as the number of standard doses for one kg animal divided by the estimated live biomass in the age group or the 
total population (in tonnes)
b) The total is adjusted for the increasing export of pigs at 30 kg (see text). “Sows” includes treatment in boars and piglets pre-weaning
c) Lincosamide/spectinomycin combinations comprise 65% of this group
d) Beta-lactamase sensitive penicillins
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Of critically important antimicrobial agents, no flouroqui-
nolones were used in 2015, and the use of cephalosporins 
decreased to approximately 1 kg.
Consumption of zinc oxide and zinc in the pig production  
Zinc is a critical trace element for animals and humans. For 
use of zinc in pig production, please see Textbox 4.3 in 
DANMAP 2014. Zinc is relevant in the context of DANMAP 
because its use may select for resistance in some bacteria, 
including MRSA. Figure 4.6 shows the use of medical zink 
in Danish pig production. Piglets must be fed a sufficient 
amount of zinc every day, since the immediately available 
plasma and body zinc pool is very limited. Since the feed 
intake is very low right after weaning, the concentration 
of zinc in compound feedstuffs and mixed diets must be 
increased to counterbalance this. Two weeks after weaning, 
the feed intake has increased to a normal level and the lower 
dietary zinc inherent in the compound feedstuffs is sufficient. 
The most commonly used product is zinc oxide (ZnO) which 
contains 80% zinc. 
The use of zinc oxide prescribed by veterinarians has in-
creased over the last decade. From 2005 to 2011 a three-fold 
increase in use of zinc and zinc oxide was reported to VetStat, 
whereas the number of pigs produced in Denmark increased 
by 14%. Since 2011, the consumption has been relative stable 
at approximately 500 tonnes of zinc oxide (ZnO) equivalent to 
400 tonnes of zinc (Zn).
4.3.2 Antimicrobial consumption in cattle
In 2015, the overall consumption of antimicrobials in cattle 
remained at approximately 13 tonnes, similar to 2014. The 
production of veal and beef remained more or less at the same 
level from year to year, while the milk production continued to 
increase (Table 3.1).
The use of fluoroquinolones in cattle has been low for the last 
decade and no use of fluoroquinolones was reported for cattle 
in 2015. Approximately 10 kg of cephalosporins were used 
systemically, which represents a 66% reduction since 2014, 
when the dairy association decided to phase out its use, and 
Note: In addition to medicinal ZnO, Zn is added to all compound feeding stuffs for pigs, up to a level of 150 ppm.
Figure 4.6. Consumption (tonnes) of zinc oxide (ZnO) and zinc (Zn) in the pig production, Denmark 2004-2015 DANMAP 2015
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Figure 4.5.  Consumption of colistin in in finishers, weaners, sows 
and piglets, Denmark
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an 85% reduction compared since 2008, when cephalosporin 
consumption was at its peak (Figure 4.7).
The majority of antimicrobials administered parenterally are 
used for dairy cows (Table 4.1), and mainly prescribed for mas-
titis. From 2005 to 2013 there was a slight reduction in the 
overall level of intramammary treatment; following an increase 
in 2014 the use of intramammary treatment decreased again 
in 2015 (Table 4.2). In 2010, the Danish Cattle Association 
(Agriculture and Food Council) introduced the “milk quality 
campaign”. The goal of the campaign is to reduce treatment of 
clinical mastitis by 50%, mainly through a reduction of treat-
ment of subclinical mastitis, but also by increased monitoring 
of cell counts to determine the need for treatment. Order (DK) 
785/2010 provides legal regulations of use of antimicrobial 
agents for mastitis in cattle (recommending using narrow spec-
trum penicillins). Furthermore, the industry has emphasized 
that farmers should use narrow spectrum penicillins to treat 
mastitis caused by Gram-positive bacteria, unless sensitivity 
testing reveals resistance towards these antimicrobials. Since 
then, the overall use of intramammary treatment, measured 
in DADDs, has been reduced by 4%. The relative proportion 
used for drying-off versus therapeutic treatment has shifted 
markedly from 22% versus 78% in 2010 to 55% versus 45% in 
2015 (Table 4.3).
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Note: For intramammary therapeutic treatment, 1 DADD is defined as the dose to treat two teats for 24 hours. For drying off treatment, 1 DADD is 
defined as the dose to treat 4 teats. One product used for both indications is included as half drying off and half therapeutic treatments.
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Total doses per indication (a) DADDs (1000's)
Drying off treatment  (4 teats) 73 75 71 76 82 99 97 117 125 140 154
Therapeutic treatment (2 teats) 420 408 388 377 378 350 307 279 253 259 227
Table  4.3. Number of treatments with antimicrobial agents for intramammary application in cattle, Denmark      
      
DANMAP 2015Table 4.2. Use of antimicrobial agents for intramammary application in cattle, Denmark
Note: For intramammary treatment, 1 DADD is defined as the dose to treat two teats for 24 hours.
a) Includes benzylpenicillin, cloxacillin, and cloxacillin-ampicillin combinations (QJ51CE, QJ51CF, QJ51RC).
b)  Mainly dihydrostreptomycin-benzyl benicillin combinations; includes also combinations of penicillin/aminoglycoside with bacitracin or nafcillin 
(QJ51RC).
c) Lincosamides, neomycin-lincomycin combinations and trimethoprim-sulfonamide combinations.
  
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Doses per antimicrobial class DADDs (1000's)
Penicillins(a) 201 211 211 236 282 314 318 324 311 317 293
Aminoglycoside-benzylpenicillin 
combinations(b)
130 104 101 101 110 93 48 47 58 90 135
Cephalosporins,
1st generation
103 98 89 85 89 89 99 105 111 113 95
Cephalosporins,
3rd and 4th generation
110 124 127 112 76 51 34 30 24 21 10
Others(c) 21 20 16 15 14 12 9 8 0 0 1
Total 566 558 544 549 570 559 508 514 504 541 535
Total DADD per cow per year 1,0 1,0 1,0 1,0 1,0 1,0 0,9 0,9 0,9 1,0 1,0
DANMAP 2015
Figure 4.7. Consumption of 3rd and 4th generation 
cephalosporins in pigs and cattle, Denmark
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4.3.3 Antimicrobial consumption in poultry
In Denmark, poultry production comprises mainly the broiler 
production, followed by egg layers and turkey production. In 
addition, there is a smaller production of ducks, geese, and 
game birds.
In 2015, the total consumption of antimicrobials in poultry 
(all species) was 2,440 kg active compound, an increase 
of 58% compared with 2014. This is the highest amount 
recorded since the DANMAP programme began.
For the first time since 2004, we also show the use of coccid-
iostats in poultry production (Textbox 4.1). The coccidostats 
do not belong to groups of antimicrobial compounds presently 
used in human medicine, i.e. their use is not seen as posing a 
hazard to consumers.
The consumption of antimicrobials could not be precisely dif-
ferentiated to the different sectors of the poultry production 
on the basis of the information entered into VetStat. There-
fore, consumption for turkeys was identified combining infor-
mation from the Central Husbandry Register with information 
provided by poultry veterinarians and the industry (personal 
communication: S. Astrup, PoultryVet, and M. Nielsen Blom, 
Danish Agriculture and Food Council) and the information in 
VetStat. 
Danish broiler farms have a very high level of biosecurity 
and the antimicrobial consumption in broiler production has 
generally been low compared with other species. Accordingly, 
a few disease outbreaks in some farms can markedly affect 
and cause considerable fluctuations in the national consump-
tion statistic.
From the late 2014 throughout 2015 the broiler industry 
experienced several serious disease outbreaks caused by E. 
coli or other infections, associated with high mortality and 
increased health problems in the affected flocks. Many of 
the affected flocks and offspring from affected parent flocks 
were treated with a combination of lincosamides and spec-
tinomycin (linco-spectin). During 2015, investigative work 
was carried out by the industry to determine the cause of 
the increase in the infections. The source of the problem was 
identified and control measures were implemented, (personal 
communication: J. Dahl and M. Nielsen Blom, Danish Agricul-
ture and Food Council).
The antimicrobial consumption in poultry (excl. turkeys), 
increased by 22% already in 2014 and this was followed by 
a further increase of 184% in 2015, from 679 kg in 2014 to 
1,931 kg. The increase included several classes of antimicro-
bials. For broilers, amoxicillin has been the most commonly 
used antimicrobial agent for more than a decade. However, 
in 2015 the consumption was also driven by increases in the 
consumption of tetracyclines, macrolides, lincosamides, and 
others (Table 4.1).  
In the turkey flocks, antimicrobial consumption decreased 
markedly in 2015 compared with 2014, representing the first 
decrease since 2012. It may be explained by several changes 
in the turkey production in 2015. A new hybrid of birds, less 
prone to arthritis, was introduced and the vaccination strat-
egy against Turkey Rhino Tracheitis virus was improved. A 
shift in type of antimicrobial agents towards using penicillins 
rather than macrolides was also observed (personal commu-
nication: S. Astrup, PoultryVet). These changes are reflected 
by an overall reduction in antimicrobial consumption of 41%, 
representing a decrease in the use of macrolides from 222 kg 
in 2014 to 77 kg in 2015 and an increase in the use of beta-
lactamase sensitive penicillins from 39 kg to 65 kg. 
4.3.4 Antimicrobial consumption in aquaculture, fur 
animals and companion animals
The antimicrobial consumption in aquaculture decreased by 
42% to 2,970 kg in 2015 compared with 2014 (Table 4.1). 
Measured in kg active compound sulphonamide/trimethoprim 
comprised 56%, quinolones 34% and amphenicols 10%, 
respectively. 
Antimicrobial consumption in aquaculture is mostly influ-
enced by the summer temperatures. During the colder sum-
mers in 2011 and 2012, consumption was very low compared 
to previous years. In the following years (2013 and 2014) 
the summer months were extraordinarily warm, which lead to 
increased occurrence of bacterial infections and an increase 
in antimicrobial consumption. Furthermore, in recent years 
the aquaculture industry has focused on developing new 
and better vaccines and improving vaccination strategies to 
reduce the risk of diseases that may require antibiotic treat-
ment. A combination of favourable weather conditions (lower 
temperatures during summer) and a positive effect of the 
revised vaccination strategies may explain the reduced con-
sumption in 2015 [personal communication: N. H. Henriksen, 
Danish Aquaculture]. 
Historically, the use of antimicrobial agents in mink produc-
tion has increased steadily from 1,948 kg in 2004 to 5,177 
kg in 2015. During the same period, the production of mink 
has also increased significantly from 12.5 million in 2004 
to 17.8 million in 2015 (Source: Kopenhagen Fur). In re-
cent years, the industry focussed on strategies to reduce 
the antimicrobial consumption, by increasing the quality of 
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feed and improving animal welfare leading to a decrease in 
antimicrobial consumption in 2013 and 2014 of 11% and 
14% respectively. However, in 2015 the consumption of 
antimicrobial agents increased by approximately 23% to 
5,177 kg active compound, mainly due to secondary bacterial 
infections associated with the biggest outbreak of plasmocy-
tosis in the history of Danish mink production. The outbreak 
affected 260 farms, which is approximately 20-25% of the 
total production. Furthermore, there was a higher occurrence 
of pneumonia caused by Pseudomonas Aeruginosa and more 
parvovirus outbreaks than in the previous years. An exten-
sive testing programme has been launched by the industry 
to test for and to help prevent similar large disease out-
breaks in the future (personal communication: Tina Struve). 
The consumption includes several antimicrobial agents, but 
was driven very mostly by penicillins, sulphonamide/thrime-
throprim and macrolides (Table 4.1). Use of fluoroquinolones 
and cephalosporins in fur animal production has been close to 
zero for more than a decade.
The information available on antimicrobial consumption in 
companion animals is not as detailed as for production ani-
mals. In 2015, the overall antimicrobial consumption amount-
ed to 1,718 kg active compound, which represents a decrease 
of 15% compared to 2014 (2,017 kg).
A large proportion of antimicrobials used for companion 
animals are prescribed for treatment of chronic or recurrent 
disease, mainly dermatitis. Particularly the consumption of 
critically important antimicrobial agents could pose a risk to 
owners of diseased dogs that are frequently treated.
In 2015, the use of fluoroquinolones for use in pets was 6 
kg, compared with 9 kg in 2014. The amount of flouroquino-
lones constituted nearly 54% the total veterinary use (kg) of 
fluoroquinolones in 2015, with the remainder used almost 
exclusively for horses. Similarly, the pets accounted for a 
significant proportion (98  kg or 57%) of the use of cephalo-
sporins used in animals.
However, over the past three years the consumption of fluo-
roquinolones and cephalosporins in pets has been reduced by 
45% and 24%, respectively. During the same period we have 
observed a shift in use of the different antimicrobial classes. 
This may be a an effect of treatment guidelines issued by 
Danish Veterinary Association in November 2012, recom-
mending that use of critically important antimicrobials should 
be reduced as much as possible.
Birgitte Borck Høg and Leonardo de Knegt
DANMAP 201540
ANTIMICROBIAL CONSUMPTION IN ANIMALS4.
 
Textbox 4.1
Consumption of coccidiostats in poultry in Denmark, 2008-2015
 
Background: Coccidiosis is one of the most important poultry diseases worldwide, and left unattended, it is a seriously limiting 
factor for intensive production of broilers on litter. Coccidia are highly host specific protozoa. Most coccidia in poultry belong to the 
genus Eimeria and grow and multiply intracellularly in epithelial and subepithelial cells, usually in the intestines. They have a direct 
life cycle. Oocysts are passed with feces to the environment where they sporulate and are ingested by the host. The life cycle in 
the gut takes about 7 days, followed by sporulation in 1-2 days under optimal conditions, resulting in hundreds of thousands of 
oocysts produced from one single ingested oocyst. The sporulated oocysts are resistant to most environmental conditions and can 
survive for months or even years outside a host, which is a key factor in the epidemiology of coccidiosis. Under field conditions, 
day old chickens are exposed to low doses of coccidia and develop immunity that will be life long as there is a frequent low-grade 
exposure to infection. Clinical outbreaks of coccidiosis are characterized by sudden onset of diarrhoea and elevated mortality. Even 
more important are subclinical infections that impair growth and feed conversion, causing considerable production losses. 
Coccidiostats: Anticoccidial agents were introduced in the 1940s and have been crucial in controlling coccidiosis especially dur-
ing the evolvement of the broiler industry. The coccidiostatic effects enable development of protective immunity. Eleven differ-
ent coccidiostats have been authorised for use in the EU; both ionophores and non-ionophores.  Ionophores (monensin, narasin, 
lasalocid, salinomycin, maduramicin) have been widely used since the early 1970s. Ionophores are fermentation products that 
affect ion transport across cell membranes in target- and non-target species. Ionophores have antibacterial activity, and there 
are toxic interactions between some ionophores and some antibiotics. Non-ionophore (chemical) coccidiostats have no antibac-
terial effect. These drugs are thiamine analogues (amprolium),  carbanilides (nicarbazin),  and triazinone derivatives  (diclazuril,  
toltrazuril). The environmental impact of coccidiostats needs further investigation. 
Consumption: The total use of coccidiostats in Denmark increased steadily from 2008 to 2015 and salinomycin has been the 
dominating anticoccidial drug used in Denmark throughout this period (Figure 1, Table 1). The use of a combination of narasin 
and nicarbacin has been increasing since 2009. Since 2014 narasin also increased, mirroring that this drug is used after the 
first 25 days of the broiler growing period, as the withdrawal time is zero days. The lower but rather constant consumption of 
monensin and lasalosid comes from the turkey producers that use monensin in winter periods and lasalosid in summer. Since 
2012,lasalocid has also been used in feed for gamebirds.
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Figure 1. Consumption (tonnes) of the most frequently used coccidiostats in poultry, Denmark DANMAP 2015
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Resistance: The efficacy of many coccidiostats has been reduced by drug resistance in coccidia - by selection, which happens 
at various speeds. Development of resistance has been slow for ionophores compared to chemical drugs. In order to avoid resis-
tance, drug programmes involving changing compounds during the growing period (“shuttle programs”), using combinations of 
ionophore and chemical coccidiostats, or changing drugs from one rotation to the next (“switching or rotation programs”) for an 
entire broiler operation have been advocated. There is currently no scientific evidence to suggest that shuttle programs delay 
the emergence of resistance. 
In recent years, there has been focus on the risk of promoting antimicrobial resistance from poultry that have been fed iono-
phores.  In 2015, The Panel of Animal Feed of the Norwegian Scientific Committee for Food Safety evaluated the risk of devel-
opment of antimicrobial resistance with the use of coccidiostats in poultry diets. They concluded that enterococci from poultry 
fed with narasin, monensin and salinomycin may become resistant to these agents, while the non-ionophore coccidiostats do 
not induce resistance in bacteria. However, data are lacking concerning the broader environmental impact of residues of coc-
cidiostats.
Alternatives / future perspectives: In a recent position paper, the Federation of Veterinarians of Europe recommends that 
coccidiostats should be under veterinary prescription and be included in the ESVAC monitoring system. Live vaccines have been 
produced from various Eimeria strains, attenuated by rapid passage in vivo, selecting “precocious strains” that are non-patho-
genic but still immunogenic. These vaccines are used in Denmark as alternative to coccidiostats in all non-caged replacement 
pullets, and in the rapidly growing production of organic broilers. Price and availability limits a wider use. A recombinant vaccine 
has been developed for breeders in order to confer antibody-mediated passive immunity to the broiler offspring. Further re-
search may lead to development of subunit, recombinant and DNA based vaccines of relevance for future coccidiosis control.
Susanne Kabell 
For further information, Susanne Kabell, (ska@seges.dk)
DANMAP 2015Table 1.Total consumption (kg) of coccidiostats in poultry, Denmark 2008-2015
E-number Name 2008 2009 2010 2011 2012 2013 2014 2015
E25 Halofuginon 1 5
E26 Salinomycinnatrium 4
E712 Flavofosfolid 1 1 0 6
E757 Monensinnatrium 489 640 622 679 503 327 347 441
E761 Metiklorpindol/metylbenzoquat 7 4 0
E763 Lasalosidnatrium 1177 1178 539 497 1060 547 585 770
E764 Halofuginon 1 0
E765 Narasin 499 617 872 1853 490 1568 1717
E766 Salinomycinnatrium 15050 16429 16274 16528 16263 15367 14958 15457
E768 Nicarbazin 3 3 8 1 2 8
E769 Nifursol 4 6
E770 Maduramacinammonium 26 6
E771 Diclazuril 0 1 7 1 0
E772 Narasin/nicarbazin 603 348 2994 4448 4922 5743 5853 7324
E773 Semduramicinnatrium 1
51772 Narasin/Nicarbazin 16
Total 17827 19221 21311 24023 22748 22479 23347 25728
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Textbox 4.2
Effect of new legislation on antimicrobial treatment of groups of 
pigs
 
Background: In June 2014, the Danish Veterinary and Food Administration (DVFA) introduced new legislation on antimicro-
bial treatment of groups of pigs. The rules apply to treatment of diarrheal or respiratory disease administered through feed 
or water. The aim is to achieve a more prudent use of antimicrobials in the pig production to support the goal to maintain a 
low level of antimicrobial resistance in Denmark. The legislation was introduced as part of the Second Veterinary Action Plan, 
covering initiatives 2013-2016 [BEK 534 of 27/05/2014].
The legislation introduced the following limitations: Antimicrobials for group treatment may only be prescribed in connection 
with a consultation on the farm, and the veterinarian must verify the clinical diagnosis by laboratory testing. The prescriptio-
period for antimicrobials for treatment of groups of pigs was also shortened compared to the general prescription rules.
Results: Since June 2014, antimicrobial use for group treatment has decreased by 17%, and the percentage of antimicrobials 
used for group treatment has been reduced from 62% to 57%. However, the decline in consumption of antimicrobials is prob-
ably mostly attributable to the reduction of the threshold levels of the Yellow Card Initiative in the same period. The effects of 
the legislation and reduction of threshold level cannot be distinguished clearly. A DVFA enforcement review in 2015 showed 
that veterinarians in general comply with the new rules. 
Elisabeth Okholm Nielsen 
For further information: Elisabeth Okholm Nielsen (eloni@fvst.dk)
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Figure 1. Prescription of antimicrobials per month (kg) in total and for group treatment of pigs, Denmark
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5. Antimicrobial consumption in humans 
    Highlights: In 2015, the total consumption of antimicrobials in humans was 18.5 defined 
daily doses per 1000 inhabitants per day (DID), very similar to the consumption in 2014 
(18.58 DID).  
 Penicillins remained the most frequently used antimicrobial agent in both primary health  
care (65%) and in hospital care (51%). Within this drug group large changes in consumption 
have taken place in the last decade (from 2006 to 2015): In the primary sector betalacta-
mase sensitive penicillins decreased by 19% (5.40 DID to 4.33 DID), while, simultaneously, 
combination penicillins increased by 1200% (0.12 DID to 1.42 DID). In the hospital sector 
betalactamase sensitive penicillins decreased by 27% (45.26 DBD to 30.52 DBD) and com-
bination penicillins increased by approximately 600% (7.77 DBD to 54.14 DBD). In 2015 
combination penicillins constituted 9% of the total antimicrobial consumption in the primary 
sector and 17% in the hospital sector, which makes them the largest antimicrobial drug 
group consumed in the hospital sector. 
 In 2015, the consumption of critically important antimicrobials was as follows at hospitals: 
Fluoroquinolones continued to constitute 9% of the consumption (9.30 DBD), cephalospo-
rines constituted 15% (11.47 DBD), an increase in the proportional consumption compared 
to 2014 (11%, The proportional consumption of cephalosporins at hospitals increased and in 
2015 they constituted 15% of the hospital consumption, corresponding to 11.47 DBD. 2nd 
generation cephalosporins make the largest share of the cephalosporins used at hospitals 
(10.37 DBD in 2015). In the primary sector the consumption of cephalosporins is close to 
zero. The consumption of carbapenems, mainly meropenem, has increased drastically during 
the last five years, in 2015 it constitutet 4% of the total con- sumption of antimicrobials at 
hospitals.
  The past decade has seen three marked changes in the overall amounts of antimicrobials 
consumed: 
  (1)  The number of DDDs per patient has increased from 17.9 DDD/patient to 21.8  
DDD/patient (22%). 
  (2)  The number of DDDs per 1,000 inhabitants increased from 5,584.5 in 2006 to  
its peak of 6,387.5 in 2011 (14%), but declined to 5,913 in 2015, yielding a  
total increase of 6% during the decade.
  (3)  The number of antimicrobial prescriptions per 1,000 inhabitants increased until 
2011 but has since declined, showing a total decrease from 587.47 in 2006 to 
511.46 in 2015 (- 13%). 
  During the past twenty years, the total consumption of antimicrobials increased by 38% (from 
13.60 DID in 1996 to 18.50 DID in 2015). This increase happened primarily from 2000 to 2011 
with large increases in 2006 - 2007 and 2009 -2010. As for the last decade, changes in the 
primary sector were mainly due to changes in the consumption of the different penicillins: the 
beta-lactamase resistant penicillins increased from 0.30 DID to 1.38 DID (360%), penicillins with 
extended spectrum increased from 2.50 DID to 3.61 DID (44%) and combination penicillins in-
creased from zero to 1.42 DID. The increase in penicillins with extended spectrum was primarily 
due to changes in the treatment of urinary tract infections from sulfonamides (from 0.40 DID to 
0.18 DID) to pivmecillinam (0.30 DID to 2.38 DID). The beta-lactamase sensitive penicillins were 
the only group of penicillins, where the consumption did not continue to increase through all 20 
years but decreased since 2007, yielding a total reduction from 4.50 DID to 4.30 DID (- 4%). 
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5.1 Introduction
In Denmark all consumption of human medicine, including 
antimicrobials is recorded through the Register of Medicinal 
Product Statistics at the Danish Health Data Authority. Sales 
are reported through the pharmacies which, for the primary 
sector include information on the generic and the brand name 
of the product, formulation, active drug, size and number of 
packages, as well as age, gender and regional residence of the 
patient. For the hospital sector sales are available through the 
hospitals pharmacy and contain information on the amount 
and formulations of antimicrobials delivered to the different 
departments. Thus for both sectors quite detailed information 
is achieved but specifications on the exact amount actually 
used are missing as are informations regarding the indication 
for the specific treatment and the condition of the patient. For 
both sectors work is in progress that will ensure these more 
specific treatment data in the future.
Recording has been performed since 1994 - for the primary 
sector this included all sales from the beginning, for the hos-
pital sector the first recordings were uncomplete and did not 
include sales from multipackages and marginal products. These 
data have been included since January 1997. For more infor-
mation on the registration of the human consumption please 
see chapter 2 “Danmap – a 20 year perspective”.
As for previous reports the consumption in the primary sector 
corresponds to all antimicrobials delivered upon prescriptions 
from the general practitioner, medical specialists and dentists as 
well as prescriptions handed out at hospitals to patients upon 
discharge. For the hospital sector only data from public somatic 
hospitals are included – data from psychiatric hospitals, hospices 
and rehabilitation centers were omitted since they contribute a 
large proportion of bed-days but presumably much lower con-
sumption of antimicrobials and thus might skew the data. 
The term `antimicrobial agents´ covers in this chapter all 
systemic antibacterial agents for human use listed in the 
Anatomical Therapeutic Chemical (ATC) Classification under the 
code J01. The only other antibacterials included are metronida-
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Figure 5.1a Total consumption of systemic antimicrobial agents in humans in primary health care vs hospital care, Denmark
  Also at hospitals, notable changes in the consumption of penicillins were observed for the 
twenty-year period: while beta-lactamase sensitive penicillins increased slightly (8.02 to 
10.03 DBD, 25%), the consumption of the other three penicillin groups increased steeply, 
penicillins with extended spectrum by 52% (11.21 to 17.01 DBD), beta-lactamase resistant 
penicillins by 120% (4.44 to 9.80 DBD) and combination penicillins by > 1000% (0.03 to 
17.90 DBD). Increases were also observed for cephalosporins (3.99 to 10.40 DBD), fluoro-
quinolones (1.46 to 9.30 DBD) and carbapenems (0.36 to 4.10 DBD). While the consump-
tion of the former two has stabilized or slightly decreased since 2010, the consumption of 
carbapenems, mainly meropenem, has continued to increase. 
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zole (ATC code P01AB01) and vancomycin (ATC code A07AA09), 
since these constitute important systemic antibacterial treat-
ment as well. Their consumption has been included since DAN-
MAP 2014 and tables and figures were updated ten years back. 
Tuberculostatica, antiviral and antifungal drugs are not included. 
5.2 Total consumption (Primary Health Care and 
Hospital Care)
In 2015 the total consumption of antimicrobials in both sectors 
was 18.50 defined daily doses per 1000 inhabitants per day 
(DID), close to the total consumption of 2014, where a total 
of 18.58 DID was registered (Figure 5.1). This corresponds to 
52,691kg active compound consumed in 2015 (table A5.1 in 
web annex).  
The total consumption calculated over 20 years shows no 
big variations for the first five years of registration from 
1996 (13.40 DID) till 2000 (13.63 DID), although there was a 
single top with a 5% higher consumption in 1998. From 2000 
onwards, continuously increasing trend was observed until the 
year 2011, where the consumption peaked with 19.31 DID, 
an overall increase of 42%.. Since 2011 the consumption has 
levelled off, primarily due to minor decreases in the primary 
sector, corresponding to a total decline of 4.2% over the past 
four years. Generally, the total consumption in the 20 year 
period increased by 38%, from 13.40 DID in 2006 to 18.50 DID 
in 2015.
Primary health care accounts for approximately 90% of the 
consumption, thus significant changes in prescription here will 
markedly influence the total consumption. 
Among the Scandinavian countries, the Danish consumption 
during the past 20 years was generally the lowest during  
the 1990s. However, continuously increasing trends in 
Denmark and simultaneously decreasing trends in Sweden, 
resulted in Denmark having the highest consumption of the 
three countries in 2014 and Sweden the lowest (www.ecdc.
europa.eu/en; Data & Tools, ESAC-database ). For Norway the 
consumption fluctuated between 16 and 18 DID during the 
20 years, showing decreasing trends for the last three years. 
In 2015 the total consumption of antimicrobials was 13.6 DID 
in Sweden and 18,8 DID in Norway. The Norwegian national 
action plan from 2015 aiming for a 30% reduction in the 
total consumption ((with 2012 as the reference point) will 
expectantly result in a much lower consumption in the years 
to come. 
At the European level, Denmark reports a comparatively low 
consumption of antimicrobial agents, specifically character- 
ized by the proportionally high consumption of penicillins 
(ESAC-Net 2014).
ATC group(a) Therapeutic group
Year
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
J01AA                        Tetracyclines               1,07 0.98 0.98 93 0.98 0.99 1.04 1.07 1.17 1.28
J01CA               Penicillins with extended spectrum 2.50 2.39 2.39 2.29 2.29 2.47 2.51 2.52 2.63 2.79
J01CE                        Beta-lactamase sensitive penicillins     4.50 4.57 4.81 4.48 4.69 4.91 5.00 5.07 5.20 5.28
J01CF                        Beta-lactamase resistant penicillins     0.30 0.34 0.40 0.48 0.52 0.65 0.77 0.85 0.92 0.97
J01CR                        
Combinations of penicillins, including beta-
lactamase inhibitors   
0.00 0.02 0.03 0.02 0.02 0.03 0.04 0.05 0.06 0.08
J01D                        Cephalosporins and other β-lactam antibiotics  0.00 0.02 0.03 0.02 0.02 0.03 0.03 0.02 0.02 0.03
J01EA                        Trimethoprim and derivatives   0.30 0.30 0.32 0.32 0.33 0.35 0.36 0.38 0.41 0.44
J01EB                        Short-acting sulfonamides       0.40 0.41 0.41 0.38 0.38 0.36 0.36 0.36 0.36 0.35
J01EE                        
Combinations of sulfonamides and 
trimethoprim, including derivatives
0.10 0.08 0.04 0.03 0.04 0.03 0.02 0.03 0.00 0.00
J01FA                        Macrolides                  1.90 2.03 2.28 2.17 2.02 2.10 2.15 2.13 2.23 2.41
J01FF                        Lincosamides                0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
J01GB Aminoglycosides 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.01
J01MA                        Fluoroquinolones            0.20 0.22 0.23 0.20 0.15 0.17 0.18 0.25 0.28 0.33
J01XA Glycopeptides 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
J01XB                        Polymyxins                 0.00 0.03 0.02 0.03 0.03 0.02 0.02 0.02 0.02 0.02
J01XC                        Steroid antibacterials (kombination fusidic acid)   0.00 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.01
J01XE Nitrofuran derivatives (nitrofurantoin) 0.04 0.35 0.36 0.36 0.38 0.39 0.41 0.42 0.43 0.45
J01XX                       Other antibacterials (methenamine >99%)                0.50 0.46 0.43 0.40 0.36 0.33 0.34 0.32 0.30 0.28
J01XD and P01AB* Nitroimidazole derivatives (metronidazole) 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20
J01+P01AB Antibacterial agents for systemic use (total) 12.20 12.24 12.76 12.15 12.21 12.85 13.26 13.53 14.06 14.96
Table 5.1a. Consumption of antimicrobial agents for systemic use in primary health care (DDD/1000 inhabitant-days),  
Denmark, 1996 - 2005           DANMAP 2015
a) From the 2015 edition of the Anatomical Therapeutic Chemical (ATC) classification system
*) all metronidazole preparations, formerly only listed as J01XD, 10 years retrospective data included in the DANMAP report since 2014
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5.3 Primary Health Care
5.3.1  Total consumption in primary health care
In 2015 the consumption in the primary sector at 16.46 
DID was almost the same as in 2014, (16.40 DID), (Table 
5.1 a and b).Since 2006 the total consumption increased by 
6% (15.45 DID to 16.46 DID). During the last 20 years the 
increase was 34%, showing gradual increases from 12.20 DID 
in 1996 to the peak of 17.34 DID in 2011 and lately reaching 
a plateau with the consumption of 2015 being close to that 
reported in 2009, (Figure 5.1b).  
The trends in the consumption of leading antimicrobials for the 
last decade are shown in figure 5.2. Beta-lactamase sensitive 
penicillins continued being the antimicrobial class with the 
highest consumption. They are the only antimicrobial class 
with an overall decreasing trend for the past deacde, decreas-
ing from 5.40 DID in 2006 to 4.33 in 2015, a decline of 19% . 
Macrolides also show decreasing trends for the 10 year period, 
from 2.31 DID in 2006 to 1.77 DID in 2015, the decrease 
being interrupted  from 2010 to the beginning of 2012 due 
to a doublem, nationwide Mycoplasma pneumoniae epidemic. 
A new Mycoplasma epidemic was registered in the autumn of 
2015, lasting until the spring of 2016; this will most likely be 
reflected in the consumption patterns for 2016. 
Most notable increases were shown for penicillins with extend-
ed spectrum and combination penicillins; these increased from 
2.95 to 3.61 DID (22%) and from 0.12 to 1.42 DID (1200%), 
respectively. Such increases may reflect changes in treatment 
recommendations for specific infections; for the penicillins 
with extended spectrum the change is probably due to shifts 
in the treatment of urinary tract infections from sulfamethizole 
to pivmecillinam as the prime drug. This change caused the 
number of DDDs to decrease from 4 g to 0.6 g per day, but 
simultaneously the duration of treatment increased. Likewise 
the change from phenoxymethylpenicillin to amoxicillin with 
ATC group(a) Therapeutic group
Year
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
J01AA                        Tetracyclines               1.38 1.48 1.54 1.61 1.69 1.64 1.76 1.96 1.66 1.61
J01CA               Penicillins with extended spectrum 2.95 3.25 3.26 3.29 3.47 3.41 3.40 3.48 3.53 3.61
J01CE                        Beta-lactamase sensitive penicillins     5.40 5.67 5.30 5.12 5.25 5.31 4.68 4.65 4.38 4.33
J01CF                        Beta-lactamase resistant penicillins     1.05 1.09 1.12 1.13 1.17 1.14 1.21 1.30 1.36 1.38
J01CR                        
Combinations of penicillins, including beta-
lactamase inhibitors   
0.12 0.19 0.27 0.45 0.68 0.89 1.05 1.22 1.30 1.42
J01D                        Cephalosporins and other β-lactam antibiotics  0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
J01EA                        Trimethoprim and derivatives   0.47 0.49 0.49 0.48 0.51 0.50 0.52 0.53 0.55 0.56
J01EB                        Short-acting sulfonamides       0.35 0.31 0.28 0.27 0.26 0.24 0.22 0.22 0.21 0.18
J01EE                        
Combinations of sulfonamides and 
trimethoprim, including derivatives
0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01 0.00 0.00
J01FA                        Macrolides                  2.31 2.42 2.28 2.21 2.44 2.47 2.19 1.93 1.79 1.77
J01FF                        Lincosamides                0.02 0.02 0.03 0.03 0.04 0.04 0.04 0.05 0.05 0.05
J01GB Aminoglycosides 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01
J01MA                        Fluoroquinolones            0.37 0.44 0.51 0.52 0.57 0.57 0.55 0.52 0.50 0.49
J01XA Glycopeptides 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
J01XB                        Polymyxins                 0.02 0.02 0.02 0.02 0.02 0.03 0.02 0.02 0.02 0.02
J01XC                        Steroid antibacterials (kombination fusidic acid)   0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01
J01XE Nitrofuran derivatives (nitrofurantoin) 0.46 0.47 0.47 0.49 0.51 0.50 0.49 0.49 0.48 0.45
J01XX                       Other antibacterials (methenamine >99%)                0.27 0.26 0.27 0.26 0.27 0.26 0.25 0.24 0.24 0.25
J01XD and P01AB* Nitroimidazole derivatives (metronidazole) 0.22 0.23 0.24 0.27 0.28 0.28 0.28 0.28 0.28 0.28
J01+P01AB Antibacterial agents for systemic use (total) 15.45 16.45 16.15 16.22 17.21 17.34 16.75 16.95 16.40 16.46
Table 5.1b. Consumption of antimicrobial agents for systemic use in primary health care (DDD/1000 inhabitant-days),  
Denmark, 2006 - 2015 DANMAP 2015
a) From the 2015 edition of the Anatomical Therapeutic Chemical (ATC) classification system
*) all metronidazole preparations, formerly only listed as J01XD, 10 years retrospective data included in the DANMAP report since 2014
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clavulanic acid for the treatment of respiratory tract infections 
led to changes in DDD from 2g to 1g per day but probably no 
noteworthy changes in the recommended duration of treatment
The 2015 distribution of the leading antimicrobial classes 
is shown in figure 5.3. Beta-lactamase sensitive penicillins 
represented the largest therapeutic group of antimicrobial 
agents consumed, constituting 26% of the consumption.  
Penicillins in general (including combinations with beta-lacta-
mase inhibitors) accounted for 65% of the total consumption. 
Macrolides accounted for 11%, tetracyclines for 10%, sulfon-
amides and trimethoprim for 4%, nitrofurantoin and Fluoro-
quinolones for each 3% (Figure 5.3). A decade ago, in 2006, 
beta-lactamase sensitive penicillins accounted for 35%, 
penicillins with extended spectrum for 19% and macrolides 
for 15%.  Tetracyklines accounted for 9%, beta-lactamase 
resistant penicillins for 8%, sulfonamides and trimethoprim 
for 6%, nitrofurantoin for unchanged 4%, fluorquinolones for 
unchanged 3% and combination penicillins for only 1% (DAN-
MAP 2006, not shown). 
Beta-lactamase sensitive 
penicillins (J01CE) ; 26%
Penicillins with extended 
spectrum (J01CA) ; 22%
Macrolides, lincosamides 
and streptogramins (J01F) ; 
11%
Tetracyclines (J01AA) ; 10% Beta-lactamase resistant 
penicillins (J01CF) ; 8%
Comb. of penicillins, incl. 
beta-lactamase inhib. 
(J01CR) ; 9%
Sulfonamides and 
trimethoprim (J01E) ; 4%
Fluoroquinolones (J01MA) ; 
3%
Other antibacterials 
(J01D,G,X, P01AB) ; 7%
Fig 5.3
Figure 5.3. Distribution of the total consumption of antimicrobial agents in primary health care, Denmark DANMAP 2015
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Figure 5.2. Consumption of leading antimicrobial groups for systemic use in primary health care, Denmark DANMAP 2015
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5.3.2 Initiatives on prudent use of antimicrobials in 
primary health care
It is assumed that patient demands for receiving antibiotic 
treatment may play an important role in the increasing total 
consumption of antimicrobial drugs as well as causing changes 
observed in the consumption of individual antimicrobial agents. 
National campaigns aimed at the population have been launched 
to target this problem, anchored on the citizen-centered homep-
age “www.antibiotikaellerej.dk” (see also DANMAP 2012).  
Another focus on the reduction of antimicrobials is improving 
diagnostics and point-of-care-tests and their applicability in 
primary health care, both at the GP and in nursing homes and 
other institutions. It is generally believed that the amount of 
antimicrobials consumed will be reduced consequently. Also 
the Danish Health Authority has in recent years focused on 
issuing guidelines on the diagnostics and treatment of specific 
infectious diseases. An example is the guidelines on diagnos-
tics and treatment of otitis media, issued in 2015. Recently, 
guidelines on the prescription of antibtiotics for odontal pro-
cesses and infections were issued.  
Data on prescription habits for the different medical specialties 
are not included in this report, but are crucial for future efforts 
on a more prudent use of antimicrobial agents. Further investi-
gations on these  will be undertaken over the next years.
5.3.3  Measures at treated patient level
In 2015, each treated patient received 21.8 DDDs per year, 
which is slightly higher than in 2014 (21.5 DDDs ). The same 
applies to the DDDs per package, which increased from 9.9 in 
2014 to 10.2 in 2015 (Table 5.2).  During the last decade the 
number of DDDs per patient per year increased by 22% and 
the DDDs per package by 17%, while the number of packages 
per patient remained quite stable around 2.1.  The number of 
patients treated decreased by 13%, from 310.3 to 270.6 pa-
tients per 1000 inhabitants per day (Table A5.2 in web annex). 
The most pronounced changes in DDD per patient since 2006 
were observed for the following drug classes: increases were 
seen for beta-lactamase resistant penicillins (+  34%), tetracy-
clines (+ 26%), combination penicillins (+ 25%),  cephalosporins 
(+ 25%) and for penicillins with extended spectrum (+ 24%) 
(Table 5.2 and Table A5.3 in web annex). 
Reductions in DDD per patient were observed for trimethoprim, 
short-acting sulfonamides and lincosamides with – 11%, - 2% 
and - 19%, respectively.
Table 5.2. Number of DDDs and packages per treated patient among leading groups of antimicrobial agents in primary health care, 
Denmark 
ATC 
group(a)
Therapeutic group Indicator
Year
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
J01AA Tetracyclines               
DDDs / patient 40.9 43.0 44.4 45.2 45.9 44.0 47.6 51.6 49.9 51.7
Packages / patient 1.9 2.0 2.0 2.0 2.0 1.9 2.1 2.1 2.1 1.9
DDDs / package 21.0 22.0 22.7 22.7 22.7 22.6 23.1 25.5 23.8 27.8
J01CA
Penicillins with extended 
spectrum
DDDs / patient 14.2 14.4 14.7 14.8 14.9 14.8 16.1 16.7 17.2 17.6
Packages / patient 1.6 1.6 1.6 1.6 1.6 1.6 1.7 1.7 1.7 1.7
DDDs / package 8.9 9.0 9.2 9.2 9.0 9.2 9.7 10.0 10.0 10.3
J01CE
Beta-lactamase sensitive 
penicillins     
DDDs / patient 11.5 11.7 11.8 11.8 11.8 11.8 11.8 12.0 11.9 12.1
Packages / patient 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4
DDDs / package 8.0 8.2 8.2 8.4 8.4 8.4 8.4 8.5 8.5 8.8
J01CF
Beta-lactamase resistant 
penicillins     
DDDs / patient 13.0 13.4 13.7 13.9 14.2 13.8 15.5 16.4 17.1 17.4
Packages / patient 1.5 1.5 1.5 1.5 1.5 1.4 1.6 1.7 1.8 1.8
DDDs / package 8.6 8.7 9.0 9.1 9.3 9.6 9.7 9.4 9.7 9.5
J01CR
Combinations of penicillins, 
incl. beta-lactamase 
inhibitors   
DDDs / patient 19.3 19.1 19.9 20.4 21.1 21.9 22.3 22.6 23.2 23.6
Packages / patient 1.8 1.6 1.6 1.5 1.5 1.6 1.6 1.6 1.6 1.6
DDDs / package 10.7 11.7 12.4 13.3 13.7 14.1 14.3 14.3 14.3 15.1
J01FA Macrolides                  
DDDs / patient 12.6 12.4 12.5 12.5 12.2 11.5 12.4 12.6 12.8 12.5
Packages / patient 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.6 1.6 1.6
DDDs / package 8.3 8.1 8.1 8.1 8.1 7.9 8.0 8.0 7.9 7.7
J01MA Fluoroquinolones            
DDDs / patient 10.3 10.6 11.0 11.2 11.2 11.5 11.7 11.8 11.9 12.0
Packages / patient 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
DDDs / package 6.9 7.0 7.5 7.6 7.6 7.7 7.8 7.8 7.9 7.9
J01
Antibacterial agents for 
systemic use (total)
DDDs / patient 17.9 17.3 18.9 19.2 19.6 19.4 20.6 21.3 21.5 21.8
Packages / patient 2.0 1.9 2.1 2.1 2.1 2.1 2.1 2.1 2.2 2.1
DDDs / package 8.7 8.9 9.1 9.3 9.3 9.3 9.7 9.9 9.9 10.2
DANMAP 2015
a) From the 2015 edition of the Anatomical Therapeutic Chemical (ATC) classification system
DANMAP 201550
ANTIMICROBIAL CONSUMPTION IN HUMANS5.
For tetracyclines, both the number of DDDs per patient and 
DDDs per package have continuously been higher than for any 
other antimicrobial group, primarily due to the fact that tet-
racyclines are commonly used for acne treatment with higher 
dosages given in treatments of typically three, but up to six 
months. 
Figure 5.4 shows the trends in consumption for the number 
of packages per 1,000 inhabitants per year compared to the 
treated patients per 1,000 inhabitants per year and the total 
consumption of DDDs per 1,000 inhabitants per day for the 
last decade, when measured against the consumption 15 
years ago. Although the trends parallel each other, DDDs per 
1000 inhabitants per day remained above 110% through all 
ten years shown, compared to the index year 2001. From 
2006 until 2011 increasing trends were observed with a 
peak of 123% in 2011, followed by gradual decreases. De-
velopment in the number of treated patients and the number 
of packages show almost equal lines, starting at 102% and 
100%, respectively, fluctuating around 100% in the period 
from 2006 to 2011 and, following distinct decreases, ending 
at 89% and 92%, respectively. 
When comparing the consumption of DDD per 1,000 inhab-
itants to the number of prescriptions and users per 1,000 
inhabitants once more changes in the consumption of DDDs 
are noted: the number of DDDs increased from 2006 to 2011 
(5,585 to 6,388 DDD/1,000 inhabitants) and slowly declined 
thereafter, reaching 5,913 DDD/1,000 inhabitants in 2015. 
The number of users and prescriptions paralleled each other 
in trends without noteworthy changes in the first six years, 
but with minor declines through the past four years. Overall 
there was a decrease through the decade from 313 to 274 
users/1,000 inhabitants and 587 to 511 prescriptions/1,000 
inhabitants, respectively (Figure 5.5).
Table 5.3 shows the number of prescriptions per 1,000 inhabit-
ants for leading antimicrobial agents in primary health care 
from 2006 to 2015. In 2015 530.62 prescriptions per 1,000 
inhabitants were redeemed at pharmacies, a decrease of 12% 
from the 603.60 receptions per 1,000 inhabitants in 2006. 
Generally, the number of prescriptions decreased by 24% from 
2006 to 2015 (171.29 to 130.07 prescriptions per 1,000 
inhabitants), compared to the 19% decrease in DID shown in 
figure 5.2. For betalactam sensitive penicillins and combination 
penicillins fluctuations in the number of prescriptions followed 
fluctuations in DIDs. However, it is generally clear that changes 
in consumption measured as DIDs do not necessarily mirror 
changes in the number of prescriptions.
For the penicillins with extended spectrum the number of 
prescriptions increased from 2006 until 2010, from 75.78 to 
85.04 prescriptions per 1,000 inhabitants, but declined again 
to 74.88 prescriptions per 1,000 inhabitants in 2015. During 
the same time, the consumption measured in DID gradually 
increased, from 2.95 DID in 2006 to 3.61 DID in 2015. 
For the beta-lactamase resistant penicillins the number of 
prescriptions increased from 2006 to 2011, (29.38 -30.34 pre-
scriptions per 1,000 inhabitants) but decreased the next four 
years to 28.85 prescriptions per 1,000 inhabitants in 2015. 
This change in trends was not reflected in the consumption of 
DID, that seemed almost unchanged but with a slight increase 
over the decade, from 1.05 DID in 2006 to 1.38 DID in 2015. 
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Such changes in DID that are not reflected in the number of 
prescriptions and vice versa probably reflect alterations in 
consumption within the same antimicrobial class. For instance 
there may be increases in DDD according to new treatment 
recommendations or clinical guidelines - this happens when 
the dosage or the daily intake increases (e.g from 200mg to 
400mg per dosage or from three to four times daily). 
A concurrent decrease in DDDs may be caused by changes in 
the recommended treatment duration (e.g.from seven days 
treatment to five days). Finally, changes in the application or 
preference of the different drugs may change over time – for 
instance, when a specific drug is used for infections other than 
the primary indication.
Table 5.4 shows the total consumption of antimicrobial classes 
at a regional level for the last five years, 2011 to 2015. All 
five regions show decreases for both the DDD per 1,000 
inhabitants per day and for the number of prescriptions per 
1,000 inhabitants per day. In 2015 the Region of Zealand had 
the highest consumption, when measured in DDD per 1,000 
inhabitants per day, while the Central Denmark Region and 
the Northern Denmark Region had the lowest consumption, 
16.9 DID and 15.2 DID, respectively. The Region Zealand had 
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Figure 5.5. Indicators of antimicrobial consumption (J01) in primary health care, Denmark DANMAP 2015
Table 5.3. Number of prescriptions per 1,000 inhabitants for leading antimicrobial agents in primary health care, Denmark   
        
ATC group(a) Therapeutic group
Year
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
J01AA                        Tetracyclines               12.25 12.52 12.73 13.02 13.44 13.66 13.53 13.85 12.20 11.32
J01CA               Penicillins with extended spectrum 75.78 82.03 81.27 81.07 85.04 84.19 77.29 76.09 75.32 74.88
J01CE                        Beta-lactamase sensitive penicillins     171.29 177.07 164.38 158.72 162.81 164.34 145.50 142.16 134.79 130.07
J01CF                        Beta-lactamase resistant penicillins     29.38 29.67 29.89 29.87 30.02 30.34 28.50 29.07 29.24 28.85
J01CR                        
Combinations of penicillins, including 
beta-lactamase inhibitors   
2.27 3.57 4.95 8.02 11.70 14.95 17.34 19.71 20.52 22.03
J01E                       Sulphonamides and trimethoprim 36.56 33.62 30.49 29.51 29.31 27.63 26.47 26.15 24.65 22.45
J01FA                        Macrolides                  67.03 71.38 66.84 64.44 72.67 78.75 64.72 56.15 51.38 51.75
J01MA                        Fluoroquinolones            13.09 15.19 17.05 16.87 18.45 18.10 17.24 16.04 15.30 15.04
J01XX                       Other antibacterials (methenamine >99%) 7.70 7.17 7.43 7.67 7.53 7.74 7.54 7.48 7.16 7.35
J01XD and 
P01AB
Nitroimidazole derivatives (metronidazole) 13.77 14.44 15.32 16.28 16.73 16.90 16.86 16.51 16.31 16.47
J01  
(incl. P01)
Antibacterial agents for systemic use (total) 603.60 630.08 606.26 595.28 628.78 638.08 582.69 565.16 542.53 530.62
DANMAP 2015
DANMAP 201552
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also the highest number of prescriptions redeemed per 1,000 
inhabitants, while the Central Denmark Region had the lowest, 
574.4 and 494.5 prescriptions per 1,000 inhabitants, respec-
tively. Interestingly Region Zealand has the highest amount 
and proportion of phenoxymethylpenicillin consumed in the 
country (data not shown). Thus the regional differences in 
consumption may resemble differences in local recommenda-
tions and treatment guidelines as well as in custome.
5.3.4. Penicillins
Penicillins account for 2/3 of all antimicrobial consumption in 
primary health care, but while this has remained unchanged 
since 2006 individual changes in the consumption of the dif-
ferent groups of penicillin have been observed. The consump-
tion of penicillins in total increased slightly in 2015 (10.74 
DID) compared to 2014 (10.58 DID). Increases have been no-
ticed for all years in the last decade except for the year 2013 
to 2014, where no apparent increase was observed. From 
2006 to 2015 the consumption of penicillins increased by 13% 
(corresponding to a total of 9.51 DID in 2006), (table 5.1).
20 year trends of the consumption of leading penicillins are 
shown in figure 5.6. The consumption of beta-lactamase sensi-
tive penicillins was almost unchanged from 2014 to 2015, 
with a slight decrease of 1%. Small increases in consump-
tion were observed for beta-lactamase resistant penicillins 
(1.5%) and penicillins with extended spectrum (2.2%). Marked 
increases were seen for ‘combination penicillins’ (9.2%). The 
consumption of these three groups has risen considerably over 
the past decade, with particular increases for beta-lactamase 
resistant penicillins from 1.05 DID to 1.38 DID (31%), penicil-
lins with extended spectrum from 2.95 DID to 3.61 DID (22%) 
and the combination penicillins with betalactamase inhibitors 
from 0.12 DID to 1.42 DID (1183%). For the 20-year period 
beta-lactamase sensitive penicillins decreased with 3.8%, 
penicillins with extended spectrum increased with 44% and 
beta-lactamase resistant penicillins increased with 360%. The 
increases in percent for the combination penicillins cannot be 
estimated for the 20-year period since the consumption in 
1996 was registered as being zero.
Consumption at the substance-level for the different peni-
cillin groups is shown in figure 5.6. As mentioned above 
phenoxymethylpenicillin is the most consumed penicillin. In a 
20-year chart trends in the consumption become very clear, 
for phenoxymethylpenicillin showing increasing trends for the 
first eleven years (from 4.50 DID in 1996 to 5.67 DID in 2007) 
and an almost equivalent but steeper decrease onwards to 
2015 (4.33 DID). For all other penicillins the trends over the 
20-year period were more stable, pivmecillinam and amoxicil-
lin with clavylanic acid showing parallel increasing trends, 
pivmecillinam from the first registration in 2000, amoxicillin 
with clavulanic acid from 2005 and onwards. Also Flucloxacil-
lin showed increasing trends paralleling the others from 2010 
until 2014; this drug was introduced to the Danish market in 
2011 following delivery problems and production cessation 
of the oral mixture for dicloxacillin. In 2015 a reduction in 
consumption was observed. 
Both pivmecillinam, pivampicillin and amoxicillin belong to the 
penicillins with extended spectrum; amoxicillin and pivampicil-
lin slowly declined over the last twenty years, while pivmecil-
linam increased steeply. The increase of pivmecillinam is due 
to changes in the recommended treatment of urinary tract 
infections (UTI), where sulfamethizole used to be the prime 
drug, see figure 5.7 - 5.9 for the treatment of UTI in women, 
1999-2015. 
Table 5.4. Consumption of antimicrobial agents for systemic use in primary health care at regional level, Denmark
Region Indicator
Year
2011 2012 2013 2014 2015
Capital Region DDD/1000 inhabitants/day  17.9  16.9  16.9  16.3  16.4 
Prescriptions/1000 inhabitants  657.6  599.2  576.7  549.4  533.6 
Region Zealand DDD/1000 inhabitants/day  17.8  16.7  16.9  16.5  16.9 
Prescriptions/1000 inhabitants  677.4  618.6  601.4  579.5  575.4 
Region of Southern Denmark DDD/1000 inhabitants/day  17.3  16.2  16.5  15.8  15.8 
Prescriptions/1000 inhabitants  658.0  598.4  588.9  556.5  540.3 
Central Denmark Region DDD/1000 inhabitants/day  16.0  15.3  15.5  15.1  15.2 
Prescriptions/1000 inhabitants  573.8  531.9  512.8  500.5  494.5 
North Denmark Region DDD/1000 inhabitants/day  16.4  15.2  15.4  15.1  15.2 
Prescriptions/1000 inhabitants  620.1  557.6  541.2  525.6  510.6 
Denmark (total) DDD/1000 inhabitants/day 17.3 16.8 17.0 16.4 16.2
Prescriptions/1000 inhabitants 637.4 581.1 564.2 542.2 530.9
DANMAP 2015
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Figure 5.6. Consumption of leading penicillins in primary health care, Denmark
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Note: the figure includes only consumtpion of the two main drugs: sulfamethizole and pivmecillinam
Figure 5.8 Consumption of antimicrobial agents by female 
urinary tract infections in primary health care, Denmark, DID
Figure 5.7 Female urinary tract infections treated per 1,000 
inhabitants in primary health care, Denmark
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Figure 5.9, number of prescriptions for women treated for urinary tract infection, 1999 - 2015
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5.3.5 Consumption of antimicrobials among children/
youngsters (0 – 18 years)
Since 2013 there has been extra focus on the consumption 
of antimicrobials in children and teenagers. Children account, 
together with the elderly, for a relatively high proportion 
of penicillins consumed. In addition, adolescents have the 
highest consumption of tetracyclines - most likely due to the 
treatment of of acne. The total consumption during the last 
decade decreased from 32.3 DID to 26.1 DID. 
Figure 5.10 shows consumption of the four leading antimicro-
bial groups in children and teenagers during the last decade. 
For the penicillins and macrolides peaks are observed in 2007 
and 2011, mirroring the trends observed for the total con-
sumption of antimicrobials in the primary sector. They also 
reflect the occurrence of the avian Flu pandemic in the winter 
2006 to 2007 and the Mycoplasma pneumoniae epidemic from 
autumn 2010 to spring 2012.  In 2015 the betalactamase 
sensitive penicillins accounted for 9.9 DID, penicillins with 
extended spectrum for 7.2 DID and macrolides for 3.3 DID.
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Inspired from initiatives performed at STRAMA in Sweden re-
garding the animicrobial use in children the national campaign 
on use of antibiotics launched on the European Awareness Day 
in 2012 focused on viral versus bacterial infections in children. 
It was followed by a campaign focusing on “red ear” (otitis 
media) in 2013. 
In 2013, following steady increases in the consumption of 
tetracyclines suspected to be related to increasing systemic 
treatment of acne teenagers, it was decided to further inves-
tigate the possible causes behind the increase (Kuhn et al, 
2016). Encouragingly, new data from 2014 showed a sudden 
unexpected decrease. This was most likely related to the raised 
public awareness of antibiotics as the cause of unwanted 
resistances in general and on the appearance of livestock-
associated MRSA in humans and speculations on a possible link 
to the use of tetracycline in the animal husbandry (see chapter 
8.5 and MRSA textbox).
5.3.6 Tetracyclines
For the second year in a row the consumption of tetracyclines 
decreased, though less marked, from 1.66 DID to 1.61 DID (3%) 
(Figure 5.11). The decrease was observed for lymecycline and 
tetracycline, while doxycycline increased. Since 2006 the con-
sumption has altogether increased with 17% (from 1.38 DID). 
5.4 Hospital Care
5.4.1 Introduction
 The antimicrobial consumption for hospital care reported was 
related only to bed-days and admissions in public somatic hos-
pitals. Specialized hospitals (psychiatric hospitals, hospices and 
rehabilitation centers) were not included as they might skew 
the data due to contribution of a large proportion of bed-days 
and admissions but only a small proportion of antimicrobial 
consumption (approximately 3%). The consumption of antimi-
crobial agents in hospital care is presented as DDD per 100 oc-
cupied bed-days (DBD) and as DDD per 100 admissions (DAD) 
to account for hospital activity. Data are also presented as DID 
to enable comparison with primary health care. During the past 
decade, the hospitalization pattern in Denmark has changed 
notably: more people are admitted to somatic hospitals while 
the average length of stay is considerably shorter (Figure 
5.12, Table A5.4 and A5.5 in web annex). Selection pressure 
for the emergence of antimicrobial resistance increases with 
increasing hospital activity and thus the selection pressure has 
increased considerably from 2006 to 2015.
 5.4.2 Somatic hospitals – DDD per 100 occupied  
bed-days (DBD) 
In 2015, the consumption of antimicrobial agents in somatic 
hospitals was 103.02 DBD, a minor decrease of 1.3% from 
2014 (104.30 DBD), but the first decrease in a decade follow-
ing continous increases (from 67.71 DBD in 2006), (Table 5.5).
Since 2006, the consumption increased with 52%. This reflects 
a combination of the described increased hospital activity and 
decreased number of hospital bed-days with an increase in 
DDDs. In 2015 combination penicillins, for the first time since 
recording of the antimicrobial consumption was begun in 1997, 
represented the largest group of antimicrobials consumed 
Fig 5.9
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(17%), closely followed by penicillins with extended spectrum 
(16%). Penicillins in general accounted for 51% of the total 
consumption. Cephalosporins (15%) and fluoroquinolones (9%) 
were also still among the most commonly consumed anti-
microbial agents in hospitals (Figure 5.13). The proportional 
consumption of cephalosporins increased from 11% in 2014. 
It is important to note delivery problems for the following 
intravenously administered antimicrobials: meropenem, van-
comycin, clarithromycin and mecillinam. Whether the shortage 
of these drugs was a consequence of increasing consumption 
is not known, but may very well be the case. The following 
additional sales to hospitals were reported from wholesalers:  
290 DDD for meropenem, 3,121 DDD for vancomycin, 316 
DDD for clarithromycin and 958 DDD for mecillinam. These 
numbers were not included in the figures and tables since it is 
not known how much of the extra deliverances actually were 
consumed. The additional sales amount only for around 0.1% 
of the total consumption and thus hardly had any impact on 
the total amounts of antimicrobials consumed. However, when 
there is shortage of important antimicrobial classes, changes 
in consumption of the other classes might happen as well, 
especially in hospital departments. The shortage of both me-
ropenem and mecillinam thus very likely caused consequential 
increases in the consumption of piperazillin with tazobactam 
and probably also in gentamicin and cephalosporins. These 
drugs are all important in the treatment of sepsis and compli-
cated urinary tract infections, as are meropenem and mecil-
linam. For vancomycin it is more difficult to estimate whether 
other antimicrobials might have been affected by the deliv-
erance shortage, since alternatives in treatment very much 
depend on the infectious disease to be treated. For clarithro-
Table5.5 Consumption of antibacterial agents for systemic use in somatic hospitals (DDD/100 occupied bed-days), Denmark 
     
ATC group(a) Therapeutic group
Year
1997 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
J01AA                        Tetracyclines               0.34 0.39 0.63 0.78 1.04 1.09 1.18 1.58 1.52 1.73 1.86
J01CA                        Penicillins with extended spectrum 11.21 13.00 13.42 13.96 15.37 14.61 14.41 14.90 15.06 16.40 17.01
J01CE                        Beta-lactamase sensitive penicillins   8.02 10.67 10.79 9.98 9.90 9.49 9.32 10.13 10.13 10.31 10.03
J01CF                        Beta-lactamase resistant penicillins   4.44 6.51 6.70 6.81 7.40 7.71 7.30 8.37 9.07 9.57 9.80
J01CR                        
Combinations of penicillins.  
incl. beta-lactamase inhibitors   
0.03 1.83 2.95 4.00 5.65 7.13 8.51 12.00 13.64 16.04 17.80
J01DB                  First-generation cephalosporins 0.13 0.14 0.13 0.18 0.13 0.13 0.13 0.12 0.11 0.06 0.04
J01DC Second-generation cephalosporins 3.99 9.38 12.31 13.32 15.76 16.21 16.14 14.15 12.32 11.68 10.40
J01DD Third-generation cephalosporins 0.50 0.83 1.03 1.25 1.42 1.26 1.39 1.07 1.08 1.02 1.06
J01DF Monobactams 0.06 0.00 0.04 0.07 0.06 0.09 0.19 0.15 0.14 0.06 0.03
J01DH Carbapenems 0.36 1.38 2.13 2.70 3.15 4.02 4.16 3.86 4.02 4.09 4.10
J01EA                        Trimethoprim and derivatives   0.42 0.42 0.44 0.44 0.44 0.36 0.36 0.38 0.41 0.52 0.46
J01EB                        Short-acting sulfonamides       1.29 0.75 0.34 0.35 0.35 0.33 0.25 0.20 0.20 0.18 0.15
J01EE                        
Combinations of sulfonamides and 
trimethoprim. incl. derivatives 
0.44 2.12 1.52 1.95 2.28 3.04 4.11 3.33 4.21 4.70 5.04
J01FA                        Macrolides                  3.45 2.83 3.08 3.06 3.42 3.52 3.69 3.56 3.39 3.88 4.56
J01FF                        Lincosamides                0.13 0.31 0.35 0.41 0.50 0.47 0.53 0.62 0.64 0.65 0.57
J01GB Aminoglycosides 3.38 1.81 1.79 1.64 1.56 1.71 1.91 2.14 2.13 1.61 1.68
J01MA                        Fluoroquinolones            1.46 6.74 8.16 9.53 10.71 10.44 10.70 10.02 9.77 9.88 9.30
J01XA Glycopeptides 0.21 0.56 0.63 0.68 0.99 1.07 1.24 1.29 1.29 1.15 1.07
J01XB                        Polymyxins                 0.04 0.12 0.05 0.05 0.07 0.10 0.09 0.09 0.16 0.27 0.25
J01XC                        Steroid antibacterials (fusidic acid)     0.25 0.28 0.28 0.26 0.31 0.34 0.27 0.23 0.22 0.23 0.16
J01XD                 Imidazole derivatives 1.42 2.78 2.62 3.27 3.84 3.93 4.19 4.16 4.08 4.48 4.25
J01XE
Nitrofuran derivatives  
(nitrofurantoin)
0.37 0.29 0.28 0.29 0.36 0.31 0.33 0.34 0.38 0.36 0.32
J01XX05 Methenamine 0.18 0.11 0.09 0.10 0.09 0.08 0.10 0.09 0.09 0.07 0.09
J01XX08 Linezolid 0.00 0.20 0.16 0.21 0.22 0.22 0.32 0.32 0.35 0.34 0.43
J01XX09 Daptomycin 0.00 0.00 0.01 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.04
P01AB01 Metronidazole 2.13 2.20 2.43 2.91 2.99 3.12 2.89 2.70 2.48 2.05
A07AA09 Vancomycin 2.11 2.19 2.43 2.93 2.96 3.12 2.93 2.75 2.55 0.47
J01
Antibacterial agents for  
systemic use (total)
42.13 67.71 74.33 80.14 90.87 93.67 97.08 98.94 99.88 104.34 103.02
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mycin other macrolides may have been used for substitution.
For most antimicrobial classes and drugs the trends in con-
sumption observed over the past decade continued (Figure 
5.14 and table 5.5). From 2014 to 2015 the following changes 
were observed: increases were seen for combination penicil-
lins (from 16.04 DBD to 17.80 DBD, 11%), for macrolides (from 
3.88DBD to 4.56 DBD, 18%) and less marked for penicillins 
with extended spectrum (3.7%), beta-lactamase resistant 
penicillins (2.4%) and 3rd generation cephalosporins (3.9%). 
Increases were also observed for the rarely used antimicrobial 
classes tetracyclines (from 1.73 DBD to 1.86 DBD, 8%) and 
linezolid (from 0.34 DBD to 0.43 DBD, 27%). These two drugs 
are primarily used in the treatment of complicated staphylococ-
cal infections and the slight but noteworthy increase might re-
flect the increasing occurrence of staphylococcal bacteremia’s 
(see chapter 8.6 for information on staphylococcal infections).  
Decreases were observed for 2nd generation cephalospo-
rins (from 11.68 DBD to 10.40 DBD, - 11%), trimethoprim 
derivatives and short-acting sulfonamides (- 12% and - 17%, 
respectively) and for beta-lactamase sensitive penicillins (from 
10.31 DBD to 10.03 DBD) - a minor decrease of - 2.7%, but in 
accordance with decreasing trends during the last ten years. 
The delivery shortage of vancomycin clearly showed in con-
sumption, decreasing from 2.55 DBD to 0.47 DBD, ( - 82%).
Special focus should be payed to the consumption of cepha-
losporines, where a decrease was observed from altogether 
12.76 DBD in 2014 to 11.50 DBD in 2015. Despite this 
decrease, the proportion of cephalosporins among the lead-
ing antimicrobial classes used at hospitals increased from 
11% in 2014 to 15% in 2015. It is alarming that the changes 
observed in the use of cephalosporins during the last five 
years have not been bigger in spite of multifaceted efforts 
on more prudent use of antimicrobials at hospitals. Although 
a significant reduction in the consumption of 2nd generation 
cephalosporins is observed from 2010 and onwards, (from 
16.21 DBD in 2010 to 10.40 DBD in 2015), this decrease 
would have been expected to be more pronounced. Most 
hospitals changed their recommendations from the use of 
cefuroxime for patients suffering from sepsis or urinary tract 
infection to either piperacillin with tazobactam or mecillinam, 
and cefuroxime as the prime drug in acutely ill patients was 
more or less omitted. Cefuroxime still plays an important 
role as a first line drug in antibiotic prophylaxis for differ-
ent surgical interventions and for patients suffering from 
nephrological diseases as well as consituting an alternative 
to beta-lactams for patients with suspected penicillin allergy. 
With a population where approximately 10% render them-
selves to be allergic to penicillin, this might lead to overuse 
of more broadspectrum antibiotics. It is thus important that 
patients suspected of having penicillin allergy are diagnosed, 
if possible through their GP or in ambulatory care, before 
Fig 5.10
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ATC group(a) Therapeutic group
Year
2006 2007 2008(b) 2009 2010 2011 2012 2013 2014 2015
J01AA                        Tetracyclines               1.67 2.59 3.19 3.63 3.55 3.66 5.15 4.97 5.37 5.65
J01CA                        Penicillins with extended spectrum 55.13 55.39 57.18 53.76 47.46 44.77 48.60 47.90 50.95 51.75
J01CE                        Beta-lactamase sensitive penicillins     45.26 44.55 40.90 34.61 30.83 28.98 33.04 33.13 32.03 30.52
J01CF                        Beta-lactamase resistant penicillins     27.60 27.64 27.89 25.86 25.04 22.71 27.30 29.64 29.73 29.82
J01CR                        
Comb. of penicillins.  
incl. beta-lactamase inhibitors   
7.77 12.17 16.37 19.74 23.15 26.47 39.14 44.60 49.81 54.14
J01DB                  First-generation cephalosporins 0.60 0.55 0.72 0.46 0.43 0.41 0.40 0.37 0.20 0.13
J01DC Second-generation cephalosporins 39.76 50.81 54.55 55.12 52.65 50.19 46.17 40.27 36.29 31.53
J01DD Third-generation cephalosporins 3.53 4.24 5.10 4.98 4.10 4.33 3.50 3.53 3.18 3.22
J01DF Monobactams 0.00 0.18 0.27 0.21 0.29 0.60 0.48 0.45 0.19 0.08
J01DH Carbapenems 5.86 8.78 11.08 11.01 13.07 12.55 12.60 13.14 12.70 12.50
J01EA                        Trimethoprim and derivatives   1.78 1.81 1.80 1.56 1.17 1.11 1.23 1.33 1.62 1.40
J01EB                        Short-acting sulfonamides       3.18 1.41 1.43 1.21 1.09 0.78 0.63 0.62 0.55 0.46
J01EE                        
Comb. of sulfonamides and trimethoprim. 
incl. derivatives 
8.98 6.28 7.98 7.96 9.88 12.79 10.87 13.76 14.53 15.32
J01FA                        Macrolides                  12.01 12.70 12.53 11.97 11.45 11.47 11.61 11.08 12.04 13.90
J01FF                        Lincosamides                1.31 1.46 1.69 1.74 1.52 1.63 2.01 2.09 2.03 1.75
J01GB Aminoglycosides 7.68 7.39 6.71 5.45 5.56 5.95 6.99 6.97 5.01 5.11
J01MA                        Fluoroquinolones            28.58 33.66 39.04 37.45 33.92 33.30 32.67 31.96 30.69 28.28
J01XA Glycopeptides 2.38 2.61 2.77 3.48 3.47 3.87 4.20 4.22 3.58 3.25
J01XB                        Polymyxins                 0.53 0.22 0.21 0.24 0.32 0.28 0.30 0.54 0.85 0.77
J01XC                        Steroid antibacterials (fusidic acid)     1.19 1.17 1.05 1.09 1.12 0.85 0.76 0.71 0.71 0.50
J01XD                 Imidazole derivatives 11.81 10.83 13.39 13.43 12.76 13.03 13.55 13.33 13.93 12.93
J01XE Nitrofuran derivatives (nitrofurantoin) 1.24 1.17 1.19 1.27 1.01 1.02 1.12 1.25 1.13 0.98
J01XX05 Methenamine 0.46 0.38 0.43 0.31 0.27 0.32 0.28 0.30 0.22 0.29
J01XX08 Linezolid 0.86 0.68 0.84 0.76 0.72 0.99 1.04 1.14 1.05 1.31
J01XX09 Daptomycin 0.00 0.03 0.06 0.06 0.07 0.05 0.06 0.07 0.10 0.12
P01AB01 Nitroimidazole derivatives (metronidazole) 9.02 9.10 9.99 10.20 9.72 9.70 9.44 8.83 7.72 6.24
A07AA09 Intestinal antiinfectives (vancomycin) 8.95 9.10 9.96 10.20 9.73 9.71 9.54 9.00 7.92 1.43
J01 Antibacterial agents for systemic use (total) 287.1 306.9 328.3 317.8 304.3 301.9 322.7 325.2 324.1 313.38
Table 5.6. Consumption of antimicrobial agents for systemic use in somatic hospitals (DDD/100 admitted patients), Denmark
a) From the 2015 edition of the Anatomical Therapeutic Chemical (ATC) classification system    
b) The number of admissions was affectedly low in 2008 due to a major hospital strike 
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Figure 5.14. Total somatic hospital consumption (DBD) by leading groups of antimicrobial agents (J01), Denmark DANMAP 2015
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acute disease demands quick action with no time for allergic 
investigation.   
The consumption of carbapenems was 4.10 DBD in 2015, al-
most unchanged to 2014 (4.09 DBD) in spite of the described 
shortage of the drug.  In 2006 the consumption was 1.38 DBD, 
an increase of 297% for the decade. Thus in spite of recom-
mendations from the National Board of Health on the reduced 
use of carbapenems and delivery problems for meropenem 
during the summer of 2014 and in 2015 no apparent decrease 
in the consumption of meropenem  was observed. 
5.4.3 Other measures of somatic hospital consumption 
DDD per 100 admissions (DAD) 
Because of the observed changes in the number of hospital 
bed-days over time, the consumption of antimicrobials in 
Danish hospitals may also be measured in relation to admis-
sions (i.e. DDD per 100 admissions, DAD). When expressed as 
DAD, the total consumption of antimicrobial agents in somatic 
hospitals showed a decrease from 2014 to 2015 (from 324.1 
DAD to 313.4, - 3.3%) (Table 5.6).  
Among the leading individual antimicrobial groups, increases 
for the year 2014 to 2015 were observed for ’combination 
penicillins’ (8.7%), penicillins with extended spectrum (1.6%) 
and macrolides (15%).  
Decreases were observed for most other antimicrobials: 
beta-lactamase sensitive penicillins (-4.6%), 2nd generation 
cephalosporins (-13%), fluoroquinolones (- 7.9%) and to a 
lesser extent for carbapenems (-1.6%). 
As observed for the consumption measured in DBD, increases 
were also observed for the rarely used tetracyclines and line-
zolid (5.2% and 26%, respectively), while vancomycin showed 
a marked decrease (-82%). 
During the past decade, DAD increased by 9.1%; an increase 
primarily driven by a higher number of DDDs but counterbal-
anced by an increase in the number of hospital admissions.
When compared to the consumption in primary health care, 
and thus calculated in DID, the consumption of antimicro-
bial agents in somatic hospitals decreased from 2.18 DID in 
2014 to 2.04 DID in 2015. During the past decade, the DIDs 
consumed at hospitals have increased by 13% (1.81 DID in 
2006), (Table A5.4 in web annex).
5.5. Comments on 20 years surveillance  
of consumption
While the consumption kept rising through the beginning of 
the new century, so were the occurrences of resistance in 
human pathogen bacteria. 
Already in 2000, time series analysis were introduced in 
DANMAP for measuring the effect of interventions on the 
control of the antimicrobial consumption. In 2004 a detailed 
analysis of changes in consumption of the different antimi-
crobial classes were given (Figur 5.15); these show the same 
trends observed for 2015, namely shifts from consumption 
of the most narrow spectrum classes to more broadspec-
trum classes. In 2007 the barometer of antibacterials was 
introduced to give a more timely and appropriate picture of 
the consumption by reporting quarterly changes in chosen 
antimicrobials classes. Unfortunately it has not been possible 
to maintain these addiditional surveillance functions. 
Despite these different attempts on measuring the antimicro-
bial consumption, no significant effect on neither consumption 
nor development in resistance were observed.  Among emerg-
ing resistances in clinical human bacteria were the outbreak of 
a multiresistant Klebsiella pneumoniae at Hillerød hospital in 
Northern Zealand in 2008, the almost simultaneously increas-
ing occurrence of Clostridium difficile in the Capital Region of 
Denmark, followed by occurrence of the first NDM-1 positive 
strain of Klebsiella pneumoniae as well as a hospital outbreak 
of vancomycin resistant enterocci at Skejby hospital in 2010 
(see DANMAP 2009 to 2011 for information). 
Resistance outbreaks certainly would have been much 
bigger if no awareness on the consumption and constant 
surveillance had taken place. The simultaneously increas-
ing resistances in other European countries combined with 
the described outbreaks were alarming and functioned as a 
trigger for the initiation of several efforts happening on local 
regional hospital levels. Among these were strong efforts to 
reduce the consumption of cephalosporins and fluoroquino-
lones. National recommendations regarding more prudent use 
of antimicrobials were issued by the National Health Authori-
ties in 2012. These give restrictions on the use of cephalo-
sporins and fluoroquinolones for both health sectors and for 
the use of carbapenems at hospitals (see  DANMAP 2012) . 
Even though the primary sector accounts for almost 90% of 
the antimicrobial consumption it has proven much more dif-
ficult to establish good and stable systems of antimicrobial 
stewardship here. Comprehensive research is undertaken 
these years investigating on the use of diagnostic tools as 
well as supporting the implementation of rational antimicro-
bial use. 
The Danish system with detailed surveillance of consump-
tion combined with the surveillance of occuring resistance 
has so far proven to prevent steep increases in these. Future 
efforts must continue to focus on prudent use, which not 
only includes lowering the total consumption but applying 
the achieved knowledge on the complex interplay between 
consumption of specific antimicrobial drugs and emergence 
of resistance in every way. Here a special focus must be paid 
on the consumption of fluoroquinolones and other more broad 
spectrum antimicrobials in the primary sector.
Maja Laursen, Katrin Gaardbo Kuhn and Ute Wolff Sönksen,. 
For further information: uws@ssi.dk
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a) The consumption of J01CR increased by 681% from 4.9 to 38.7 DDD/1,000 discharged patients.    
Fig 5.12
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Figure 5.15. Historical figure AB2 from DANMAP 2004. Changes in hospital consumption of antibacterials 
for systemic use between 2000 and 2004, Denmark.         
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Textbox 5.1
Incidence of Neisseria gonorrhoeae, multiresistant bacteria  
and consumption of antimicrobial agents in Greenland
 
Background: Greenland has a population of 55,984 inhabitants (January 2015) and Nuuk is the capital with around 16,000 
inhabitants. Greenland has its own Ministry of Health and the country is divided into five health regions: Qeqqa (Sisimiut and 
Maniitsoq), Disko (Aasiaat, Kangaatsiaq, Qeqertarsuaq and Qasigiannguit), Avannaa (Ilulissat, Uummannaq, Upernavik and 
Qaanaaq), Sermersooq (Nuuk, Paamiut/Ivittuut, Tasiilaq and Illoqqortoormiut), and Kujataa (Qaqortoq, Nanortalik and Narsaq). 
There are several smaller hospitals and health care centres in the five health regions. The largest hospital, Dronning Ingrids 
Hospital, is situated in Nuuk (182 beds). Around 15-16,000 persons are admitted to hospital once or several times a year. 
The hospital clinics are used for open access for patients from the primary health care. In Nuuk a large health care centre has 
combined functions as medical clinic, emergency room and primary health care with doctors and nurses. The settlements have 
nursing stations (supervised by doctors via phone or telemedicine and doctors visiting three to four times a year). Medication 
on prescription is free of charge. Patients with specific/serious diseases that can not be treated at Dronning Ingrids Hospital 
are transferred to Denmark or Iceland for further treatment (e.g. hemodialysis, cancer treatment, brain surgery etc.).  
Neisseria gonorrhoeae: Gonorrhoea has been a major health challenge in Greenland for several decades. In 2015, 1.582 
new cases of gonorrhoea were reported in Greenland, corresponding to an incidence of 2.825 per 100.000 inhabitants. Ten 
years ago, in 2005 the incidence was markedly lower (915 per 100.000 inhabitants) so this sexually transmitted infection is 
an increasing problem in Greenland. In Denmark and other European countries resistance to ciprofloxacin in Neisseria gonor-
rhoeae isolates increased rapidly more than fifteen years ago and treatment of gonorrhoea has therefore changed to ceftriax-
one and, more recently, to ceftriaxone with azithromycin for infections with unknown susceptibility pattern. This increase in 
quinolone resistance was not seen in Greenland until recently. The first reports of ciprofloxacin-resistant N. gonorrhoeae came 
in the beginning of 2014 with an overall resistance rate of 31% for 2014 increasing to 55.9% in 2015. Resistance to ceftriax-
one in gonococci has not yet been seen in Greenland.
Since 2011 the diagnosis of gonorrhoea in Greenland has been performed on urine samples with nucleic acid amplification 
tests (NAATs) and all hospitals/health care clinics in Greenland submit their NAATs to The Central Laboratory at Dronning 
Ingrids Hospital in Nuuk. This test is fast and automated, and the number of individuals tested increased from 17.000 in 2010 
to 19.000 in 2015. However, it does not allow antimicrobial susceptibility testing. 
Surveillance for antimicrobial resistance in gonococci is performed at the Primary Health Care Center in Nuuk where efforts 
are made to achieve samples for culture of N. gonorrhoeae from all NAAT positive men. Due to logistic difficulties in getting 
samples to Nuuk for culture, surveillance of antimicrobial resistance is not performed routinely outside of Nuuk. 
The sudden increase in resistance to ciprofloxacin led to a change in the treatment regimen. Whereas ciprofloxacin was the 
first line treatment of gonorrhoea until October 2014 the treatment regimen was changed to a single dose of 500 mg ceftri-
axone intramuscularly in combination with 2 g azithromycin orally, in accordance with the recently updated European guide-
line on this topic.
Resistant bacteria: From 2004 to 2015, 22 patients have been diagnosed with methicillin-resistant Staphylococcus aureus 
(MRSA), 70 patients with ESBL-producing Enterobacteriaceae, one patient with vancomycin-resistant enterococci (VRE), and 
47 out of 119 patients with Clostridium difficile infection had the 027 type. 
The number of patients with MRSA has increased during this last year due to outbreaks with two different strains of MRSA 
in two towns. In Aasiaat there was an outbreak during the late 2014 to 2015 consisting of seven persons (four children and 
three adults) with the same MRSA-strain not previously seen in Greenland. Six of the seven persons were from the same fam-
ily and one child was from the same kindergarten as two of the other children and found by the screening of all 70 children 
and employees in the kindergarten. The first child diagnosed with MRSA had a clinical middle-ear-infection. All the others 
were only colonized with MRSA (nose or throat or both). It is still a mystery where this MRSA-strain (t902 CC22) came from 
because this strain has not yet been seen in Denmark and none of the family members have been travelling or admitted to 
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hospitals abroad. The other outbreak consisted of two persons (a couple) in Maniitsoq and the husband was a cancer-patient 
who was treated for a long period of time in a Danish hospital. When the patient was referred back to Maniitsoq Hospital he 
had a wound infection with MRSA (t002 CC5) and his wife became colonized in the nose with the same strain. Close family 
contacts and a few nurses were examined for MRSA but none of these had MRSA. Both outbreaks illustrates the fact that 
MRSA is mainly spread by close contact in families, and rarely to other contacts  in the community.
In spite of outbreaks in Denmark with VRE, so far only one patient has been diagnosed with VRE in Greenland. This was a five-
months-old child being colonized in the rectum with VRE after admission to a Danish hospital. The mother of the child and other 
close family members were examined but none of these were colonized with VRE and no transmission was seen at the ward.
Most of the other resistant bacteria were imported from Denmark or abroad, but in some cases, especially in patients with 
ESBL-producing Enterobacteriaceae, treatment with broad-spectrum antimicrobial agents in Greenland has probably selected 
for these bacteria. Since 2011, there has been an increasing problem with C. difficile infections (mainly type 027) in the hos-
pitals, and transmission within the country has occurred. A project focusing on identification of risk factors for acquisition of C. 
difficile infections, mapping of C. difficile types and prevention strategies will be performed in the future. 
Consumption of antimicrobial agents:  All antimicrobial agents in Greenland are purchased and disseminated from the 
National Pharmacy. Figure 1 shows the total purchase of selected antimicrobial agents in DDD per 1,000 inhabitants per day 
(DID) from 2007 to 2015. From 2007–2013, an increase of narrow-spectrum (18%) and broad-spectrum penicillins (12%) has 
been seen, but from 2013 to 2014 a decrease of 23% and 4%, respectively, has occurred. An increase was seen again from 
2014 to 2015 of 31% and 28%, respectively. From 2014 to 2015 a minor increase in broad-spectrum antimicrobial agents 
such as macrolides (5%), tetracyclines (6%), and cephalosporins (7%) has been seen. Meropenem increased 36% whereas 
fluoroquinolones decreased 34% from 2014 to 2015. The largest increases from 2014 to 2015 were seen in piperacillin-tazo-
bactam (81.5%), and in gentamicin (500%). 
Conclusion: The consumption data for antimicrobial agents are based on purchases and fluctuations are therefore seen from 
year to year. However, as a result of the increased focus on prescription of antibiotics (especially at Dronning Ingrids Hospi-
tal, where teaching on prescription and antibiotic audits are performed on a yearly basis) a continued increase in purchase of 
piperacillin-tazobactam has been seen. A remarkable increase was also seen for gentamicin. Due to the change in treatment of 
gonorrhoea a decrease in purchase of fluoroquinolones was seen. It is – however - a bit worrying that the purchase of merope-
nem has increased again after a decrease last year. 
Continued focus in Greenland on the use of broad-spectrum antimicrobial agents - both in hospitals and in primary health care 
- and on the incidence of sexually transmitted infections, e.g. gonorrhoea, as well as on multiresistant bacteria is very impor-
tant in the future.
Anne Kjerulf, Jette Holt, Anne Birgitte Jensen, Sine Berntsen, Michael Lynge Pedersen, Jørgen Skov Jensen, Peter Poulsen, Inge Mortensen 
For further information: Anne Kjerulf (alf@ssi.dk)
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Figure 1. Consumption of selected antimicrobial agents in humans in Greenland (DDD/1,000 inhabitants/day) 2007–2015: (a) 
consumption of narrow- and broad-spectrum penicillins, macrolides and tetracyclines; and (b) consumption of cephalosporins, 
meropenem, fluoroquinolones, piperacillin/tazobactam and gentamicin. (Note: Narrow-spectrum penicillins include 
benzylpenicillin, phenoxymethylpenicillin and dicloxacillin, and broad-spectrum penicillins include ampicillin, pivampicillin, 
amoxicillin and amoxicillin with enzyme inhibitor). 
0,0
1,0
2,0
3,0
4,0
5,0
6,0
7,0
8,0
2007 2008 2009 2010 2011 2012 2013 2014 2015
D
D
D
/1
00
0 
in
ha
bi
ta
nt
 d
ay
s
Consumption of selected antimicrobial agents in humans in Greenland (DDD/1,000 inhabitants/day) 2007 – 2015: consumption of 
narrow- and broad-spectrum penicillins, macrolides and tetracyclines
Penicillins (narrow-spectrum)
Penicillins (broad -spectrum)
Macrolides
Tetracyclines
0,0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
2007 2008 2009 2010 2011 2012 2013 2014 2015
D
D
D
/1
00
0 
in
ha
bi
ta
nt
 d
ay
s
Consumption of selected antimicrobial agents in humans in Greenland (DDD/1,000 inhabitants/day) 2007 – 2015: consumption of 
cephalosporins, meropenem, fluoroquinolones, piperacillin/tazobactam and gentamicin 
Cephalosporins
Meropenem
Fluoroquinolones
Piperacillin/tazobactam
Gentamicin
DANMAP 2015
DANMAP 2015
DANMAP 201564
ANTIMICROBIAL CONSUMPTION IN HUMANS5.
Textbox 5.2
Continuous focus on antimicrobial resistance and usage  
of antimicrobials in the Faroe Islands
 
Background: The Faroe Islands (FI) consists of 18 islands, inhabited by approx. 49,000 inhabitants, 19,000 of whom live in 
the capital Tórshavn. The main hospital (Landssjúkrahúsið, LS, with 170 beds) is located in Tórshavn, and there are two smaller 
hospitals in Klaksvik (36 beds) and Súðuroy (26 beds). The healthcare system is comparable to the Danish healthcare system 
with general practitioners responsible for primary care and secondary care provided by the hospital. LS has a local as well as 
a centralized function. In the case of specified diseases, patients are referred to hospitals in Denmark or other foreign hospi-
tals. The healthcare staff constitutes a stable workforce but consultants, mainly from Denmark, perform specialized treatment 
where the number of patients is too small to support full-time specialist employment.
Data and data sources. Data for antimicrobial consumption for FI and for LS were supplied by the Chief Pharmaceutical Of-
fice. Data on MRSA and other resistant bacteria were obtained from LS, as were bed-days; the latter were derived from another 
administrative source than earlier, which is the reason why hospital data in this report only go as far back as 2011 and are not 
fully consistent with data supplied in Danmap reports 2012 and 2013.
Resistant microorganisms. Since the first case of MRSA in 2004, a total of 47 cases of MRSA have been identified (27 with 
infection and 20 carriers). From 2006–2015, 46 ESBL-producing Enterobacteriaceae (Escherichia coli and Klebsiella pneumoniae) 
have been detected. Since April 2015, vancomycin-resistant enterococci (VRE) have been an increasing problem – especially at LS.
Study of VRE in the FI and antibiotic usage. A retrospective case-control study was performed consisting of 247 patients 
divided into VRE-negative (n=168) and VRE-positive (n=79). The aim of the study was to determine if the use of broad- and/
or narrow-spectrum antibiotics influenced the risk of being colonized with VRE. Data regarding patients’ VRE status (positive vs 
negative), the use of antibiotics two calendar months prior to a positive- or negative rectal swab, administration time, gender 
and age were collected. The data regarding antibiotics usage were divided into two groups consisting of broad- and narrow-
spectrum antibiotics and were measured in how many days the patients were exposed to antimicrobial agents. The length of 
administration of antibiotics was named antibiotic pressure. Acquisition of VRE colonization was effected by broad- and/or 
narrow-spectrum antibiotics. The VRE-positive patients had received significantly more antibiotics in several of the antibiotic 
classes, 2 calendar months prior to a positive swab test. 
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Figure 1.   Consumption of selected antibiotics (narrow and broad-spectrum) at LS 2011-15 (DDD/100 bed-days)
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Data from this study were provided by the following authors: H. Djurhuus, A. E. Lisberg, M. Stegger, W. Smith, and S. Gaini.
Antimicrobial consumption at LS. Total antimicrobial consumption was 50.11 DDD/100 bed-days (DBD), similar to the use in 
2014 but representing a 24.5 % increase compared to 2013. Of particular concern in 2015 is a further increase in the use of 
three broad-spectrum antimicrobials: Cefuroxim (9 % increase compared to 2014 and 33 % compared to 2013), ciprofloxacin 
(4 % increase compared to 2014 and 36 % compared to 2013), and meropenem (61 % increase compared to 2014 and 162 % 
compared to 2013), especially in the light of the current VRE prevalence. See details in figure 1 and 2. 
It is, however, noteworthy to see that the use of mecillinams is increasing. Although still at a low level due to an earlier ban 
(1.32 DBD in 2015), it increased by 59 % compared to 2014 and 214 % compared to 2013. Besides, the use of penicillinase-
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Figure 2. Consumption of ciprofloxacin and mecillinams LS (hospital, DBD) and P (primary healthcare, DID)
Fig. 3. Consumption of ampicillins vs. amoxicillin w/ enzyme inhibitor LS (hospital, DBD) and P (primary healthcare, DID)
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sensitive penicillin increased in 2015 (89 % increase compared to 2014 and 119 % compared to 2013), as well as penicillin-
ase-stable penicillin (14 % increase compared to 2014 and 77 % compared to 2013). See details in Figure 1 and 2.
Another striking observation, both in hospital and primary healthcare, is the increase in the use of amoxicillin with enzyme 
inhibitor (EI), shown in Figure 3. The cause of this increase remains to be elucidated.
Antimicrobial consumption in primary healthcare. Total antimicrobial consumption in 2015 was 14.57 DDD/1,000 inhabit-
ants/day (DID) which represented an increase compared to 2014 (13.92 DID) but was similar to earlier years. Narrow-spectrum 
antimicrobials made up 55 % of the use in 2015; penicillinase-sensitive penicillin constituted 35 % of total DID. The share of 
broad-spectrum antimicrobials was 14 %, among these the use of tetracyclins has decreased since 2013 but still constitutes 
10 % of the total DID. A further development in the use of pivmecillinam and ciprofloxacin is anticipated. See details in Fig. 2 
and 4. 
Conclusion. Antimicrobial consumption is still increasing, at LS as well as in primary healthcare. Annual antibiotic audits have 
been in place since 2011. Implementation of antibiotic stewardship and increased focus on adherence to general infection 
control precautions are the next steps in the effort to reduce development and spreading of antimicrobial resistance in LS and 
in primary healthcare.
Elsebeth Tvenstrup Jensen, Anne Kjerulf, William Smith, Hjørdis Reinert, Shahin Gaini, Kjartan Mohr, Ann Winther Jensen, Niels Joensen. 
For further information: etj@ssi.dk
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6. Resistance in zoonotic bacteria
Zoonoses are infectious diseases that can be transmitted be-
tween animals and humans, either through direct contact with 
animals or indirectly by contaminated food. Zoonotic bacteria, 
such as Salmonella and Campylobacter, can develop resistance 
towards antimicrobial agents, which subsequently may lead 
to limited treatment possibilities or even treatment failure of 
human infectious diseases. The development and spread of an-
timicrobial resistance is multi-factorial and can happen in many 
ways, including antimicrobial treatment of animals and humans, 
transfer of genes between bacteria or spread of very persistent 
and strong survivor strains carrying resistance genes. 
A more detailed description of the trends and sources of 
zoonoses in Denmark and of national surveillance and control 
programmes can be found in the Annual Report on Zoonoses in 
Denmark 2015 [www.food.dtu.dk].
Zoonotic bacteria (Salmonella Typhimurium, Salmonella Enter-
itidis, Campylobacter jejuni and Campylobacter coli) have been 
included in the DANMAP programme since 1995, where iso-
lates were recovered for susceptibility testing in samples from 
broilers, cattle and pigs as well as from human cases. Sampling 
of fresh meat was initiated from 1997.
6.1 Salmonella
Salmonella is the second most important zoonotic bacterial 
pathogen in Denmark and can have a severe impact on both ani-
mal production and human health [Annual Report on Zoonoses 
in Denmark 2015]. 
In Denmark and the rest of the Europe, S. Enteritidis and S. 
Typhimurium are the serotypes most frequently found to be 
associated with human illness. Human cases caused by  
S. Enteritidis are most commonly associated with the con-
sumption of contaminated eggs or poultry meat, whereas S. 
Typhimurium cases are mostly associated with the consump-
tion of contaminated pork, beef or poultry meat.
Salmonella isolates for DANMAP 2015 were derived from 
national surveillance and control programmes. Pig isolates 
originate from slaughterhouses, where representative samples 
of healthy pigs (caecum samples) and pork (carcass swabs) 
are sampled each year. Salmonellosis is a notifiable disease 
and isolates from all reported human S. Typhimurium cases are 
susceptibility tested. Only one isolate per farm, meat sample 
or human case was included. For details see Chapter 9, Materi-
als and Methods.
Salmonella from domestic broilers, layers and cattle as well as 
some other types of meat including imports are also monitored 
in Denmark each year. However, they do not contribute to 
DANMAP 2015, as only few isolates were found and thus, fall 
below the inclusion threshold for DANMAP of 15 isolates per 
population.  These data are however reported to EFSA, and are 
included in the European Union summary report on antimicro-
bial resistance in zoonotic and indicator bacteria from humans, 
animals and food in 2015.
The DANMAP report primarily presented resistance among S. 
Typhimurium. Resistance in all Salmonella serotypes detected 
    Highlights: The occurrence of monophasic Salmonella Typhimurium, which are often multi-
resistant, has increased in pigs, pork and among isolates from human infections over the 
past decade leading to the current high levels of resistance to ampicillin, sulfonamide and 
tetracycline (50-80%). Previously, human cases associated with travel had significantly 
higher levels of resistance compared to domestic cases; however in 2015 the monophasic 
clone resulted in similar levels of resistance for many antimicrobial agents. An exception be-
ing resistance to quinolones that was higher among isolates from the travel-related human 
cases. As a result of pig producers’  highly restrictive use of antibiotics critical for human 
treatment, fluoroquinolone (ciprofloxacin) resistance has been absent from S. Typhimurium 
from pigs and domestically produced pork for several years. Resistance to 3rd generation 
cephalosporins and carbapenems have remained very low in S. Typhimurium from domestic 
cases and absent among the Salmonella isolates from Danish pigs and pork.
  Over the last 15 years, resistance to fluoroquinolone and tetracycline has slowly increased 
among Campylobacter jejuni from broilers; however most isolates remain fully sensitive.  
The level of fluoroquinolone resistance in Campylobacter jejuni continues to be higher 
among isolates from imported broiler meat compared with isolates from Danish broilers.
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by the national control programme for pigs and Danish pork 
is however presented for 2011 and onwards; the year when 
Denmark started to susceptibility test all serotypes according 
to EU legislation.
In DANMAP, S. Typhimurium includes the monophasic variants 
with antigenic formulas S. 4, [5],12:i:- as recommended by the 
European Food Safety Authority [EFSA journal 2010. 8(10): 
1826]. In the text, the term generic S. Typhimurium refers to 
results on isolates of the non-monophasic variants only.
In 2014 the panel for susceptibility testing was changed to 
follow the recommendations of EFSA by excluding apramycin, 
ceftiofur, florfenicol, neomycin, streptomycin and spectino-
mycin and including ceftazidime, meropenem and tigecycline 
instead. 
MIC distributions for isolates from pigs, pork and humans are 
presented in the web annex (Tables A6.1 - A6.5).
6.1.1 Salmonella in pigs and domestically produced pork 
– all serotypes
In total, 803 samples from pigs caeca (pigs) and 15,905 pig 
carcass swabs (pork) yielded 217 Salmonella isolates tested 
for antimicrobial resistance.
As in the previous years, S. Typhimurium (including the mono-
phasic variants) and S. Derby were the most common sero-
types isolated from Danish pigs and pork in 2015; representing 
92% of all the isolates (Figure 6.1). The majority of S. Derby 
isolates from Danish pigs and pork were fully sensitive to all 
antimicrobial agents tested in opposition to S. Typhimurium, 
where only 15% of isolates exhibited full sensitivity. The 
serotype distribution has remained fairly constant in Denmark 
in many years suggesting a stable endemic situation for Sal-
monella serotypes in the pig population with no rare outbreak 
Antimicrobial agent Pigs Pork
Danish 
%
Danish  
%
Tetracycline 40 31
Tigecycline 0 0
Chloramphenicol 6 5
Ampicillin 33 36
Cefotaxime 0 0
Ceftazidime 0 0
Meropenem 0 0
Trimethoprim 10 10
Sulfonamide 36 38
Azithromycin 1 1
Gentamicin 4 0
Ciprofloxacin 1 0
Nalidixic acid 1 0
Colistin 0 0
Number of isolates 139 36
Table 6.1. Resistance (%) among Salmonella isolates  
(all serotypes) from pigs and pork, Denmark DANMAP 2015
Figure 6.1. Relative distribution (%) of Salmonella serotypes from pigs and Danish pork, Denmark    
The number of isolates varies between years (pigs: n = 139-402, Danish pork: n = 60-148). Before 2011, not all serotypes
were susepctibility tested. Number of isolates included each year is presented i the parentheses.
0
10
20
30
40
50
60
70
80
90
100
2011 2012 2013 2014 2015 2011 2012 2013 2014 2015
(340) (374) (402) (173) (139) (148) (120) (148) (60) (78)
Pe
rc
en
t 
Derby 4,[5],12:i:- Typhimurium Infantis Livingstone London Other serovar Not typeable
Pigs Pork
Danish
0
10
20
30
40
50
60
2011 2012 2013 2014 2015 2011 2012 2013 2014 2015
(340) (374) (402) (173) (139) (148) (120) (148) (60) (156)
%
 r
es
is
ta
nt
 i
so
la
te
s
Ampicillin Streptomycin Sulfonamide Tetracycline Trimethoprim
Pigs Pork
Danish
DANMAP 2015
DANMAP 201570
RESISTANCE IN ZOONOTIC BACTERIA6.
strains in 2015. Furthermore, the serotype distribution in the 
Danish pork is similar to the distribution among isolates from 
pigs suggesting that Salmonella usually arrives at the slaugh-
terhouse with the live pigs rather than reside in the slaughter 
houses.
Resistance to at least one antimicrobial agent was found in 
68 (49%) of the isolates from pigs and in 39 (50%) of isolates 
from pork. As in the previous years, the highest levels of resis-
tance were found to ampicillin, sulfonamide and tetracycline 
(Table 6.1). Among the resistant isolates, isolates were primar-
ily co-resistant to ampicillin, sulfonamide and tetracycline 
(ASuT resistance profile) with further resistance up to three 
more antibiotics. 
The level of resistance to tetracycline was lower in 2015 than 
in 2014 in isolates from pigs and pork, but no significant dif-
ference was observed among changes in resistance to other 
antimicrobial agents (Figure 6.2). 
None of the Salmonella isolates from pigs or pork were 
resistant to cephalosporins (cefotaxime and ceftazidime) or 
carbapenems (meropenem).   
Even though S. Derby is very common among pigs, only few 
human S. Derby cases (N = 13) were reported in Denmark in 
2015 [www.ssi.dk]. The majority of the S. Derby isolates from 
pigs were fully sensitive (72%) or resistant to tetracycline only 
(17%, data not presented), and the overall occurrences of resis-
tance among S. Derby in pigs and Danish pork were lower than 
observed among the S. Typhimurium isolates only. Quinolone 
resistance was found in two S. Derby isolates; one resistant to 
nalidixic acid and one to ciprofloxacin. The quinolone resis-
tance was also additional to an ASuT-profile in both isolates. 
Figure 6.2. Resistance (%) in all Salmonella serotypes from pigs and Danish pork, Denmark    
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Antimicrobial 
agent
Pigs Pork Human cases
Danish
%
Danish
%
Domestically 
acquired
% 
Travel  
abroad 
reported
%
Total
%
Tetracycline 66 50 55 74 61
Tigecycline 0 0 2 3 2
Chloramphenicol 11 8 12 24 16
Ampicillin 74 72 65 67 64
Cefotaxime 0 0 2 14 6
Ceftazidime 0 0 2 11 5
Meropenem 0 0 0 0 0
Trimethoprim 19 17 14 11 13
Sulfonamide 83 72 66 76 68
Azithromycin 2 3 0 3 1
Gentamicin 8 0 1 11 3
Ciprofloxacin 0 0 2 20 7
Nalidixic acid 0 0 2 8 3
Colistin 0 0 2 2 2
Number of 
isolates
53 36 129 66 231
Table 6.2. Resistance (%) among Salmonella Typhimurium(a) 
isolates from pigs, Danish pork and human cases(b), Denmark 
a) Include isolates verified as monophasic variants of S. Typhimurium 
with antigenic formulas S. 4,[5],12:i:- 
b) An isolate was categorised as ‘domestic’ if the patient did not travel 
outside Denmark one week prior to the onset of the disease
DANMAP 2015
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6.1.2 S. Typhimurium in pigs, domestically produced and 
imported pork
A total of 89 S. Typhimurium (including monophasic strains) 
were isolated from Danish pigs and pork.  Of these 27 were 
generic Typhimurium and 62 monophasic, which continued 
the historic increasing trend of the proportion of monophasic 
isolates, illustrating the spread of these novel serotypes.
The level of fully sensitive S. Typhimurium isolates in both pig 
and pork in 2015 remained similar to the level in 2014 (17% 
and 20%, respectively). No important differences in resistance 
levels were found between S. Typhimurium isolates from pig 
and pork (Table 6.2) and resistance to the tested antimicrobial 
agents was similar to levels reported in 2014. 
As in the previous years, the highest resistance levels were 
observed to ampicillin, tetracycline and sulfamethoxazole.  
The occurrence of ASuT multi-resistance has been increasing 
among S. Typhimurium from pigs since 2010, partly due to 
an increase in the occurrence of the monophasic variants of 
S. Typhimurium, which often carry the ASuT multi-resistance 
(Figure 6.3). This year 63% of the monophasic isolates carried 
ASuT mostly in combination with resistance to one or more 
antibiotics, whereas the ASuT- profile only was seen in 32% of 
the generic Typhimurium isolates. The increasing occurrence 
of multi-resistant monophasic S. 4,[5],12:i:- is also happen-
ing in Europe [Hopkins et al. 2010. Eurosurveillance 3:1]. 
This illustrates how spread of antimicrobial resistance among 
Salmonella can be highly influenced by the spread a multi-
resistant clones highlighting the multifactorial causes of global 
antibiotic resistance. 
Tetracyclines, beta-lactamase sensitive penicillins, pleuromutil-
ins and macrolides (mainly Tylosin and Tilmicosin) are the main 
antimicrobial agents used for weaners and pigs in Denmark 
(Figure 4.4). The use of tetracycline and to some extent 
macrolides increased from 2004 to 2009, where after the 
consumption was reduced over the following years. However 
these changes in usages of tetracycline and macrolides is not 
reflected in the observed levels of resistance in S. Typhimurium 
from pigs and domestically produced pork (Figure 6.3) – as the 
trends is dominated by the increasing occurrence of monophasic 
S. 4,[5],12:i:- clones.
None of the S. Typhimurium isolates from pigs or pork were re-
sistant to quinolones (ciprofloxacin or nalidixic acid), cephalo-
sporins (cefotaxime and ceftazidime) or carbapenems (merope-
nem); and the use of flouroquinolones and cephalosporins in 
the Danish pig production has been very low for at last decade 
(web annex , Table A4.2) . Two S. Typhimurium (one of these 
monophasic) isolates were resistant to azithromycin (assuming 
the cutoff MIC>16), one originating from live pigs and one from 
pork. In both cases, the isolates also carried an ASuT-profile.
6.1.3 Salmonella in humans
In 2015, Salmonella continued to be the second most frequent 
cause of bacterial intestinal infections in Denmark. A total of 
925 human laboratory-confirmed cases of salmonellosis was 
reported (16.3 cases per 100,000 inhabitants). The most com-
mon serotypes were S. Typhimurium (including the monophasic 
variants) and S. Enteritidis with 4.1 and 4.6 cases per 100,000 
inhabitants, respectively [Annual report on Zoonoses in Den-
mark 2015]. 
6.1.4 S. Typhimurium in humans
S. Typhimurium, including the monophasic variants, was the 
second most common serotype among the human cases (233 
cases), S. Enteritidis being the most common (259 cases).The 
monophasic variants represented half the S. Typhimurium 
cases (117 monophasic versus 116 generic Typhimurium). 
Available isolates were susceptibility tested (n = 231).
Information on travel history was collected through phone 
interviews, and among the reported human S. Typhimurium 
isolates included in DANMAP 2015, 29% of the cases were 
categorised as travel associated, whereas 56% most likely had 
acquired their infection in Denmark (Table 6.2). In 2015, only 
one outbreak with the monophasic variant of S. Typhimurium 
was detected and only 6 human cases were considered 
‘outbreak-related’. In contrast to previous years, domestically 
acquired human cases includes sporadic as well as out-break 
related cases (Table 6.2).  
Again this year, high levels of resistance to ampicillin, sulfon-
amide, and tetracycline were observed. Resistance to ampicil-
lin was observed at the same level (65-67%) among isolates 
from domestic and travel-associated cases (Table 6.2). For 
domestically acquired cases the level of ampicillin resistance 
had increased significantly from 2014 to 2015 (from 54% to 
65%). Resistance to sulfonamide and tetracycline increased 
significantly in travel associated cases from 2014 to 2015, 
where 76% and 74% were resistant in 2015 respectively. 
Overall, 48% of all S. Typhimurium isolates carried the ASuT 
multi-resistance profile (n = 112) alone or in combination with 
other antimicrobials. Comparison with previous years showed 
that the proportion of isolates resistant to these antimicrobial 
agents have stabilised at this fairly high level. The level of 
resistance to trimethoprim increased in domestically acquired 
cases from 2014 to 2015 (6% to 14%, including both sporadic 
and outbreak related cases) reaching the same level as for 
travel-associated cases (11% in 2015).
There is a tendency for higher levels of resistance among 
travel-associated isolates compared with domestic infections 
in 2015. Both ciprofloxacin and nalidixic acid resistance were 
higher in isolates from travel-related cases (20% and 8% 
respectively) compared with isolates from domestic cases 
(2% for both antibiotics). Resistance to both tetracycline and 
gentamicin were also significantly higher in travel-associated 
cases (74% and 11% respectively) when compared to do-
mestically acquired cases (55% and 1% respectively). Finally, 
resistance to chloramphenicol increased significantly in both 
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Figure 6.3. Resistance (%) in Salmonella Typhimurium in(a) pigs, pork and human cases(b), Denmark DANMAP 2015
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domestically and travel associated cases from 2014 and 2015 
and resistance to chloramphenicol in the travel associated 
cases (24%) were also significantly higher in 2015 when 
compared to the domestically acquired cases (12%).  
Regarding resistance to antimicrobial agents critical for 
treatment of human infections, resistance to 3rd generation 
cephalosporins (cefotaxime and/or ceftazidime) was found in 
11 S. Typhimurium isolates (5% of cases); from 8 travel-related 
cases and 3 domestic cases. The resistance being significantly 
higher in isolates from travel-related cases (12%) when com-
pared to isolates from domestic cases (2%). 
Among all S. Typhimurium isolates tested between 2002 
and 2015, there is a decline in resistance to all antimicrobi-
als tested in the years 2008 and 2009 (Figure 6.3). Starting 
in 2008 we had one of the largest outbreaks ever seen in 
Denmark that ran for two years. The outbreak was caused by a 
fully sensitive S. Typhimurium clone and therefore has a huge 
impact on the trend graph. Resistance to spectomycin, chlor-
amphenicol and florfenicol has declined between 2002 and 
2015, due to a general decline of the S. Typhimurium DT104 
clone holding resistance to these antimicrobials. Resistance 
to ampicillin, sulfonamide, streptomycin and tetracycline are 
generally high over the 14 year period as the declining DT104 
clone was replaced by a new emerging variant of monophasic 
S. Typhimurium; both clones possessing resistance to ampicil-
lin, sulfonamide, streptomycin and tetracycline.
Johanne Ellis-Iversen, Helle Korsgaard and Mia Torpdahl
6.2 Campylobacter
Thermotolerant Campylobacter are the most commonly re-
ported causes of gastrointestinal bacterial infections in humans 
in Denmark as well as in the European Union [EU Summary 
Report 2014, ECDC/EFSA 2015]. The species most commonly 
associated with human infections is C. jejuni, but other species 
may also cause infections. In Denmark, 85-95% of the human 
campylobacteriosis cases are caused by C. jejuni.
Campylobacter are widespread in nature and the most impor-
tant reservoirs are the alimentary tract of wild and domesti-
cated birds and mammals. Among sporadic human cases, broilers 
have been identified as the primary source of infection, though 
other sources also exist, e.g. water from untreated water 
sources and other infected animals.
For Campylobacter, DANMAP 2015 includes randomly col-
lected isolates from broilers and cattle at slaughter (cae-
cum samples) and from broiler meat ready for retail (meat 
samples). Campylobacteriosis is a notifiable disease, however 
only a random selection of isolates from reported human C. 
jejuni cases are susceptibility tested. Only one isolate per 
farm, meat sample or human case was included. For details 
see Chapter 9, Materials and Methods.
In 2014 the panel for susceptibility testing was changed to fol-
low the recommendations of EFSA by excluding chlorampheni-
col. MIC distributions for C. jejuni from broilers and cattle, broiler 
meat and humans are presented in the web annex (Tables A6.6 
- A6.8).
6.2.1 C. jejuni in broilers and domestically produced 
broiler meat
A total of 286 samples from broilers and domestically pro-
duced meat resulted in 83 C. jejuni isolates, which were tested 
for antimicrobial resistance. This was much lower than the 191 
isolates in 2014 where monitoring of poultry was mandatory 
in the EU. 
The level of fully sensitive C. jejuni isolates in both broilers and 
Danish broiler meat in 2015 (Table 6.3) remained similar to 
2014 (68% and 74%, respectively). Among the resistant iso-
lates, resistance to ciprofloxacin and nalidixic acid is dominant 
(21 of 24 isolates, in total). For both broilers and Danish broiler 
meat, resistance levels in C. jejuni isolates were comparable to 
2014. 
However, over the last 15 years the proportion of isolates from 
Danish broilers fully sensitive to the six antimicrobial agents 
included in the current test panel has decreased from around 
90%, as a result of an increase in resistance to tetracycline and 
quinolones (Figure 6.4) - following the trend in Europe even 
though at a slower rate [EU Summary Report 2014, ECDC/EFSA 
2015]. 
From 2002 to 2011, a steady increase in resistance to cipro-
floxacin was observed in C. jejuni isolates from broilers and 
Danish broiler meat; even after 2009 where the poultry indus-
try stopped using fluoroquinolones in the broiler production. 
However, during the last five years, resistance to ciprofloxacin 
has fluctuated reaching 27% in 2015 (Figure 6.4). The EU 
average 2014-level of ciprofloxacin and tetracycline resistance 
among C. jejuni from broiler was 66% and 54%, respectively 
[EU Summary Report 2014, ECDC/EFSA 2015].
In contrast to the overall increasing occurrence of quinolone 
resistant C. jejuni isolates from broilers, the increase has 
discontinued for tetracycline resistance over the last two 
years (Figure 6.4). The consumption of antimicrobial agents 
in Danish broilers is generally low, but tetracycline has 
been one of the most commonly used antimicrobial agents 
in Danish broilers over the last decade.  Consumption of 
tetracyclines, sulphonamide/trimethoprim, aminoglycosides 
and lincosamides increased considerably in 2015 due an 
increased occurrence of E. coli or other infections, associ-
ated with high mortality and increased health problems in 
the affected flocks. However, this is not reflected in the 
resistance patterns in C. jenuni isolates from broilers or 
broiler meat in contrast to increased resistance in indicator 
E. coli (Figure 7.3).
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As in most of Europe, resistance to macrolides (erythromycin), 
aminoglycosides (gentamicin and streptomycin) and chloram-
phenicol have remained at a very low level. 
6.2.2 C. jejuni from imported broiler meat
As in previous years, the levels of resistance quinolones (79%) 
and tetracycline (56%) in imported poultry meat (N=62) were 
higher than the levels of observed in isolates from domesti-
cally produced broilers (Table 6.3). 
Most of the imported broiler meat tested originated from 
EU Member States, and the trends in resistance among the 
DANMAP isolates reflect the general increase in resistance 
to tetracycline and quinolones (Figure 6.4). Interestingly, the 
decline in tetracycline resistance observed among the isolates 
from Danish broilers is also observed among the isolates from 
imported broiler meat (from 80% in 2013 to 56% in 2015).
6.2.3 C. jejuni in cattle
A total of 138 Campylobacter spp. isolates were derived from 
183 cattle ceaca from all of Denmark, and a total of 101 C. 
jejuni isolates were susceptibility tested. 
Most of the isolates (68%) were fully sensitive to the six 
antimicrobials included in the test panel, and the remaining 
isolates were resistant to quinolones (25%) and/or tetracycline 
(12%). One isolates were resistant to streptomycin only (Table 
6.3).
Over the last 15 years the proportion of fully sensitive isolates 
has varied between 66% and 95%. From 2004 to 2005 resis-
tance to quinolones increased from 2% to 32%, however only 
27 isolates were tested in 2005 (Figure 6.5). Despite contin-
ued low consumption of fluoroquinolones in cattle, resistance 
to fluoroquinolones (ciprofloxacin) among C. jejuni from cattle, 
resistance levels varied between 16% and 22% from 2006 to 
2014. Initially, quinolone-resistant C. jejuni isolates came from 
cattle farms in Southern Jutland, but has now spread to other 
parts of Denmark. 
Most years, resistance to tetracycline has been below 5%. In C. 
jejuni from cattle, however, tetracycline resistance increased 
from 2014 to 2015, reaching the highest level of tetracycline 
resistance reported in C. jejuni from Danish cattle since 2002 
(Figure 6.5). This is not a reflection of an increase in the use of 
tetracyklines in cattle, which remained at the same level as in 
2014. 
6.2.4 C. jejuni in humans
In 2015, Campylobacter continued as the most frequent cause 
of bacterial intestinal infections in Denmark. A total of 4,348 
human laboratory confirmed cases of campylobacteriosis were 
reported (77 per 100,000 inhabitants) [Annual report on Zoo-
noses in Denmark 2015].
A random selection of the Campylobacter isolated from stool 
samples in three of five geographical regions were submitted 
to SSI for species identification and susceptibility testing. In 
2015,  188 C. jejuni isolates were susceptibility tested. 
Information on travel history was collected through phone in-
terviews, and among the tested isolates, 23% were from travel-
associated cases and 77% were domestically acquired.  Among 
the domestically acquired infections, 54% were fully sensitive 
to all the antimicrobial agents tested, while the percentage of 
fully sensitive isolates was much lower among isolates from 
travel associated cases (9%). The occurrence of resistance to 
ciprofloxacin and tetracycline continued to be significantly 
higher in travel associated C. jejuni isolates (79% and 72%, 
respectively) compared to isolates from domestically acquired 
infections (42% and 23%, respectively) (Table 6.3).
Among the resistant isolates, most were resistant to ciproflox-
acin and nalidixic acid often in combination with tetracycline 
Cattle Broilers Broiler meat Humans
Antimicrobial agent
Danish
%
Danish
%
Danish
%
Import
%
Domestically 
acquired
%
Travel  
abroad
%
Total
%
Tetracycline 12 11 10 56 23 72 34
Erythromycin 0 0 3 5 4 2 4
Streptomycin 1 2 5 8 4 7 5
Gentamicin 0 0 0 0 1 5 2
Ciprofloxacin 25 27 23 79 42 79 51
Nalidixic acid 25 23 23 76 42 79 51
Number of isolates 101 44 39 62 145 43 188
Table 6.3. Resistance (%) in Campylobacter jejuni isolates from animals, meat of Danish  
and imported origin and human cases(a), Denmark
a) An isolate is categorised as ‘domestic sporadic’ if the patient did not travel outside Denmark one week prior to the onset of disease
DANMAP 2015
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Figure 6.4. Resistance (%) in Campylobacter jenuni from broilers and broiler meat, Denmark DANMAP 2015
Note: Number of isolates included each year is presented i the parentesis. The '-' indicate data for application of 2015 cut-offs not availeble or  
less than 25 isolates were included.          
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(26 of 43 among domestic cases and 30 of 61 travel associ-
ated cases). All isolates resistant to gentamicin (four in total) 
were multi-resistant, two were acquired domestically and two 
were travel related. Seven isolates were found resistant to 
erythromycin, all in combination with at least one other anti-
microbial agent, six were acquired domestically and one was 
from a travel associated case.  
Among all isolates tested from 2004-2015 resistance to 
chloramphenicol did almost not exist, and only 1% of the 
tested isolates were found resistant in three separate years. 
Resistance to erythromycin and gentamicin were below 5% 
and streptomycin resistance was below 10%; resistance in 
all isolates tested for these three antimicrobials were quite 
stable over the 12 years included. Resistance to ciprofloxa-
cin, nalidixic acid and tetracycline is fluctuating over the 12 
years with a slight increasing tendency. For ciprofloxacin and 
nalidixic acid, the percentage of resistant isolates seen were 
from 32% to 54% with an average of 44% and tetracycline 
resistance was seen in 19% to 42% of the isolates tested 
with an average of 29% (Figure 6.6).
Johanne Ellis-Iversen, Helle Korsgaard and Mia Torpdahl
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Figure 6.5. Resistance (%) in Campylobacter jejuni from cattle, Denmark 
Note: Number of isolates included each year is presented i the parentesis. The '-' indicate data for application of 2015 cut-offs not availeble or  
less than 25 isolates were included
DANMAP 2015
DANMAP 2015
Note: Number of isolates included each year is presented i the parentesis. The '-' indicate data for application of 2015 cut-offs not availeble or  
less than 25 isolates were included.
a) Includes all suscptabilty tested isolates irrespectively of known origin . 
Figure 6.6. Resistance (%) in Campylobacter jejuni from human cases(a), Denmark   
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Textbox 6.1
Resistance in bacteria from diagnostic submissions from pigs
 
Surveillance of antimicrobial resistance in veterinary pathogens is important as support for practicing veterinarians in prescrib-
ing effective drugs for treatment. Since 2013, the DANMAP report has not presented data on antimicrobial resistance from 
diagnostic submissions from animals, unlike SVEDRES and NORM-VET. This has mainly been due to lack of availability of iso-
lates. Most routine diagnostic services on production animals take place at private, commercial laboratories, with no or limited 
tradition for storing bacterial isolates for research or surveillance. 
However, in 2015 the Danish Veterinary and Food Administration set aside resources to initiate an investigation of specified 
organisms from production animals. The focus in 2015 was on bacteria from pigs. Isolates and MIC data were obtained from 
SEGES, The Danish Pig Research Centre’s Laboratory for Pig Diseases (VSP) in Kjellerup. Escherichia coli O149, Streptococcus 
suis, and Actinobacillus pleuropneumoniae are among the most important pathogenic bacteria in pigs and were analysed for 
antimicrobial resistance. 
The antimicrobial susceptibility testing was carried out using the broth dilution method with SensiTitre. The clinical break-
points are a combination of Clinical and Laboratory Standards Institute (CLSI) breakpoints if available, and those routinely used 
at VSP Kjellerup and DTU – Vet.
E. coli O149
Enterotoxigenic E. coli (ETEC) is a major cause of diarrhoea in pigs and  E. coli containing the haemolytic, F4 fimbria and 
enterotoxin producing serotype O149 are the most virulent for pigs. Although systematic vaccination and breeding against 
resistance to the F4 fimbria has somewhat reduced the problems with this type in the first weeks after birth as well as post 
weaning, it remains the most prevalent type of ETEC in Danish pigs. Percent resistant isolates are shown in Table 1. Resis-
tance levels are high for ampicillin, sulphonamides, streptomycin, and tetracyclines (ASSuT – resistance pattern also known 
from Salmonella), but also for spectinomycin and trimethoprim. This was not unexpected as similar resistance levels were also 
recorded in 2012 and the preceding 10 years (DANMAP 2012, p.104). An increase in the number of isolates resistant to flor-
fenicol compared to 2012 is not statistically significant, but considering the increase in use of florfenicol in recent years, this 
development may be relevant to follow. Two isolates were resistant to ceftiofur (3rd generation cephalosporin), and these two 
isolates were also the only isolates that were resistant to amoxicillin with clavulanic acid and cefotaxime, strongly suggesting 
that these isolates were ESBL. Resistance to nalidixic acid was recorded in 11 % of the isolates although quinolones have not 
been used for pigs since 2002. Notably, no isolates were resistant to colistin. 
Streptococcus suis
Streptococcus suis is the cause of a plethora of infections in pigs, such as meningitis, arthritis, pneumonia, and septicaemia, 
and causes losses to the farmers due to increased mortality and veterinary costs. Percent resistant isolates are shown in Table 
1. Most notably, no isolates were resistant to simple penicillin. Resistance was highest to macrolides and tetracyclines, but low 
or zero for most other compounds.
Actinobacillus pleuropneumoniae
Actinobacillus pleuropneumonia is the cause of a severe pleuropneumonia in pigs. This disease has a rapid onset in pig farms 
and spreads through the farm. Symptoms include fever, coughing, depression, loss of appetite, bloody discharge from the 
nose, and pathological findings include fibrinous pleuritis and pericarditis and haemorrhagic and necrotizing pneumonia. A 
rapid diagnosis and initiation of proper treatment is essential. Fortunately, there is little resistance to this organism, and apart 
from erythromycin, resistance was zero of very low to all other compounds (Table 1). Notably, all isolates were susceptible to 
simple penicillin, although this is a Gram negative organism. Most of the isolates belonged to the serotypes O2 and O6, but no 
difference in resistance patterns was recorded between serotypes.
In 2016 the AMR surveillance is extended to include bacteria from cattle, poultry, mink.
Karl Pedersen, Desireé Corvera Kløve Lassen, Birgitta Svensmark, Sven Erik Jorsal 
For further information: Karl Pedersen, kape@vet.dtu.dk
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continued ... Textbox 6.1
Antimicrobial agent E coli  
O149 
%
Actinobacillus 
pleuropneumoniae 
%
Streptococcus  
suis 
%
Tetracycline 64 0 47
Chloramphenicol 29 - 0
Florfenicol 10 0 0
Ampicillin 40 0 -
Penicillin - 0 0
Amoxicillin/clavulanic acid 4 - -
Ceftiofur 4 0 -
Trimethoprim 51 - 2
Sulfonamide 70 - 19
Sulfa-trimethoprim - 0 0
Erythromycin - 100 67
Streptomycin 65 - 47
Gentamicin 2 - 0
Neomycin 6 - -
Apramycin 2 - -
Tulathromycin - ND -
Tilmicosin - 3 -
Ciprofloxacin 0 0 0
Nalidixic acid 11 - -
Colistin 0 - -
Tiamulin - 0 19
Spectinomycin 45 0 26
Number of isolates 53 70 43
Table 1. Resistance (%) among clinical isolates from pigs, Denmark   
Note: Some of the E. coli 149 isolates were not tested for Chloramphenicol (n=45), Florfenicol (n=52), Ampicillin (n=52), Amoxicillin/clavulanic 
acid (n=45), Trimethoprim (n=51), Streptomycin (n=52), Apramycin (n=48), Ciprofloxacin (n=52) and Nalidixic acid (n=46). Proportion of 
tulathromycin resistant isolates is not calculated (ND)   
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Enterococci are included in the DANMAP programme to monitor 
resistance in Gram-positive bacteria, while Escherichia coli are 
included as representatives of Gram-negative bacteria. In the 
early 90ties, focus was especially on resistance in Gram-posi-
tive bacteria, since most growth promotors used then targeted 
Gram-positive bacteria. The chosen bacteria species were se-
lected as indicators for occurrence of antimicrobial resistance 
in the different reservoirs through the food chain for several 
reasons: they are ubiquitous and present as major commensals 
in both the animal and human reservoirs; they can acquire an-
timicrobial resistance as a response to selective pressures, and 
finally they have the potential for transferring resistance to 
pathogenic bacteria and can cause infection in humans. From 
enterococci, both Enterococcus faecium and Enterococcus fae-
calis were used due to natural resistance to used antimicrobial 
agents such as flavomycin and streptogramins and observed 
differences in levels of resistance.
7. Resistance in indicator bacteria
    Highlights: Resistance to tetracycline and erythromycin was observed at moderate to high 
levels in Enterococcus faecalis from Danish broilers and pigs as well as in meat thereof. 
During the last years, resistance levels in enterococci isolated from domestically produced 
broiler meat has increased and now approaches resistance levels found in imported meat. 
From 2014 to 2015, tetracycline resistance among enterococci from domestically produced 
broiler meat increased; an increase that is probably related to the increased use of tetracy-
cline in the poultry production. For E. faecalis from pigs, levels of resistance to tetracycline, 
erythromycin and gentamicin has been declining to levels equal to or lower than 15 years 
ago. Resistance levels have consistently been lower in E. faecalis from domestically pro-
duced pork compared to isolates from the Danish pigs. Resistance to tetracycline is also 
lower in E. faecalis from domestically produced pork compared with isolates from imported 
pork. 
  Most of the Enterococcus faecium from domestically produced beef and broiler meat, as 
well as from imported beef, were fully sensitive to all antimicrobial agents included in the 
test panel.  Resistance to tetracycline, ampicillin, erythromycin and ciprofloxacin was lower 
in E. faecium from domestically produced broiler meat compared with isolates from imported 
broiler meat.
  The occurrence of resistance to ampicillin, tetracycline, sulfonamides and trimethoprim 
increased significantly in indicator Escherichia coli from broilers compared to 2014. This 
is most likely linked to the increased use of antimicrobial agents in the broiler production. In 
E. coli from Danish broilers, pigs and meat thereof, approximately half of the isolates exhib-
ited resistance to at least one of the antimicrobial agents tested, while the proportion of 
antimicrobial resistant isolates was remarkably low in isolates from Danish cattle and beef. 
As in previous years, proportions of antimicrobial resistant E. coli were generally higher in 
imported meat than in domestically produced meat independent of the meat type (broiler 
meat, pork, beef).
  Third-generation cephalosporin-resistant (ESBL/AmpC) E. coli were observed in pigs, 
cattle and meat thereof. The occurrence in pigs was higher than in 2009-2013, mainly due 
to a high frequency of samples containing E. coli with AmpC upregulation. We consider that 
the changes in methodology implemented in 2015 may have had an important impact on 
the observed results.
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E. faecalis, E. faecium and E. coli have been included in the 
DANMAP programme since 1995, where isolates were recov-
ered for susceptibility testing in samples from broilers, cattle 
and pigs. Sampling of fresh meat was initiated from 1997. 
Indicator enterococci and E. coli from healthy humans was col-
lected from 2002 to 2005.  Results from surveys of ESBL-pro-
ducing bacteria from animals and meat have been presented in 
DANMAP reports since 2006-2007.
7.1 Enterococci
For enterococci, DANMAP 2015 includes randomly collected 
Enterococcus faecalis isolates from healthy pigs (caecum 
samples) and E. faecalis and E. faecium from domestically 
produced and imported broiler meat, pork and beef sold at 
wholesale and retail outlets (meat samples). Only one isolate 
per farm or meat sample was included. For details on method-
ology, see Chapter 9, Materials and Methods.
In 2014, the panel for susceptibility testing was changed to 
follow the recommendations of EFSA by excluding kanamycin, 
penicillin, salinomycin and streptomycin, but including dapto-
mycin. 
MIC distributions for E. faecium and E. faecalis from animals 
and meat are presented in the web annex (Tables A7.1 – A7.3).
7.1.1 E. faecalis from domestically produced broiler meat 
From a total of 217 samples of domestically produced broiler 
meat, 48 E. faecalis isolates was recovered and tested for anti-
microbial resistance (Table 7.1). Enterococci were not collected 
from broilers in 2015. 
As in 2014, approximately half of the E. faecalis isolates from 
domestically produced broiler meat were fully sensitive to 
the antimicrobial agents included in the test panel (not includ-
ing quinupristin/dalfopristin).  Among the resistant isolates all 
were tetracycline-resistant, representing a significant increase 
compared to 2014 (48% versus 35% of all isolates). Increasing 
resistance levels were observed for several bacterial species 
isolated from Danish broilers and broiler meat in 2015, and 
may likely be related to the increase in usage of antimicrobial 
agents for broilers in 2015 (Table 4.1). Resistance to tetracy-
cline and erythromycin in E. faecalis from Danish broilers and 
broiler meat has increased over the last five years; reaching 
levels for isolates from domestically produced broiler meat 
similar to what was observed in 2002-2004 (Figure 7.1). 
There are no data to verify if the increase in resistance levels 
in Danish broilers continued in 2015.
However, none of the E. faecalis isolates from domestically 
produced broiler meat were resistant to fluoroquinolones or 
vancomycin in 2015, and resistance levels to these antimicro-
bial agents among E. faecalis from Danish broilers and meat 
hereof, has been close to zero for the last 15 years.
7.1.2 E. faecalis from pigs and domestically  
produced pork
A total of 703 samples from pigs and domestically produced 
pork resulted in 160 E. faecalis isolates, which were tested for 
antimicrobial resistance.
Generally, the level of resistance is higher in E. faecalis from 
pigs compared to isolates from broilers.  In 2015, the level of 
E. faecalis isolates from pigs that were fully sensitive to the 
antimicrobial agents included in the test panel (not including 
quinupristin/dalfopristin) was slightly higher than observed in 
2014 (25% versus 15%).   
As in previous years, most of isolates from pigs were resis-
tant to tetracycline and resistance to erythromycin was also 
Antimicrobial agent Broiler meat Beef Pigs Pork
Danish 
%
Imported 
%
Danish 
%
Imported 
%
Danish 
%
Danish 
%
Imported 
%
Tetracycline 48 58 12 22 72 14 44
Tigecycline 0 0 0 0 0 0 0
Chloramphenicol 2 0 0 2 15 4 0
Ampicillin 0 0 0 0 0 0 0
Erythromycin 25 33 2 2 35 6 11
Gentamicin 0 1 0 0 10 2 4
Ciprofloxacin 0 5 0 0 0 0 0
Vancomycin 0 0 0 0 0 0 0
Teicoplanin 0 0 0 0 0 0 0
Linezolid 0 0 2 0 0 0 0
Daptomycin 0 0 0 0 0 0 0
Number of isolates 48 78 57 59 40 120 27
Table 7.1. Resistance (%) among Enterococcus faecalis from animals and meat of Danish and imported origin, Denmark DANMAP 2015
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common (Figure 7.2). Most of the isolates were resistant 
to erythromycin, chloramphenicol and/or gentamicin (3 of 
4 isolates) was also resistant to tetracycline. The levels of 
resistance were comparable with those from 2014, and re-
sistance levels have generally been very stable over the last 
15 years. An exception to this is resistance to erythromycin, 
which slowly increased until 2012, where after the resis-
tance declined reaching levels equal to what was observed in 
2001 (Figure 7.2). 
Resistance to tetracycline, chloramphenicol, erythromycin and 
gentamicin in E. faecalis from domestically produced pork 
was significantly lower than in the isolates from pigs. The 
majority (86%) of the isolates from pork were fully sensitive 
to the tested antimicrobial agents (not including quinupristin/
dalfopristin).  These differences in resistance levels between 
isolates from Danish pigs and domestically produced pork 
have been apparent since the start of the DANMAP monitor-
ing programme (Figure 7.2); however no explanation has been 
documented.
7.1.3 E. faecalis from domestically produced beef
From a total of 132 samples of domestically produced beef, 57 
E. faecalis isolates was recovered and tested for antimicrobial 
resistance (Table 7.1). Enterococci were not collected from 
cattle in 2015. 
In E. faecalis from domestically produced beef, most of the 
isolates (88%) were fully sensitive to the antimicrobial agents 
included in the test panel (not including quinupristin/dalfopris-
tin). All resistant isolates (n=7) were resistant to tetracycline, 
and one of these isolates was also resistant to erythromycin 
and linezolid (Table 7.1). Levels of antimicrobial resistances 
were similar to those from 2014.
7.1.4 E. faecalis from imported meat
During 2015, a total of 164 E. faecalis isolates, from 345 
processed samples from imported broiler meat, pork and beef, 
were tested for antimicrobial resistance (Table 7.1).  
The proportion of isolates fully sensitive to the tested anti-
microbial agents (not including quinupristin/dalfopristin) were 
lower among E. faecalis from imported broiler meat (38%), pork 
(55%) and beef (78%) compared to the isolates from domesti-
cally produced meat. 
Generally, the levels of resistance observed in E. faecalis 
from imported meat were comparable to 2014. Resistance to 
tetracycline and co-resistance to tetracycline and erythromycin 
was most commonly observed (Table 7.1). Among all E. faecalis 
tested, ciprofloxacin resistance was only detected in isolates 
from imported boiler meat (n = 4).
Previously, higher levels of resistance to tetracycline, erythro-
mycin and streptomycin (as well as several other compounds) 
have been observed in E. faecalis from imported broiler meat 
compared to isolates from domestically produced broiler meat. 
However, resistance in E. faecalis from imported and domesti-
cally produced broiler meat has, in recent years, approached 
similar levels, and no significant differences were observed in 
2015 (Figure 7.1). 
Resistance to tetracycline was higher in E. faecalis from 
imported pork compared with isolates from domestically pro-
duced pork. This tendency has been observed for years (Figure 
7.2) with a small increase in levels of tetracycline resistance 
for imported pork meat.
As observed in most years, resistance levels are similar in 
E. faecalis from imported beef and domestically produced 
beef. Tetracycline resistance has only been found significantly 
higher in isolates from imported beef in 2012 and 2014.  
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Figure 7.1. Resistance (%) in Enterococcus faecalis from broilers and broiler meat, Denmark       
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Figure 7.2. Resistance (%) in Enterococcus faecalis from pigs and pork, Denmark        
   
Note: Number of isolates included each year is presented i the parentesis. The '-' indicate data for application of 2015 cut-offs not availeble or 
less than 25 isolates were included.
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7.1.5 E. faecium from domestically produced meat 
During 2015, a total of 543 processed samples from do-
mestically produced broiler meat, pork and beef resulted in 
216 E. faecium isolates, which were tested for antimicrobial 
resistance (Table 7.1).  Since only 12 E. faecium isolates were 
recovered from domestically produce pork, these data are not 
presented. 
In the E. faecium isolates from domestically produced broiler 
meat and beef, most of the isolates were fully sensitive to all 
antimicrobial agents included in the test panel (75% and 88%, 
respectively). Among the resistant isolates tetracycline and 
erythromycin resistance was most common, whereas a few 
isolates were resistant to ampicillin (n = 6 from broiler meat), 
gentamicin (n = 1 from broiler meat and beef, respectively) and 
daptomycin (n=2 from broiler meat, n = 1 from beef). Resis-
tance to quinupristin/dalfopristin and ciprofloxacin was only 
detected in broiler meat (n = 7 and n = 1, respectively) (Table 
7.1) All six ampicillin resistant isolates from broiler meat were 
also  resistant to tetracycline and erythromycin. 
The levels of tetracycline resistance in domestically produced 
broiler meat increased from 2014 to 2015 (Figure 7.3). This in-
crease is very likely linked to the general increase in the use of 
antimicrobial agents for poultry in Denmark in 2014 and 2015, 
especially increased use of tetracyclines (Table 4.1).
7.1.6 E. faecium from imported meat
During 2015, a total of 345 processed samples from imported 
broiler meat, pork and beef resulted in 103 E. faecium isolates, 
which were tested for antimicrobial resistance (Table 7.2). Only 
six E. faecium isolates were recovered from imported pork, and 
data are therefore not presented.   
Resistance levels were low among E. faecium from imported 
beef, and 79% were fully sensitive to all antimicrobial agents 
included in the test panel. Among isolates from imported 
broiler meat 37% were fully sensitive.
As in 2013 and 2014, resistance to tetracycline, ampicillin, 
erythromycin and ciprofloxacin was significantly more frequent 
in E. faecium from imported broiler meat than in isolates from 
domestically produced broiler meat (Figure 7.3). Overall, 10% 
of the E. faecium isolates from imported broiler meat were 
resistant to more than three tested antimicrobials; all but one 
were resistant to tetracycline, erythromycin and ampicillin. 
In isolates from imported beef, one isolate was resistant to 
tetracycline, erythromycin and ampicillin. When comparing data 
from 2014 and 2015, only resistance levels to erythromycin in 
imported broiler meat decreased significantly.
Lars Bogø Jensen and Helle Korsgaard
Table 7.2. Resistance (%) among Enterococcus faecium from 
meat of Danish and imported origin, Denmark
Antimicrobial agent Broiler meat Beef
Danish 
%
Imported 
%
Danish 
%
Imported 
%
Tetracycline 22 49 8 17
Tigecycline 0 0 0 0
Chloramphenicol 0 0 0 0
Ampicillin 3 12 0 4
Erythromycin 11 32 4 8
Quinupristin/dalfopristin 4 4 0 0
Gentamicin 1 0 4 0
Ciprofloxacin 1 5 0 0
Vancomycin 0 0 0 0
Teicoplanin 0 0 0 0
Linezolid 0 0 0 0
Daptomycin 1 0 4 4
Number of isolates 180 73 24 24
DANMAP 2015
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Figure 7.3. Resistance (%) in Enterococcus faecium from broilers and broiler meat, Denmark 
Note: Number of isolates included each year is presented i the parentesis. The '-' indicate data for application of 2015 cut-offs not availeble or 
less than 25 isolates were included.
87DANMAP 2015
7.RESISTANCE IN INDICATOR BACTERIA
7.2 Indicator  Escherichia coli 
For indicator E. coli, DANMAP 2015 includes randomly collected 
isolates from healthy pigs, broilers and cattle at slaughter (cae-
cum samples) and from domestically produced and imported 
broiler meat, pork and beef sold at wholesale and retail outlets 
(meat samples). Only one isolate per farm or meat sample was 
included. For details on methodology, see Chapter 9, Materials 
and Methods.
In 2014 the panel for antimicrobial susceptibility testing was 
changed to follow the recommendations of EFSA by excluding 
apramycin, ceftiofur, florfenicol, neomycin, streptomycin and 
spectinomycin and replacing them with ceftazidime, merope-
nem and tigecycline. The MIC distributions and occurrence of 
resistance among indicator E. coli are presented in the web 
annex (Tables A7.4 and A7.5). 
7.2.1 Indicator E. coli from broilers and domestically 
produced broiler meat
A total of 396 processed samples from broilers and domesti-
cally produced meat resulted in 309 E. coli isolates, which were 
tested for antimicrobial resistance. The number of isolates was 
much lower compared to previous years as, according to the EU 
legislation, antimicrobial susceptibility testing of E. coli isolates 
from chickens was not mandatory in 2015. 
Approximately half (56%) of indicator E. coli isolates from 
broilers were susceptible to all antimicrobials tested. High 
occurrence of resistance was detected towards ampicillin, tet-
racyclines, trimethoprim and sulfonamides, low occurrence of 
resistance was detected towards quinolones (Table 7.3). The 
most common co-resistance profiles were resistance to ampicil-
lin and sulfonamides in combination with trimethoprim alone 
(n=9) and with trimethoprim and tetracyclines (n=7).  
Fluoroquinolone resistance was observed in eight isolates 
from broilers and in five (62%) of these isolates, fluoroqui-
nolone resistance was exhibited together with resistance to 
other antimicrobials (ampicillin, azithromycin, chloramphenicol, 
gentamicin, sulfonamides, tetracyclines and trimethoprim in 
various combinations). Occurrence of fluoroquinolone-resistant 
E. coli was significantly higher in broilers compared to pigs and 
cattle.
No resistance to cefotaxime, ceftazidime, colistin, meropenem 
and tigecycline was detected in isolates from broilers (Table 
7.3). Nevertheless, by using a pre-enrichment procedure, 
cefotaxime-resistant E. coli were detected, as reported in 
Textbox 7.1.
Compared to 2014, a significant increase in resistance to 
ampicillin, tetracyclines, trimethoprim and sulfonamides was 
observed. These are the highest proportions of isolates resis-
tant to ampicillin, tetracyclines and sulfonamides detected in 
DANMAP since 2001 (Figure 7.4), whereas the proportion of 
isolates resistant to trimethoprim was the highest detected in 
DANMAP since 2007 (data not presented). Due to changes in 
the range of tested trimethoprim concentrations, trimethoprim 
data of earlier DANMAP iterations cannot be used for compari-
son.
The use of antimicrobial agents increased considerably in 
2014 and 2015 due to E. coli or other infections in a large 
number of broiler flocks, thus it appears that the occurrence of 
antimicrobial resistance generally correlates with antimicrobial 
use. The use of tetracyclines, penicillins (other), sulfonamides 
and trimethoprim has increased steadily in broilers since 2012, 
whereas increase in the use of penicillins (b-lactamase sensi-
tive), aminoglycosides and lincosamides was observed since 
2014 (Section 4.3). Fluoroquinolones have not been used in 
the Danish broiler production from 2010 to 2014, and were 
used in very small amounts in 2015, which likely explains 
the low occurrence of fluoroquinolone resistance detected. 
Similarly, very low occurrence of chloramphenicol resistance is 
likely linked to limited use of amphenicols since 2010.
Among E. coli isolates from Danish broiler meat, the occur-
rence of susceptibility and resistance paralleled that observed 
in broilers. Thus, 54% of isolates were susceptible to all antimi-
crobials, and high proportions of isolates showed resistance to-
wards ampicillin, tetracyclines, trimethoprim and sulfonamides. 
Low occurrence of resistance was detected towards quino-
lones and very low occurrence of resistance was detected 
towards cefotaxime (0.4%), gentamicin and chloramphenicol 
(Table 7.3). No resistance to azithromycin, ceftazidime, colistin, 
meropenem and tigecycline was detected. 
The proportion of broiler meat isolates susceptible to all an-
timicrobials diminished compared to 2014, when it was 70%. 
The occurrence of resistance towards ampicillin, tetracyclines 
and trimethoprim was significantly higher than that observed 
in domestically produced broiler meat in 2014 (Figure 7.4). 
Overall, in 2015, the occurrence of resistance to the different 
antimicrobial agents for which data are available over time, 
were the highest observed since 2004, with the notable 
exception of 3rd generation cephalosporins, for which the 
highest occurrence of resistance was observed in 2011 and 
has been decreasing since then (Figure 7.4).
7.2.2. Indicator E. coli from pigs and domestically 
produced pork
During 2015, processing of a total of 403 samples from pigs 
and domestically produced meat resulted in 231 E. coli iso-
lates, which were tested for antimicrobial resistance.
Among the E. coli from pigs, high occurrence of ampicillin, 
tetracycline, trimethoprim and sulfonamide resistance was de-
tected (Table 7.3), and only 47% of the isolates were suscepti-
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Table 7.3. Resistance (%) among Escherichia coli from animals and meat of Danish and imported origin, Denmark
Broilers Broiler meat Cattle Beef Pigs Pork
 
Antimicrobial agent
Danish 
%
Danish 
%
Imported 
%
Danish 
%
Danish 
%
Imported 
%
Danish 
%
Danish 
%
Imported 
%
Tetracycline 22 21 41 9 9 11 36 25 27
Tigecycline 0 0 0 0 0 0 0 0 0
Chloramphenicol 2 3 7 6 4 8 2 0 0
Ampicillin 31 29 53 8 5 17 32 23 27
Cefotaxime 0 <1 2 1 0 3 0 0 0
Ceftazidime 0 0 2 0 0 3 0 0 0
Meropenem 0 0 0 0 0 0 0 0 0
Trimethoprim 24 23 37 6 0 6 24 18 13
Sulfonamide 28 28 39 10 7 14 36 19 27
Azithromycin 1 0 1 0 0 0 1 0 0
Gentamicin 1 1 1 1 0 3 1 0 0
Ciprofloxacin 8 7 32 0 0 6 1 0 0
Nalidixic acid 8 7 29 0 0 6 1 0 0
Colistin 0 0 1 0 0 0 1 0 0
Number of isolates 95 214 148 144 55 36 174 57 15
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ble to all tested antimicrobial agents. Among isolates display-
ing resistance to one antimicrobial agent (n = 27), tetracycline 
resistance was by far the dominant phenotype detected in 14 
(52%) isolates, whereas among the isolates resistant to more 
than one antimicrobial agent (n = 66), the most frequent phe-
notype was ampicillin, tetracycline, trimethoprim and sulfon-
amide resistance detected in 19 (29%) isolates. Resistance to 
cefotaxime, ceftazidime, meropenem and tigecycline was not 
observed (Table 7.3). Nevertheless, by using a pre-enrichment 
procedure, cefotaxime-resistant E. coli were detected, as 
reported in section 7.3 and Textbox 7.1.
The proportions of isolates resistant to ampicillin, tetracy-
clines, trimethoprim and sulfonamides remained at levels com-
parable to those observed in 2014. Ciprofloxacin and colistin 
resistances were detected in one isolate each in 2015 but 
were not observed in 2014. Although no drastic fluctuations 
over time were observed, the proportions of isolates resistant 
to ampicillin, tetracyclines and sulfonamides were among the 
highest detected in all DANMAP iterations, with the exception 
of the levels observed in 2004 (Figure 7.5). 
Among the E. coli isolates from domestically produced pork, 
63% were susceptible to all antimicrobial agents tested. High 
occurrence of resistance to ampicillin, tetracyclines, trim-
ethoprim and sulfonamides was detected, whereas resistance 
to the other tested antimicrobial agents was not observed 
(Table 7.3). The most common resistance profiles were as ob-
served among isolates from pigs: tetracycline resistance (n=7) 
and co-resistance to ampicillin, tetracyclines, trimethoprim 
and sulfonamides (n=5). Overall, occurrence of resistance was 
slightly lower in E. coli from pork than in E. coli from pigs (Table 
7.3), though this difference was statistically significant only 
for sulfonamide-resistant isolates. 
Occurrence of resistance to ampicillin, tetracyclines, trim-
ethoprim and sulfonamides declined compared to 2014 (Figure 
7.5, only statistical significant for sulfonamide). The propor-
tions of ampicillin- and tetracycline-resistant E. coli were the 
lowest observed since 2008, whereas proportions of sulfon-
amide and trimethoprim resistance were comparable to those 
observed in 2010, being in both years the lowest levels ever 
observed in DANMAP.
7.2.3 Indicator E. coli from cattle and domestically 
produced beef
During 2015, a total of 379 processed samples from cattle and 
domestically produced meat resulted in 199 E. coli isolates, 
which were tested for antimicrobial resistance.
Among E. coli from cattle, the majority of isolates (87%) were 
susceptible to all tested antimicrobial agents, and mainly 
low occurrence of resistance to ampicillin, chloramphenicol, 
sulfonamides, tetracyclines and trimethoprim was observed 
(Table 7.3). The majority of resistant isolates (17 out of 19) 
exhibited co-resistance to antimicrobials belonging to two or 
more classes, but there was no dominant resistance profile. No 
resistance to azithromycin, ceftazidime, meropenem, colistin, 
nalidixic acid, ciprofloxacin and tigecycline was observed. 
Results on occurrence of cefotaxime-resistant E. coli obtained 
by a pre-enrichment procedure are reported in section 7.3 and 
Textbox 7.1.
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Figure 7.4. Resistance (%) in Escherichia coli from broilers and broiler meat, Denmark       
   
Note: Number of isolates included each year is presented i the parentesis. The '-' indicate data for application of 2015 cut-offs not availeble or 
less than 25 isolates were included.          
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Figure 7.5. Resistance (%) in Escherichia coli from pigs and pork, Denmark         
 
Note: Number of isolates included each year is presented i the parentesis. The '-' indicate data for application of 2015 cut-offs not availeble or 
less than 25 isolates were included.          
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Figure 7.6. Resistance (%) in Escherichia coli from cattle and beef, Denmark        
  
Note: Number of isolates included each year is presented i the parentesis. The '-' indicate data for application of 2015 cut-offs not availeble or 
less than 25 isolates were included.          
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These results are in line with those observed since 2001, 
although very minor fluctuations were observed over time. 
Increasing occurrence of ampicillin and trimethoprim resistance 
was observed since 2008, whereas sulfonamide and tetracy-
cline resistance increased from 2008 to 2014 (Figure 7.6).
Also among E. coli isolates from domestically produced beef, 
most isolates (89%) were susceptible to all antimicrobials, and 
resistance paralleled that observed in cattle. Comparable low 
levels of resistance have been observed over the last 15 years 
(Figure 7.6).
7.2.4 Indicator E. coli from imported meat
During 2015, a total of 362 processed samples from imported 
broiler meat, pork and beef resulted in 199 E. coli isolates, 
which were tested for antimicrobial resistance. As in previous 
years, the levels of resistance were significantly higher in im-
ported broiler meat than in broiler meat produced in Denmark, 
a trend that is no longer apparent for Danish vs. imported pork 
(Table 7.3). 
Among the E. coli from imported broiler meat, only 29% were 
susceptible to all tested antimicrobial agents. Occurrence of 
resistance was very high for ampicillin, high for nalidixic acid, 
ciprofloxacin, sulfonamides, tetracyclines and trimethoprim, 
moderate for cefotaxime, ceftazidime and chloramphenicol, 
and low for azithromycin, colistin and gentamicin (Table 7.3). 
No resistance to tigecycline and meropenem was observed 
(Table 7.3). Ampicillin resistance was present in the majority 
of isolates displaying a multidrug resistance profile, and was 
shared among 27 antimicrobial resistance profiles. Ampicillin 
resistance was often combined with resistance to sulfon-
amides, trimethoprim and tetracyclines in various combinations 
and generally in association with resistance to additional an-
timicrobials.  Fluoroquinolone resistance was exhibited by 40 
isolates either alone (n = 7) or in combination with resistance 
to other antimicrobials. Co-resistance to ampicillin, nalidixic 
acid, ciprofloxacin, tetracycline, sulfonamides and trimethoprim 
was observed in nine (11%) isolates. 
Compared to 2014, occurrence of ampicillin, sulfonamides 
and tetracycline resistance slightly increased and occurrence 
of cefotaxime and ciprofloxacin resistance decreased (Figure 
7.4). In the period 2008-2015, the proportions of ampicillin-
resistant isolates ranged between 48% (2008) and 64% 
(2013), thus the level detected in 2015 (53%, Table 7.3) 
represented a fluctuation similar to what observed previously 
(Figure 7.4). The proportions of ciprofloxacin and tetracycline 
resistant isolates were comparable to those observed in 2008, 
being in both DANMAP iterations the lowest levels observed 
in the period 2008-2015 (Figure 7.4). The proportion of cefo-
taxime and sulfonamide resistant isolates were the lowest de-
tected in DANMAP since 2008. In section 7.3 and Textbox 7.1, 
results on occurrence of cefotaxime-resistant E. coli obtained 
by a pre-enrichment procedure are reported.
Among E. coli isolates from imported pork, 60% were 
susceptible to all tested antimicrobial agents. A high propor-
tion of isolates showed resistance to ampicillin, sulfonamides 
and tetracyclines, whereas a moderate proportion of isolates 
showed resistance to trimethoprim (Table 7.3). No resistance 
to the other antimicrobial agents was observed, however the 
number of isolates was very limited (n = 15, Table 7.3). The 
proportion of isolates susceptible to all antimicrobial agents 
increased compared to 2014 (when it was 48%) and the pro-
portion of isolates displaying resistance to any antimicrobial 
agent decreased compared to 2014 and overall was the lowest 
recorded in DANMAP since 2008 (Figure 7.5). An exception 
was resistance to 3rd generation cephalosporins for which no 
resistance was observed also in 2009-2010 and 2013-2014 
(Figure 7.5). 
The majority (81%) of E. coli isolates from imported beef 
was susceptible to all tested antimicrobial agents. Ampicillin, 
sulfonamide and tetracycline resistance occurred in a moder-
ate proportion of isolates, whereas cefotaxime, ceftazidime, 
chloramphenicol, gentamicin, nalidixic acid, ciprofloxacin 
and trimethoprim resistance occurred in a low proportion of 
isolates (Table 7.3). No resistance to azithromycin, colistin, 
meropenem and tigecycline was observed (Table 7.3). Only 
minor differences were observed compared to 2014, however 
the proportions of isolates resistant to the different antimicro-
bials were the highest (ampicillin and sulfonamides) or close 
to the highest (tetracyclines) observed in DANMAP since 2008 
(Figure 7.6).
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7.3 Extended spectrum beta-lactamase  
(ESBL)/AmpC- and carbapenemase-producing E. coli 
DANMAP 2015 includes randomly collected ESBL/AmpC E. coli 
isolates from healthy pigs and cattle at slaughter (caecum 
samples) and from domestically produced and imported broiler 
meat, pork and beef sold at wholesale and retail outlets (meat 
samples). Only one isolate per farm or meat sample was in-
cluded. Antimicrobial susceptibility testing was only performed 
on isolates from pigs, cattle and meat thereof in line with 
European Commission Decision 2013/652/EU on the monitor-
ing and reporting of antimicrobial resistance in zoonotic and 
commensal bacteria. 
The samples were collected, and isolates were recovered, 
identified and tested for antimicrobial susceptibility in 
accordance with Decision 2013/652/EU. It is important 
to note that the changes in methodology introduced by 
Decision 2013/652/EU most likely increased the recovery 
of ESBL-, AmpC- and carbapenemase-producing E. coli in 
2015. Thus, caution should be taken when evaluating the 
occurrence of ESBL/AmpC E. coli in samples from 2015 
and when comparing these data with results from previ-
ous years. For details on methodology, see Textbox 7.1 
and Chapter 9, Materials and Methods.
In E. coli, an ESBL phenotype is defined by i) resistance to 
cefotaxime or ceftazidime and ii) susceptibility to cefoxitin and 
iii) synergy with clavulanic acid (synergy being defined as a ≥ 3 
twofold concentration decrease in a MIC for either cefotaxime 
or ceftazidime tested in combination with clavulanic acid versus 
the MIC of the agent when tested alone. E.g. MIC FOT : FOT/CL 
or TAZ : TAZ/CL ratio ≥ 8). Differently, an AmpC-phenotype is 
characterized by i) resistance to cefotaxime or ceftazidime and 
ii) resistance to cefoxitin and iii) no synergy with clavulanic acid. 
A carbapenemase (CPE) phenotype is defined by resistance to 
meropenem.
The MIC distributions and occurrence of resistance among 
ESBL/AmpC E. coli are presented in the web annex (Tables 
A7.6 and A7.7). 
7.3.1. ESBL/AmpC-producing E. coli from pigs and 
domestically produced and imported pork 
Using the pre-enrichment procedure, cefotaxime-resistant 
E. coli were detected from pigs (29% of samples), domesti-
cally produced pork (2% of samples) and imported pork (2% 
of samples) (Table 7.4). The majority of isolates of domestic 
origin displayed an AmpC-phenotype, and only 12 of 82 
isolates displayed an ESBL-phenotype (Textbox 7.1 for further 
discussion). No carbapenemase phenotype was detected.
Among the ESBL/AmpC-producing E. coli isolates from pigs, 
resistance to gentamicin (n = 6) or chloramphenicol (n = 1) oc-
curred in a low proportion of isolates. Azithromycin resistance 
was observed in three isolates using the tentative cut-off of 
MIC>16 µg/ml, and no resistance to ciprofloxacin was detected 
(Table 7.4). 
A low number of ESBL/AmpC-producing E. coli isolates (n = 
4) was isolated from domestically produced pork. In these 
isolates, co-resistance patterns and levels were similar to 
those observed in ESBL/AmpC-producing E. coli from Danish 
pigs. Only one ESBL/AmpC-producing E. coli strain was isolated 
from imported pork. This isolate exhibited an ESBL pheno-
type together with resistance to ciprofloxacin, sulfonamides, 
tetracyclines and trimethoprim (Table 7.4). The carbapenemase 
phenotype was not found in either domestically produced or 
imported pork 
7.3.2 ESBL/AmpC-producing E. coli from cattle and 
domestically produced and imported beef
Using the pre-enrichment procedure, cefotaxime-resistant 
E. coli were detected from cattle (8% of samples), domesti-
cally produced beef (1% of samples) and imported beef (4% 
of samples). Half of the isolates displayed an AmpC pheno-
type, and slightly less than the remaining half of the isolates 
displayed an ESBL phenotype (Table 7.4 and Textbox 7.1 for 
further discussion). One isolate did not fall within the defini-
tions of AmpC and ESBL phenotype (other phenotypes) and no 
carbapenemase phenotype was observed.  
Among the ESBL/AmpC -producing E. coli isolates from cattle, 
co-resistance to gentamicin and chloramphenicol occurred in 
a low number of isolates, whereas co-resistance to sulfon-
amides, tetracyclines and trimethoprim was slightly more 
common (Table 7.4). None of the isolates displayed resistance 
to azithromycin, colistin, nalidixic acid, ciprofloxacin and tigecy-
cline (Table 7.4).
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Following the same trend observed for general indicator E. coli 
(Table 7.3), occurrence of resistance to sulfonamides, tetracy-
clines and trimethoprim was lower among ESBL/AmpC E. coli 
from cattle compared to ESBL/AmpC E. coli from pigs (Table 7.3 
and 7.4).
Only two ESBL-producing E. coli were isolated from domesti-
cally produced beef. Such isolates did not show resistance to 
antimicrobials other than beta-lactams (Table 7.4). No AmpC- 
and carbapenemase-producing E. coli were isolated from 
domestically produced beef.
Six ESBL- producing E. coli were isolated from imported beef 
(Table 7.4). Co-resistance to chloramphenicol (n = 1), cipro-
floxacin (n = 2) and gentamicin (n = 2) was observed in those 
isolates (Table 7.4). No AmpC- and carbapenemase-producing 
E. coli were isolated from imported beef.
All ESBL/AmpC -producing E. coli were susceptible to colistin, 
nalidixic acid and tigecycline (Table 7.4). Colistin susceptibility 
indicates that none of the isolates harboured either the newly 
discovered colistin-resistance genes (mcr-1 and mcr-2) or the 
chromosomal mutations associated with colistin resistance 
(PmrA and PmrB) [Agersø et al, 2011; Foodborne Pathog 
Dis. 9(4):367-9] [Hasman et al 2015; Euro Surveill. 20(49)] 
[Xavier et al, 2016; Euro Surveill. 21(27)]. The fact that the 
isolates from imported beef were susceptible to nalidixic acid 
and resistant to ciprofloxacin (MIC compatible with low level 
resistance) indicates presence of qnr genes [Jacoby 2005; Clin 
Infect Dis.41 Suppl 2:S120-6].
Valeria Bortolaia, Rene S. Hendriksen,  Helle Korsgaard
Table 7.4. Resistance (%) and 3rd generation cephalosporin-resistance phenotype among ESBL/AmpC-producing  
Escherichia coli from cattle, pigs and meat thereof, Denmark
Cattle Beef Pigs Pork
Danish Danish Imported Danish Danish Imported
Antimicrobial agent % % % % % %
Tetracycline 14 0 50 54 75 100
Tigecycline 0 0 0 0 0 0
Chloramphenicol 7 0 17 1 25 0
Ampicillin 100 100 100 100 100 100
Cefoxitin 57 0 0 74 50 0
Cefotaxime 100 100 100 100 100 100
Ceftazidime 93 100 100 97 100 100
Cefepime 43 100 100 37 75 100
Meropenem 0 0 0 0 0 0
Ertapenem 0 0 0 0 0 0
Imipenem 0 0 0 0 0 0
Trimethoprim 14 0 33 49 75 100
Sulfonamide 14 0 50 56 75 100
Azithromycin 0 0 0 4 0 0
Gentamicin 7 0 33 8 0 0
Ciprofloxacin 0 0 33 0 25 100
Nalidixic acid 0 0 0 0 0 0
Colistin 0 0 0 0 0 0
ESBL phenotypes 43 100 100 24 50 100
AmpC phenotypes 50 - - 74 50 -
CPE phenotypes - - - - - -
Other phenotypes 7 - - 1 - -
Number of isolates 14 2 6 78 4 1
Number of samples 180 149 166 273 239 50
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Textbox 7.1
Extended-spectrum beta-lactamase (ESBL)/AmpC- and 
carbapenemase-producing Escherichia coli from animals and meat
Background: Extended-spectrum beta-lactamase (ESBL/AmpC) -producing bacteria exhibiting resistance to 3rd generation 
cephalosporins are one of the fastest emerging resistance problems in both humans and production animals worldwide. Lately, 
several studies have found similar ESBL/AmpC genes, plasmids and clones of E. coli isolates in animals, meat and human 
infections, suggesting a zoonotic link [Vieira et al, 2011; Foodborne Pathog Dis 8(12):1295-301] [de Been et al, 2014; PLOS 
Genetics 10:12] [Börjesson et al, 2016; Emerg Infect Dis 22:634] [Hartung et al. 2016; Appl Environ Microbiol 82:4705]. Fur-
thermore, the occurrence of carbapenemase-producing Enterobacteriaceae (CPE) is an even greater threat to human medicine, 
since carbapenems are the last line antimicrobial agents for treatment of infections caused by multidrug-resistant Gram-nega-
tive bacteria. Carbapenemase-producing E. coli and Salmonella have recently been discovered in the primary production of pigs 
in Germany [Fisher et al, 2016; j.vetmic.2016.04.026, Epub ahead of print], thus it cannot be excluded that carbapenemase-
producing E. coli and Salmonella entered the German food production chain. To date, only ESBL/AmpC -producing bacteria 
have been found by the Danish surveillance of antimicrobial resistance in food and food-producing animals with no signs of 
carbapenem-resistant bacteria in either meat or food-producing animals in Denmark.
Cephalosporin and carbapenem resistance can be selected by usage of cephalosporins and/or carbapenems as well as by 
antimicrobial usage in general, through co-selection. In July 2010, the use of cephalosporins in the Danish pig production was 
discontinued, whereas it is still applied for systemic and intramammary treatment in cattle [Agersø et al, 2013; J Antimicrob 
Chemother. 68(3):569-72]. Cephalosporins have not been used in the Danish broiler production for at least a decade, but were 
used in the foreign production of grandparent animals of the Danish broilers before May 2012 [DANMAP 2012]. At present, 
carbapenems are not licensed for use in food-producing animals in Denmark or other parts of the world [EFSA Journal 2013; 
11(12):3501].
The 12th of November 2013, the European Commission issued the Implementing Decision 2013/652/EU on the monitoring 
and reporting of antimicrobial resistance in zoonotic and commensal bacteria. The decision lays down specific requirements 
regarding isolation, identification and antimicrobial susceptibility testing for monitoring ESBL-, AmpC- and carbapenemase-
producing E. coli in certain food-producing animals and meat, which should be performed according to the most recent version 
of the protocol of the European Union Reference Laboratory for Antimicrobial Resistance [www.eurl-ar.eu]. These specific 
requirements also indicate that poultry samples are monitored in even years and pigs and cattle samples in odd years.
Materials and methods: From January to December 2015, samples were collected for monitoring ESBL-, AmpC- and carbapen-
emase-producing E. coli according to the Decision 2013/652/EU. Caecal samples from pigs and cattle as well as meat samples 
of pork and beef were collected from all regions of Denmark according to the regulation. In addition, meat samples from duck 
and broiler meat were collected in relation to the national surveillance. Table 1 presents number of samples collected. For de-
tails on sampling, see chapter 9, Materials and Methods. There was no monitoring of ESBL/AmpC-producing E. coli from broilers 
in 2015.
One gram of caecal material and 25 gram of meat material were pre-enriched in 9 ml and 225 ml of non-selective peptone 
water without an antibiotic supplement, respectively, and were incubated at 37 °C for 18-22 hours. After this pre-enrichment, 
the samples were inoculated onto MacConkey agar plates supplemented with 1µg/ml cefotaxime and incubated at 44 °C for 
18-22 hours. To specifically isolate carbapenemase producing E. coli (including strains producing only OXA-48-like enzymes), 
a loop-full of 10 µl of the pre-enriched sample was inoculated onto selective agar. Colonies with the expected E. coli mor-
phology were inoculated onto non-selective agar plates and incubated at 37 °C for 18-22 hours and stored for antimicrobial 
susceptibility testing following the European Commission Implementing Decision 2013/652/EU.  
It is important to note that the changes in methodology introduced by Decision 2013/652/EU most likely increased the 
recovery of ESBL-, AmpC- and carbapenemase-producing E. coli in 2015. Thus, caution should be taken when comparing the 
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continued ... Textbox 7.1
  
occurrence of ESBL/AmpC E. coli in samples from 2015 with data from previous years. As a consequence, statistical analysis to 
describe temporal trends in occurrence of ESBL/AmpC -producing E. coli in pigs, cattle and meat thereof could not be performed.  
It is noteworthy to mention that no comparative evaluation between the two methodologies applied in 2009-2014 and 2015 
has been conducted. 
Whole genome sequencing (WGS) and in silico bioinformatics tools were used to detect the genetic background for the ESBL 
and AmpC phenotypes identified. The strains were sequenced using the Illumina Hiseq platform followed by de novo assembly 
and prediction of antimicrobial resistance genes, virulence genes, plasmid replicons and MLST using the online freely available 
in silico bioinformatics tool; Bacterial Analysis Pipeline - Batch Upload (version 1.0) from Center of Genomic Epidemiology (www.
genomicepidemiology.org; https://cge.cbs.dtu.dk//services/all.php) [Thomsen et al, 2016; PLoS One 21;11(6) :e0157718]. 
The sequences of isolates negative for all ESBL-, AmpC- and carbapenemase-encoding genes were investigated for promoter 
mutations compatible with up-regulation of chromosomal ampC expression by the use of a specific script executed via MyDb-
Finder (version 1.1, https://cge.cbs.dtu.dk//services/all.php). All genome sequences were submitted to the European Nucleotide 
Archive (ENA). 
Results: Proportion of samples from animals and meat positive for ESBL/AmpC-producing E. coli are reported in paragraph 7.3 
and only genotypic data are presented here. No carbapenemase-producing E. coli (including strains producing only OXA-48-like 
enzymes) were identified by screening the samples on selective agar.
ESBL/AmpC-producing E. coli from pigs and domestically produced and imported pork
Among the 78 ESBL/AmpC-producing E. coli isolates from pigs, five different ESBL/AmpC genes or mutations were identified. 
Table 1. Distribution (%) of ESBL/AmpC and CPE enzymes detected in Escherichia coli isolates from  
animals and meat of Danish and imported origin, Denmark
Broiler meat Ducks Cattle Beef Pigs Pork
Danish Imported Imported Danish Danish Imported Danish Danish Imported
Enzyme % % % % % % % % %
CARB-2 3 - - - - - - - -
AmpC upregulation 7 - 25 57 - - 75 40 -
CMY-2 20 39 50 - - - 2 - -
CTX-M-1 70 43 25 21 50 - 20 40 -
CTX-M-14 - - - 7 - 100 2 - -
CTX-M-15 - - - - 33 - - 20 100
CTX-M-32 - - - - 17 - - - -
CTX-M-55 - - - - - - 2 - -
SHV-2 - 4 - - - - - - -
SHV-12 - 4 - - - - - - -
TEM-52B - 4 - 14 - - - - -
TEM-84 - 4 - - - - - - -
Total number of :
Enzyme count (a) 30 23 8 14 6 2 64 5 1
ESBL/AmpC positive samples (b) 61 125 11 14 6 2 78 4 1
Meat samples tested 238 196 111 180 166 149 273 239 50
Note: Proportion of total number of enzymes. In three isolates AmpC upregulation enzymes was found as well as CTX-M-15 (Danish pork), CMY-2 
or and CARB-2 (Danish broiler meat). 
(a) Total number of enzymes present.  Each enzyme is counted based on the number of strains in which it is present and not based on the type 
(e.g. CTX-M-1 present in two strains counts as 2). 
(b) Samples were processed according to the EURL-AR laboratory protocol (October 2015), thus number of samples and number of isolate 
coincide. Whole genome sequencing was only perforemd on a selection of the presumptive ESBL/AmpC from Danish broiler meat (28 out of 60 
isolates), imported broiler meat (23 out of 125 isolates), imported duck (8 out of 11 isolates) and pigs (63 out of 78 isolates).
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The most common ESBL type was CTX-M-1 (n = 13), but CTX-M-14 (n = 1) and CTX-M-55 (n = 1) were also observed. Among the 
AmpC enzymes, CMY-2 was identified in one isolate. The occurrence of isolates producing these four enzymes is comparable to 
previous years (web annex, Table A7.8). Surprisingly, the majority (n = 48) of isolates displayed an AmpC phenotype linked to 
upregulation of chromosomal ampC expression (Table 1). The occurrence of samples containing E. coli with upregulated chromo-
somal ampC expression changed from 1% in 2013 to 18% in 2015. Monitoring from 2009 to 2013 only recovered E. coli with 
upregulation of chromosomal ampC expression in 1-4% of samples from pigs (Figure 1). 
The 13 strains producing CTX-M-1 were associated to ten different sequence types (ST); including ST23, ST75, ST88 (n = 2), 
ST101 (n = 3), ST117, ST295, ST367, ST3564, ST4373, and ST4580. The strains producing CTX-M-14, CTX-M-55, and CMY-2 
enzymes belonged to ST88, ST2952 and ST58, respectively. The upregulated AmpC’s belonged to 13 STs, where ST23 (n = 17) 
and ST88 (n = 12) (Figure 2) constituted the majority.
The ESBL/AmpC-producing E. coli strain isolated from imported pork harboured the CTX-M-15-encoding gene, whereas the 
isolates from domestically produced pork harboured genes encoding CTX-M-1 (n = 2) and CTX-M-15 (n = 1) and exhibited muta-
tions leading to upregulation of chromosomal ampC (n = 2, Table 1). Monitoring of domestically produced and imported pork has 
been performed since 2009 and in all years ESBL/AmpC-producing E. coli was observed in less than 5% of the samples, mainly in 
association with CTX-M-1 enzymes (web annex, Table A7.8) 
ESBL/AmpC-producing E. coli from cattle and domestically produced and imported beef
Among the 14 sequenced ESBL/AmpC-producing E. coli isolates from cattle, three ESBL types were detected, and each strain 
produced one enzyme only. Most of the strains (n = 8) displayed an upregulation of chromosomal ampC and belonged to five 
STs: ST441 (n = 3), ST392 (n = 2), ST155, ST56, and ST1611 (Table 1, Figure 2). The remaining six strains displayed CTX-M-1 
(n = 3)-, CTX-M-14 (n = 1)-, and TEM-52B (n = 2)-encoding genes. The three strains harbouring the CTX-M-1-encoding gene 
belonged to three MLSTs: ST58, ST362, and ST647. The two TEM-52B-producing strains belonged to ST10 (Figure 2). 
ESBL/AmpC-producing E. coli from domestically produced and imported broiler meat
In 2015, whole genome sequencing was only performed on a selection of the presumptive ESBL/AmpC isolates from domestic-
produced broiler meat. A total of 28 out of 61 isolates were sequenced. Among these isolates, four ESBL/AmpC types were 
detected and two isolates produced two enzymes simultaneously (Table 1). A total of 23 out of 125 isolates from imported 
broiler meat were sequenced. Six ESBL/AmpC variants were detected, and each strain produced one enzyme only. Therefore, 
proportions of samples containing ESBL/AmpC -producing E. coli could not be calculated for Figure 1.
From 2009 to 2011, a significant increase in AmpC-producing E. coli was observed in the domestic-produced broiler meat (Fig-
ure 1). However, after discontinuation of the use of 3rd generation cephalosporins in grandparent animals exported to the Dan-
ish broiler production, the occurrence of AmpC-producing E. coli in broiler meat significantly decreased [DANMAP 2014]. As in 
2014, the ESBL/AmpC phenotype in isolates from domestic-produced broiler meat was mainly linked to CTX-M-1 (n = 21, Table 
1) and, in only a few isolates, to CMY-2 (n = 6).
The CTX-M-1-encoding gene was linked to 10 STs; ST10, ST88 (n = 5), ST752 (n = 5), ST162, ST295 (n = 2), ST770, ST1147, 
ST1640, ST4980 (n = 3), and an unknown ST. CMY-2-encoding genes and upregulation of chromosomal ampC expression were 
observed in strains belonging to ST38, ST101, ST154, ST2309 and unknown STs (Figure 2). The CARB-2-encoding gene was 
detected in three isolates from domestic-produced broiler meat belonging to ST101. In 2014, most of the ESBL/AmpC -produc-
ing E. coli from domestically produced broiler meat belonged to ST752 (n=7) and ST181 (n=3), and mainly harboured the CTX-M-
1-producing gene [DANMAP 2014].
CTX-M-1-encoding gene was detected in 43% (n = 10) of the ESBL/AmpC -producing E. coli from imported broiler meat, and all 
these strains exhibited different MLSTs except for two strains belonging to ST752. The remaining MLSTs were: ST117, ST602, 
ST1431, ST1640, ST2070, ST2197, ST4243, and one unknown ST (Figure 2). Interestingly, ST752 was also represented among 
strains harbouring the CTX-M-1-encoding gene from Danish broiler meat. Four MLSTs were associated with the remaining ESBLs 
detected in imported broiler meat: ST115 (SHV-12), ST69 (SHV-2), ST2607 (TEM-52B), and ST10 (TEM-84) (Table 1). The nine 
AmpC-producing strains from imported broiler meat (all CMY-2 producers) belonged to seven STs; ST23, ST117, ST131 (n = 2), 
ST354 (n = 2), ST355, ST665, and ST2040 (Figure 2). In 2014, ESBL/AmpC-producing E. coli from imported broiler meat also 
belonged to a multitude of different STs, mainly associated to genes encoding CTX-M-1 and CMY-2 enzymes [DANMAP 2014].
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continued ... Textbox 7.1
Conclusion: In 2015, changes in the methodology for detection of ESBL/AmpC -producing E. coli were enforced by EU to enhance 
the sensitivity of the detection method. In the previous studies, ESBL/AmpC-producing E. coli were recovered from 1 g caecal and 
5 g meat after selective enrichment in MacConkey broth with ceftriaxone (1 μg/ml). Due to the change in methodology, comparing 
results over years to assess temporal trends should be done with great caution. Unfortunately, no comparative evaluation between 
past and present methodologies was conducted to assess the effect inferred by the change in methodologies. 
No of carbapenem-resistant bacteria was observed in the samples from meat or food-producing animals, and the overall proportions 
of the samples positive for ESBL / AmpC were similar to the levels detected in previous years from all sources - except for pigs. 
The observed level of ESBL/AmpC -producing E. coli in pigs, however, was higher than in previous years. The increase was 
linked to high occurrence of E. coli with upregulation of chromosomal ampC expression not previously observed among pigs. 
This increase might have been caused by the changes in methodology enforced by EU to enhance the sensitivity of the detec-
tion method. Theoretically, increased consumption of antimicrobials may also contribute to an increased occurrence of AmpC-
producing E. coli among Danish pigs. However, this does not seem to be the case, since the total antimicrobial use for weaners 
and finishers has declined over the last five years, and consumption of fluoroquinolones and cephalosporins, described as a risk 
factor for carriage of ESBL/AmpC -producing E. coli in humans, has been very low for more than a decade.
Similar to previous years, ESBL/AmpC -producing E. coli was only isolated from a few samples of domestically produced and 
imported pork and beef. The occurrence of ESBL/AmpC -producing E. coli from cattle was also relatively low.  Only a subset of 
presumptive ESBL/AmpC-producing isolates from domestically produced and imported broiler meat was investigated (by WGS) in 
2015, thus calculation of distribution of ESBL/AmpC types among samples cannot be compared with previous DANMAP itera-
tions. Nevertheless, CTX-M-1 was by far the most common ESBL enzyme in E. coli from Danish broiler meat, and only a few 
isolates produced CMY-2.
Rene S. Hendriksen, Valeria Bortolaia, Helle Korsgaard 
For further information: Rene S. Hendriksen, rshe@food.dtu.dk
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Figure 1. Occurrence (%) of samples with Escherichia coli from broiler meat, cattle and pigs containing ESBL and AmpC enzymes, Denmark 
Note: Isolates recovered by the selective enrichment methods (See previous DANMAP reports). Distribution is based on WGS data, and feacal 
samples were collected from pigs and cattel between 2009 and 2013. During the period 2009-2014, E. coli isolates containing ESBL or AmpC 
enzymes were recoved from none or less than 2% of the samples of beef (ESBL enzymes, n=7) and pork (ESBL enzymes, n=23; AmpC enzymes, 
n=2). Data from 2015 is not included in the figure, as the selective enrichment methods was changed [EURL-AR laboratory protocol, October 2015] 
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Figure 2. Distribution (%) of ESBL, AmpC and CPE enzymes in Escherichia coli MLST types in isolates from  
pigs, cattle and broiler meat, Denmark         
Note: Isolates recovered by the selective enrichment methods described in the EURL-AR laboratory protocol (October 2015). Whole genome 
sequencing was applied ESBL/AmpC suspect isolates from cattle (14 isolates),  pigs (63 isolates, recovering 64 enzymes), Danish broiler meat 
(28 isolates, recovering 30 enzymes) and imported broiler meat (23 isolates)
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Indicator bacteria from humans – historical review
Escherichia coli as indicator of resistance in humans
In some of the years since the DANMAP programme was established, indicator E. coli were collected from either rectal swabs 
or faecal samples from different groups of people, theoretically exposed to different resistant bacteria through their work, or 
as representatives of the “normal” healthy Danish population. In 1997, 50 isolates from 60 pig producers, 41 isolates from 58 
abattoir workers, 50 isolates from 57 nurses and 88 isolates from 112 army recruits were susceptibility tested. In 2008, again 
a collection of 75 E. coli isolates from 84 army recruits was tested. In the five-year period from 2002 to 2006, a surveillance 
of stool samples from healthy human volunteers in the community was conducted (NorMat). Subjects selected for participation 
were found through the Danish Civil Register system (CPR) with a selection algorithm based on the age and gender distribution 
of the total Danish population (DANMAP 2002, Appendix 1). In total 48 to 111 E. coli isolates from 57 to 125 human volunteers 
were tested.
Textbox7.2
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Figure 1. Resistance (%) to ampicillin, ciprofloxacin, gentamicin and 3rd generation cephalosporins in human E. coli  
clinical isolates and from the intestinal flora of different population groups
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Note: Ciprofloxacin resistance was not observed in E. coli from recruits, abattoir workers and nurses in 1997 or in E. coli from healthy human 
volunteers from the community in 2004. Gentamicin resistance was not observed in E. coli from recruits, abattoir workers and pig producers 
in 1997 or in E. coli from healthy human volunteers from the community in 2002, 2003 and 2004. None of the E. coli from healthy volunteers 
(2002-2006) were resistant to 3rd generation cephlosporins. E. coli from recruits, pig producers, abattoir workers and nurses were not tested 
towards 3rd generation cephalosporin susceptibility in 1997          
 
0
1
2
3
4
5
6
7
8
9
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
%
 r
es
is
ta
nt
 i
so
la
te
s
3rd generation cephalosporins
0
2
4
6
8
10
12
14
16
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
%
 r
es
is
ta
nt
 i
so
la
te
s
Ciprofloxacin
0
1
2
3
4
5
6
7
8
9
19 7 19 8 19 20 20 1 20 2 20 3 20 4 20 5 20 6 20 7 20 8 20 9 2010 2011 2012 2013 2014 2015
%
 r
es
is
ta
nt
 i
so
la
te
s
3rd generation cephalosporins
0
2
4
6
8
10
12
14
16
19 7 19 8 19 20 20 1 20 2 20 3 20 4 20 5 20 6 20 7 20 8 20 9 2010 2011 2012 2013 2014 2015
%
 r
es
is
ta
nt
 i
so
la
te
s
Ciprofloxacin
DANMAP 2015
Figure 1 presents the resistance data from these indicator samplings together with the clinical E. coli from blood and urines. For 
ampicillin the resistance profile of indicator bacteria stayed well below that of the clinical isolates. This was not the case for cip-
rofloxacin and gentamicin. In 1997, 2% of E. coli from pig producers harboured ciprofloxacin resistance, while none of the E. coli 
isolates from abattoir workers, nurses or army recruits were ciprofloxacin resistant. Also, the clinical E. coli from 2000 to 2003 
and the E. coli from healthy human volunteers in the community in 2002 to 2005 harboured low or no ciprofloxacin resistance, 
but in both groups of isolates there was an increase to 5-7% resistance in 2006. In 2008 army recruits posed 13% ciprofloxacin 
resistance, which was in the high end but similar to the prevalence in clinical isolates. For gentamicin the same applies as for 
ciprofloxacin. It is surprising though, that E. coli from army recruits in 2008 had so relatively high gentamicin resistance. Report-
ing of resistance to 3rd generation cephalosporin started in 2008/2009 for clinical E. coli isolates, where it was around 4%. For 
E. coli isolated from healthy human volunteers in the community, 3rd generation cephalosporin resistance was reported in the 
five-year period from 2002 to 2006 and there were none resistant isolates, while E. coli isolates from army recruits in 2008 
harboured 3% 3rd generation cephalosporin resistance. 
Sissel Skovgaard, and Stefan S. Olsen 
For further information: Sissel Skovgaard, sisk@ssi.dk
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Textbox7.3 
Comparison of ESBL/AmpC-producing Escherichia coli isolates 
from Danish and imported meat with E. coli isolates obtained from 
human bloodstream infections
Background: ESBL/AmpC-producing bacteria are widespread worldwide in both humans and production animals. Studies have found 
similar ESBL/AmpC genes, plasmids and clones of E. coli isolates from animals, meat and human infections, suggesting a zoonotic link.
Materials and methods: ESBL/AmpC-producing E. coli isolates from meat (Textbox 7.1) obtained in 2014 and 2015 and  ESBL/AmpC-
producing E. coli isolates from human bloodstream infections (Textbox 8.1) obtained during 2015 were compared for clonal relationship 
by whole-genome-based SNPs analysis, if sharing the same ESBL/AmpC gene and belonging to the same sequence types (STs). The 
CGE web tool CSI-phylogeny version 1.3 [https://cge.cbs.dtu.dk/services/CSIPhylogeny/] was used to call SNPs between the 
isolates to infer the phylogeny [Kaas et al. 2014, PLoS ONE 2014; 9(8): e104984].  
For each comparison a reference genome with identical STs was used.
Results: The same combinations of ESBL/AmpC genes and STs were detected from E. coli isolates of human origin and E. coli 
isolates from meat in three occasions; CMY-2-producing E. coli isolates belonging to ST38 and ST354, and CTX-M-1-producing 
isolates belonging to ST131. Three SNP comparisons were produced for each of the tree combinations (Table A7.9, web annex).
The CMY-2-producing E. coli isolates belonging to ST38 represented five isolates of veterinary origin from 2015 (three isolates 
from Danish broiler meat and two from imported duck meat) and one human bloodstream isolate from 2015 (Figure ST38 CMY-
2, Table A7.9, web annex). More than 6,000 SNPs were detected between the E. coli isolate of human origin and E. coli isolates 
from meat. 
The CMY-2-producing E. coli isolates belonging ST354 encompassed one imported broiler meat E. coli isolate from 2014, two 
imported broiler meat E. coli isolates from 2015 and one human bloodstream E. coli isolate from 2015 (Figure ST354 CMY-2, 
Table A7.9, web annex). More than 2,680 SNPs were detected between the human isolate and the broiler meat isolates.
One ST131/CTX-M-1-producing E. coli isolate from Danish broiler meat from 2015 was compared with three ST131/CMX-M-
1-producing E. coli isolates from human bloodstream infections (Figure ST131 CTX-M-1, Table A7.9, web annex). More than 
1,640 SNPs were detected between the broiler isolate and the human isolates.
Discussion and conclusion: CTX-M-15, CTX-M-14, CTX-M-27 were the most frequently detected enzymes among the ESBL/
AmpC-producing E. coli isolates from human bloodstream infections in 2015, whereas CTX-M-1 and CMY-2-variants  were de-
tected to a lesser extent (Textbox 8.1). None of the E. coli isolates from Danish and from imported meat contained any known 
carbapenemase gene. Therefore, we conclude that presently fresh meat available on the Danish market seems to be a minor 
source of the ESBL/AmpC-producing bacteria causing bloodstream infections in humans, and not a source of carbapenemase-
producing bacteria causing human infections in Denmark.  
In 2015, similar SNP profiles were not detected between ESBL/AmpC-producing E. coli from human bloodstream infections and 
ESBL/AmpC-producing E. coli isolates from meat. From this limited dataset, we did not detect any indication of zoonotic clonal 
spread of ESBL/AmpC-producing E. coli. 
Besides clonal spread, genes encoding ESBL/AmpC enzymes can spread among bacteria of animal and of human origin by 
horizontal plasmid transfer. Plasmid comparison was not performed in the present study. However, similar plasmids with ESBL/
AmpC-encoding genes have been detected from broilers and humans in Denmark, in Sweden and in the Netherlands. [de Been 
et al. 2014 PLOS Genetics 10:12; Börjesson et al. 2016 Emerging Infectious Diseases 22:634; Hartung et al. 2016 Applied and 
Environmental Microbiology 82:4705]. Further monitoring, which also could include ESBL/AmpC-producing E. coli isolates from 
urinary tract infections, and larger studies are needed to investigate and quantify the possible zoonotic link between ESBL/
AmpC- and carbapenemase-producing E. coli from meat/animals and human severe infections.
Louise Roer, Anette M. Hammerum, Helle Korsgaard, Valeria Bortolaia, Henrik Hasman and Rene S. Hendriksen 
For further information for the human isolates: Anette M. Hammerum (ama@ssi.dk) 
For further information for the meat isolates: René S. Hendriksen (rshe@food.dtu.dk)
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    Highlights: DANMAP 2015 is the first DANMAP report with data on resistance in blood iso-
lates referred from all Danish DCM, thereby covering all of the Danish population. 
  E. coli from bloodstream infections is the only clinically important human bacteria, where 
resistance has been continuously reported through all 20 years. In 2015, no significant 
changes in resistance were reported for E. coli isolates obtained from bloodstream infec-
tions: resistance to ciprofloxacin was 12%, cefuroxime 9%, 3rd generation cephalosporins 
7 % and gentamicin 9%, respectively. One carbapenemase-resistant and four intermediary 
resistant E. coli isolates were reported. During the last decade steady increases in resistance 
occurred for E. coli from bloodstream infections, most pronounced for 2006 to 2011, since 
levelling off. Over the last twenty years the resistance to ampicillin increased from 35% to 
45% for E. coli, also here, the most pronounced changes happened from 2006 to 2011.
  During the last twenty years, the resistance levels have continuously increased for E. coli ob-
tained from urinary tract infections from hospitalized patients. Whereas decreases for most 
antimicrobial classes were observed for E. coli isolates obtained from patients with unitary 
tract infections from primary healthcare. 
  For K. pneumoniae isolates obtained from bloodstream infections in 2015, gentamicin 
resistance decreased to 2.5% (4.6% in 2014). Resistance to most antimicrobials has steadily 
decreased since 2009. In 2015, 11% of the K. pneumoniae isolates were resistant to cefu-
roxime, 8% to 3rd generation cephalosporins and 6% to ciprofloxacin. The only antimicrobial 
with increasing resistance since registration was begun in 2009 was piperacillin-tazobac-
tam. In 2015, 8% of the K. pneumoniae isolates from blood were resistant to piperacillin-
tazobactam. None carbapenem-resistant and two intermediary resistant K. pneumoniae 
isolates were reported in 2015.
  For K. pneumoniae isolates obtained from urins from patients with urinary tract infections 
resistance to ciprofloxacin decreased from 8% to 6% in urinary isolates from hospitals and 
from 7% to 5% in urinary isolates from primary health care.
  In 2015, whole-genome sequencing was performed on 275 ESBL- and/or carbapenemase-pro-
ducing E. coli isolates from blood and on additional 59 carbapenemase-producing Enterobacte-
riaceae (CPE), 19 carbapenemase-producing A. baumannii and nine carbapenemase-producing 
Pseudomonas spp. (Textboxes 8.1 and 8.2). The occurrence of these carbapenemase-produc-
ing bacteria in Denmark is increasing, a trend worrisome to patients and clinicians. Especially 
the spread of CPE worries due to their ability to be carried in the gut for a long time.
  Staphylococcus aureus bacteremia’s accounted for 1,973 cases, the third year in a row 
where the number of cases was higher than the previous year. Twenty-nine (1.5%) of these 
were caused by MRSA and three of them by MRSA CC398. The mortality was 23% for the 
methicillin susceptible cases and 24% for the cases with MRSA. Resistance towards eryth-
romycin, clindamycin, fusidic acid and norfloxacin has been steadily increasing in the last 
decade. In 2015 it was 7%, 7%, 16% and 6%, respectively. For the first time in recent years, 
the number of new MRSA cases (colonized or infected patients) stabilized with 2,971 cases 
compared to 2,965 cases in 2014.  
8. Resistance in clinical bacteria from  
humans and animals
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8.1 Escherichia coli
Escherichia coli is part of the normal intestinal flora in both 
humans and animals but also one of the most common causes 
of infections. In humans, E. coli is the most frequent cause of 
community- and hospital-acquired urinary tract infections and 
of bacteremia. E. coli also accounts for the majority of travel-
related diarrhea. It further occasionally causes meningitis in 
newborns. 
For E. coli, DANMAP 2015 includes data on resistance referred 
from all 11 Departments of Clinical Microbiology (DCM), thus 
for the first time covering the total Danish population. These 
data cover all blood and urinary isolates from hospitals and a 
selected number of urines from primary health care. 
Blood isolates from hospital patients 
DANMAP received data on the antimicrobial susceptibility of 
4,618 E. coli isolates from blood. As in previous years resis-
tance testing was primarily performed by disc diffusion and 
the referred data consisted of interpretation of resistance 
results based on the S-I-R system. 
A minor increase in the total number of E. coli isolates from 
blood was observed from 2014 to 2015 (Figure 8.1). The 
increase corresponds to the increase in contribution of the last 
DCM to DANMAP 2015. The increasing tendency of the total 
number of E. coli isolates from blood, registered since 2010 
and commented in DANMAP 2014, did not continue in 2015. 
Still an increase in the number of bacteremias might continue 
to some extent in the future caused by demographic changes 
with an ageing population, since the elderly are at the highest 
risk of bacteremia and have the highest incidence. Increasing 
trends in the rates of bacteremias seem not only to resemble 
demographic changes but to be a combination of several 
factors like advances in health care with improved treatment 
options as well as lowered thresholds for taking blood cultures 
and improvement in blood culturing systems. 
No significant changes in occurrence of antimicrobial resistance 
were observed in 2015 compared to 2014 (Figure 8.1 and 
Table 8.1) For interpretation of mecillinam resistance testing 
results, more restrictive breakpoints than EUCAST breakpoints 
are used for blood isolates by some DCM and interpretation 
rules have changed over time as discussed in DANMAP 2014. 
This makes comparison of results from resistance testing 
for mecillinam over time not valid. Therefore in Table 8.1 the 
number is presented, but without any comparison to former 
years. If referral of inhibition zone diameters is to be used in 
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Figure 8.1. Resistance (%) in Escherichia coli  
blood isolates from humans, Denmark
Note: The number (n) in parentheses represents the number of isolates 
tested for susceptibility in 2015
DANMAP 2015
  In 2015, a further increase of vancomycin-resistant enterococci in the Capital Region and the 
Region of Zealand was noted, reaching a total of 372 clinical isolates, through typing charac-
terized as belonging primarily to sequence types (ST), ST80, ST117 and ST203, (Textbox 8.3).
  2015 was also the year with the highest incidence of drug-resistant Mycobacterium tu-
berculosis, with five multidrug-resistant tuberculosis (TB) cases and the second case with 
extensively-drug-resistant TB ever noticed in the country. Even though the global incidence 
of TB is declining, the emergence of drug-resistant strains is challenging, also in Denmark 
(Textbox 8.6).
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the years to come, a more stringent surveillance will be pos-
sible, independent of local interpreting rules that make sense 
in the clinical situation for treatment of a specific infection but 
are not harmonized for national surveillance purposes. 
One carbapenem (meropenem) resistant and five intermedi-
ary resistant E. coli blood isolates were reported in 2015. In 
2014, there were none carbapenem resistant E. coli blood 
isolates. This might reflect the general and worrisome increase 
in carbapenem resistant enterobacteriacae observed in 2015 
commented in textbox 8.2.  
In the 10-year period from 2006 to 2015, resistance in E. coli 
blood isolates has altogether increased steadily, the increase 
being most pronounced from 2006 to 2011, since showing 
a slight stagnation for most antibiotics. For ciprofloxacin a 
decrease is observed from its peak of 14% resistance in 2009 
to 2012, to 12% resistance in 2015, but still far from the 7% 
resistance in 2006. This development parallels the trends in 
total antimicrobial consumption, which showed pronounced 
increase until 2010 with a peak of 19.25 DID and since a slow 
decrease to a total of 18,50 DID in 2015 giving a drop in total 
consumption of 0.75 DID (Figure 5.1). Resistance to piperacil-
lin/tazobactam has been surveilled since 2009. In this 7-year 
period a rather constant resistance profile has been observed, 
with 4.7% resistance in 2009, dropping to 4.0% resistance 
in 2010 to 2013 and then moving back up to 5 % resistance 
in 2014 and 2015. The trend for piperacillin/tazobactam is 
observed closely since changes in the consumption owing to 
a shift from cefuroxime as most used antibiotic in the treat-
ment of E.coli infections and sepsis in hospitalized patients 
to piperacillin/tazobactam have resulted in an increase of the 
consumption of piperacillin/tazobactam in Danish hospitals 
from 2008 and onward (Figure 5.11). 
Urine isolates from hospital patients 
DANMAP received data on 46,723 E. coli isolates from urine in 
hospitalized patients.
Not all DCM tested for all antibiotics reported here. (Table 8.1 
and Figure 8.2) For at least 82% of isolates all 11 DCM reported 
data on mecillinam and ciprofloxacin susceptibility, while 10 
DCM reported data on ampicillin, gentamycin and cefuroxime 
susceptibility. Data on piperacillin/tazobactam, 3rd generation 
cephalosporins and meropenem susceptibility was reported by 8 
DCM and sulfamethizole susceptibility was reported by 7 DCM.
There was a slight but significant increase in resistance to me-
cillinam, piperacillin/tazobactam and cefuroxime from 7.2% to 
7.7%, 3.5% to 3.9% and 6.6% to 7.0% respectively compared 
to 2014. 
In 2015, three carbapenem (meropenem) resistant and 11 
intermediary resistant E. coli isolates from hospital urine were 
reported. For comparison, there was none meropenem resis-
tant and one meropenem intermediary resistant E. coli isolate 
from hospital urine in 2014. As already mentioned there was 
a worrisome increase in carbapenem resistance in general 
among Gram negative pathogens in 2015, which is addressed 
further in textbox 8.2.
Urine isolates from primary health care 
DANMAP received data on 61,073 E. coli isolates from urine 
from patients in primary health care.
In Denmark culturing and susceptibility testing of urines from 
primary health care varies substantially between the different 
regions. Many GP´s perform local testing and thus primarily 
urines from patients with known resistance problems are sent 
to the DCM at the regional hospital. Other GP´s use their local 
Table 8.1. Resistance (%) in Escherichia coli isolates from humans, Denmark
Substance
Blood isolates, hospitals
%
Urine isolates, hospitals
%
Urine isolates, primary health care
%
Ampicillin 45 42 39 #
Mecillinam 10 b) 8 * 5
Piperacillin/tazobactam 5 4 * 4
Sulfonamide 32 31 #
Gentamicin 7 5 4
Ciprofloxacin 12 11 9
Cefuroxime 9 7 * 5
3rd generation cephalosporins a) 7 6 4
Meropenem <1 <1 <1
Max. number of isolates tested 4595 46572 61047
*) An asterisk indicates a significant increase from 2014 to 2015
#) A number sign indicates a significant decrease from 2014 to 2015
a) Tested 3rd generation cephalosporins were ceftazidime, ceftriaxone, cefpodoxime and cefotaxime 
b) Mecillinam resistance from blood isolates is repported without data from Skejby as in 2014 but no significance testing have been done 
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DCM more extensively and frequently. The amount of culturing 
and susceptibility testing performed at the different DCM will 
vary accordingly. All DCM reported data on mecillinam suscep-
tibility and almost all reported data on ampicillin, ciprofloxacin 
and 3rd generation cephalosporin susceptibility, while 7 DCM 
reported data on sulfamethizole, 6 reported data on cefurox-
ime, 5 reported data on gentamycin and meropenem suscep-
tibility and 4 DCM reported data on piperacillin/tazobactam 
susceptibility.  
In 2015 there was a small decrease in ampicillin and 
 sulfonamide resistance compared to 2014. Otherwise no 
significant changes when comparing data from 2015 to 2014 
were found. (Table 8.1 and Figure 8.3)
In 2015, four carbapenem (meropenem) resistant and nine 
intermediary resistant isolates were reported from E. coli 
urine from primary health care. In 2014 those numbers were 
two and one, respectively. Routine meropenem testing was 
performed at five DCM in 2015.
20 years of E. coli surveillance
The surveillance of E. coli has been part of all 20 years in 
DANMAPs history and thus will be covered more extensively in 
this chapter. In the beginning, invasive E. coli infections were 
reported by two DCM: SSI and Aarhus. These two laborato-
ries covered 16% of the Danish population. The surveillance 
expanded during the following 9 years and from 2004 until 
2014 all DCM, except one, participated. DANMAP 2015 is the 
first DANMAP report with data from all Danish DCM, thereby 
covering 100% of the Danish population (Figure 8.4). During 
the first years of DANMAP, it was essential to take precautions 
in the comparison of data from year to year and from reporting 
department to reporting department as well as it was neces-
sary to generalize some of the observations. This was because 
of quite different and changing methods in the susceptibility 
testing and because of the rather small number of participat-
ing DCMs. From 2011 on, all DCMs except one agreed upon us-
ing the same method as a standard in the susceptibility testing 
following EUCAST principles and standards. From November 
2015 all Danish DCM followed EUCAST principles. 
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Figure 8.4 Surveillance of invasive E. coli - percentage of the 
Danish population covered
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Figure 8.3. Resistance (%) in Escherichia coli urine isolates from 
humans in primary health care, Denmark
Note: The number (n) in parentheses represents the number of isolates 
tested for susceptibility in 2015
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Figure 8.2. Resistance (%) in Escherichia coli urine  
isolates from humans in hospitals, Denmark
Note: The number (n) in parentheses represents the number of isolates 
tested for susceptibility in 2015
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In general, the data reported from clinical human samples have 
become increasingly consistent and adequate during the years.
Still carefulness in interpretation and comparison of data is im-
portant. For the year 2015, the DCMs reported zone diameters 
as well as interpretations of antimicrobial resistance which 
made it possible to compare local interpretations with EUCAST 
interpretational breakpoints. From the differences in these, it is 
clear, that different rules for reporting results of the suscepti-
bility of the isolate to the clinicians still exist. For the antibiot-
ics mostly affected, this is commented below in the relevant 
sections. In addition, differences between patient populations 
covered by the different DCMs can influence the comparability 
of resistance prevalence in-between DCMs. Furthermore, for 
each pathogen, DANMAP counts resistance data on the first 
isolate per patient per year per DCM. Thereby transportation of 
chronically ill patients in-between hospitals or regions can in-
fluence the results, since the patient might be counted twice. 
It seems more appropriate instead to compare clinical depart-
ments of the same medical specialty, for example hematology, 
across the DCMs, which we foresee could be done more readily 
in the future with databases like the MiBa II and eRES (see the 
jubilee chapter for more information).
When looking at invasive E. coli during all 20 years of report-
ing (Figure 8.5) data stem from four DCM covering 1995 to 
1999. For two of the DCMs data were not included in the first 
DANMAP reports but those data were included later. From 
2000 and onwards data covered at least 63% of the Danish 
population, and since then an average value of resistance for 
Denmark is presented. 
The trend for ampicillin resistance is a crawling increase over 
the 20 years with resistance of around 35% of invasive E. 
coli in 1995 to 1998, around 40% from 2000 to 2006 and 
from 2007 and onwards the ampicillin resistance in E. coli is 
around 45%. The earliest EARS-Net data are from 1999 with 
Norway reporting 27% resistance in 584 E. coli isolates and 
Germany reporting 36% resistance in 166 E. coli isolates. The 
increasing trend has been the same in the European coun-
tries with most countries in 2014 showing 50-60% resis-
tance and a few reaching above 70% resistance, while the 
Nordic countries stay below 45% [EARS-Net 2014]. In this 
20 year period the consumption of penicillins with extended 
spectrum in total increased significantly in Denmark mainly 
driven by a steep increase in the consumption of (piv)mecilli-
nam, while the consumption of (piv)ampicillin decreased both 
in primary care and in the hospital sector. Thus there is no 
direct link between the occurence of ampicillin resistance and 
the consumption of the drug class. 
For ciprofloxacin resistance, a steep increase in resistance 
was observed, from 2-3 % around year 2000 to 14% in 
the years 2009 to 2012. For the last three years, a small 
decrease was observed, with 12% resistance in 2015 (Figure 
8.6). The same pattern was observed for E. coli isolated from 
urine both from hospitalized patients and from the primary 
health care sector. Ciprofloxacin was appointed special focus 
in Denmarks action plan on antimicrobial resistance in 2010 
and one of the three antimicrobials with recommendations 
on restricted use by the Danish Health Authorities in 2012 
showing a slight decrease in consumption observed since 
2011 (Figure 5.2). 
Figure 8.5. Resistance (%) in Escherichia coli blood isolates from humans, Denmark, 20 years  
of surveillance, incl. ampicillin.
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Gentamycin and cefuroxime (figure 8.6) show a similar trend 
with an increase in resistance continuing until around 2011 
and thereafter reaching a stabilization, but without a following 
decreasing trend in resistance as observed for ciprofloxacin 
resistance in E. coli. For cefuroxim one DCM, (Skejby), reported 
relatively high resistances in 1995 to 1998 with a peak of 
9% resistance in 1997. Whether this had a methodologically 
explanation or any other explanations is yet to be elucidated.
Sissel Skovgaard, Ute Wolff Sönksen and Stefan S. Olsen
8.2 Klebsiella pneumoniae
Klebsiella pneumoniae is part of the normal intestinal flora in 
humans but can also be the cause of urinary tract-, respiratory 
tract-, and bloodstream infections. Many of these infections 
are hospital acquired and can become life threatening, espe-
cially if the strains are resistant to antimicrobial agents. 
For K. pneumoniae, DANMAP 2015 includes data on resistance 
referred from all 11 Departments of Clinical Microbiology 
(DCM). 
Blood isolates from hospital patients 
Statens Serum Institut has since 2006 received data on the 
antimicrobial susceptibility of K. pneumoniae isolates from 
blood, and following a sudden increase in resistance (owing 
to an outbreak with the so called epi-K.pn.in 2007) data were 
included in the DANMAP report from 2008 and onwards. In 
2015, DANMAP received data on 943 K. pneumonia isolates.
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Figure 8.7. Resistance (%) in Klebsiella pneumoniae blood 
isolates from humans, Denmark 
Note: The number (n) in parentheses represents the number of 
isolates tested for susceptibility in 2015. 
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Figure 8.6 Resistance (%) in Escherichia coli blood isolates from humans, Denmark, 20 years of  
surveillance, excl. ampicillin
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In general, the level of antimicrobial resistance decreased 
since its peak in 2009. This is probably due to clonal shifts in 
the infectious strains happening over the years. Piperacillin/
tazobactam is the only antimicrobial with continuously slowly 
increasing resistance from its first registration in the DANMAP 
report 2010 until 2014 (Figure 8.7). This is concordant to an 
increased use of this agent due to a change in the Danish an-
tibiotic policy preferring piperacillin/tazobactam for 2nd and 3rd 
generation cephalosporins that happened in the years 2008 
and onwards and might have lessened the selection pressure 
from cephalosporins at Danish hospitals. In 2015 there was a 
non-significant decrease (P=0,061) in piperacillin/tazobactam 
resistance, from 8% in 2014 to 6% in 2015 (Table 8.2 and 
Figure 8.7).
The year 2015 is the first year where the DCM reported data 
on zone diameter (not shown) as well as interpretations of 
resistance. From this it became clear that rules for interpret-
ing resistance in enterobacteriaceae are not completely the 
same in Denmark. Some DCM report as tested according to the 
measured zone diameter, others have different local (expert) 
rules. This might for example be inferring all ESBL producing 
isolates as fully or intermediary resistant towards any beta-
lactams or combinations of a penicillin with a beta -lactamase 
inhibitor, no matter of the measured zone diameters. Accord-
ing to EUCAST expert rules, it should be “reported as tested 
and enclosed a warning on uncertain therapeutic outcome 
for infections other than urinary tract infections” (version 2.0 
available from 29 Oct, 2011). These varying local interpreta-
tions developed for helping in the choice of the clinically most 
relevant treatment might interfere with surveillance analysis 
when interpreting trends for the different drugs e.g. piperacil-
lin/tazobactam resistance. A more stringent surveillance of 
AMR is expected in the future with reporting of zone diame-
ters rather than, sometimes, individual interpretations that are 
meaningful in treatment of the patient in a clinical situation 
but not in harmonized national surveillance. 
The only significant change in 2015 compared to 2014 is ami-
noglycoside resistance, which decreased from 4.6% in 2014 to 
2.5% in 2015. This decrease is not paralleled by a decrease in 
aminoglycoside consumption at hospitals (table 5.5).
Resistance to 2nd generation cephalosporins (cefuroxime) was 
11% and resistance to 3rd generation cephalosporins was 8%. 
The resistance to 3rd generation cephalosporins is the highest 
reported level in EARS-Net among the Nordic countries (which 
in 2014 were reported below 6% for the other Nordic coun-
tries), but remains lower than the occurrence reported by most 
other European countries. [EARS-Net 2014]. 
In 2015, none carbapenem (meropenem) resistant and two 
intermediary resistant K. pneumoniae blood isolates were 
reported. These data cover the first K. pneumoniae isolate per 
patient per year and might thus be different from the number 
of resistant isolates referred to the reference laboratory for 
further resistance analysis. In 2014, 3 carbapenem (merope-
nem) resistant and one intermediary resistant isolates were 
reported. This is divergent from the general trend for 2015, 
where an increase in carbapenem resistance in enterobacte-
riacae and non-fermenters is observed. (Textbox 8.2) The level 
of resistance to ciprofloxacin, which decreased insignificantly 
from 7.0% in 2014 to 5.5% in 2015, came to the same lower 
level as in the other Nordic countries. This is the first time 
since the reporting of resistance in K. pneumoniae from blood 
isolates began in 2008.
Urine isolates from hospital patients 
DANMAP received data on 7175 K. pneumoniae isolated from 
urine in hospitalized patients.
Resistance levels to all the reported antibiotics were un-
changed compared to 2014, except for ciprofloxacin where a 
decrease from 8% to 6% was observed. (Table 8.2 and  
Figure 8.8) 
In 2015, carbapenem (meropenem) resistance was reported in 
four and intermediary resistance in seven K. pneumoniae urine 
isolates from hospitalized patients. Not all DCM performed 
routine susceptibility testing for meropenem, thus the number 
of these strains represents a selected population. 
Urine isolates from primary health care 
DANMAP received data on the antimicrobial susceptibility 
of 6372 K. pneumoniae isolates from urine from patients in 
primary health care. 
In 2015, there was a significant decrease in resistance to-
wards ciprofloxacin from 7% to 5% compared to 2014. (Table 
8.2 and Figure 8.9) The overall trend, as in K. pneumonia from 
hospital urines and blood, the level of antibiotic resistance has 
been decreasing compared to 2009.
In 2015, one carbapenem (meropenem) resistant and three 
intermediary resistant K. pneumoniae urine isolates from pa-
tients in primary health care were reported. As for the hospital 
urine isolates, this number represents a selected population, 
since meropenem is only routinely tested for in urine samples 
from primary health care by four DCM
Sissel Skovgaard, Stefan S. Olsen and Ute Wolff Sönksen
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Table 8.2. Resistance (%) in Klebsiella pneumoniae isolates from humans, Denmark 
Substance Blood isolates, hospitals Urine isolates, hospitals Urine isolates, primary health care
% % %
Mecillinam 9 10 9
Piperacillin/tazobactam 6 6
Sulfonamide 18 19
Gentamicin 3# 4
Ciprofloxacin 6 6# 5#
Cefuroxime 11 10
3rd generation cephalosporins a) 8 7 5
Meropenem <1 <1 <1
Max. number of isolates tested 937 7106 6015
*) An asterisk indicates a significant increase from 2014 to 2015
#) A number sign indicates a significant decrease from 2014 to 2015
a) Tested 3rd generation cephalosporins were ceftazidime, ceftriaxone, cefpodoxime or cefotaxime
DANMAP 2015
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Figure 8.8. Resistance (%) in Klebsiell  pneumo iae urine 
isolates from humans in hospitals, Denmark
Figure 8.9. Resistance (%) in Klebsiella pneumoniae urine 
isolates from humans in primary health care, Denmark
Note: The number (n) in parentheses represents the number of isolates 
tested for susceptibility in 2015
Note: The number (n) in parentheses represents the number of isolates 
tested for susceptibility in 2015
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Textbox 8.1 
Characterization of ESBL/AmpC-producing and carbapenemase 
producing Escherichia coli from bloodstream infections, 2015 
Background: Third-Generation cephalosporin-resistant Escherichia coli (3GC-R Ec) is increasing in Europe [EARS-Net report, 
2014]. The extended-spectrum cephalosporin-resistance in E. coli can be due to production of extended-spectrum beta-lacta-
mases (ESBLs), plasmid-mediated AmpC (pAmpCs) or constitutive overexpression of the chromosomal ampC gene due to muta-
tions within the promoter/attenuator region. 
The worldwide spread of ESBL-producing E. coli is in part due to the spread of the pandemic clone O25b:-ST131. Evidently, this 
clone is strongly related to the presence of antimicrobial resistance genes, including CTX-M-15 and other ESBL enzymes, as well 
as virulence factors. 
Before 2007, the occurrence of 3GC-R Ec was low among E. coli isolated from bloodstream infections in Danish patients. How-
ever, the rate of resistance among invasive E. coli in Denmark has increased from 2.5% in 2006 to 7.2% in 2015.
Carbapenemase producing E. coli are also of concern (see Textbox 8.2 Carbapenemase producing bacteria in Denmark, 2015).
The aim of the present study was to characterize ESBL (including pAmpC) and carbapenemase producing E. coli from blood-
stream infections according to genes and Multilocus Sequence Types (MLSTs).
Material and Methods: During January 2015 through December 2015, 10 out of the 11 Danish departments of clinical micro-
biology collected all their 3GC-R Ec (reported as ceftazidime, ceftriaxone, cefpodoxime or cefotaxime resistance) from blood-
stream infections. Furthermore, carbapenemase produing E. coli from bloodstream infections were included in the study. Only 
one isolate per patient was included in the study.
The isolates were sent to Statens Serum Institut for further characterization. 
Genomic DNA was extracted from the isolates (DNeasy Blood and Tissue Kit, QIAGEN, Copenhagen, Denmark). Fragment libraries 
were constructed using the Nextera Kit (Illumina, Little Chesterford, United Kingdom) followed by 251-bp paired end sequenc-
ing (MiSeq, Illumina) according to the manufacturer’s instructions. The paired-end Illumina data was assembled using CLC bio’s 
Genomic Workbench 8.0.
The ResFinder web server, (www.genomicepidemiology.org, version 2.1) was used to identify acquired ESBL (including plasmid 
AmpCs) and carbapenemase genes from the assembled WGS data.
The MLST web server (www.genomicepidemiology.org, version 1.9) was used for detection of MLST-profiles. For isolates with 
no ESBL genes detected, the sequences were investigated for mutations presumed to up-regulate chromosomal AmpC by the 
use of CLCbio Genomic Workbench.
Results: Whole genome sequence data were obtained from 294 E. coli isolates. Genes encoding ESBL production (including 
pAmpCs) and/or carbapenemase production were detected in 275 isolates. Nineteen isolates were hyper AmpC producers only; 
these isolates were not investigated further. 
The distribution of the 275 isolates with genes encoding ESBL and carbapenemase production in relation to the five Danish 
regions is shown in Table 1.
One hundred-sixty-six (61%) of the patients were men and the average age at diagnosis was 70 years (ranging from below one 
to 98 years).
Among the 275 isolates, 20 different ESBLs (including pAmpCs) and carbapenemases were detected (Table 2).  CTX-M-15 domi-
nated (51%) followed by CTX-M-14, and CTX-M-27 (Table 2). Different variants of CMY were detected in 16 (6%) isolates. Three 
isolates produced carbapenemases; one OXA-48 and two OXA-181. In several isolates more than one gene encoding ESBLs and/
or carbapenemases were detected (Table 2). Additionally, the plasmid-mediated colistin resistance gene, mcr-1, was found in an 
isolate together with CMY-2 and CTX-M-55 [Hasman et al. Eurosurveillance 2015].
The 275 isolates belonged to 48 different MLSTs. ST131 was the most common sequence type (ST), 135 (49%) of the isolates 
belonged to this type. Other major types were ST38 (8%), ST405 (4%), ST410 (4%), ST69 (4%), ST648 (4%), and ST12 (3%), 
whereas the rest of the isolates belonged to STs, which only were detected in 1-5 isolates (<1-2% per type) (Table 3). 
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Among the 135 isolates belonging to ST131, CTX-M-15 (56 %) was most common, followed by CTX-M-27 (20%), CTX-M-101 
(11%) and CTX-M-14 (7%). The two isolates producing OXA-181 and CMY-2 belonged to ST410, whereas the isolates producing 
OXA-48 belonged to ST38.
Conclusion: From 2014 to 2015, the reported cases of 3GC-R Ec slightly increased from 245 to 281 (261 and 294 including 
hyper AmpC producers). Comparing the distribution of ESBLs (including pAmpCs), carbapenemases and MLSTs, from the present 
study to the results reported in DANMAP 2014, no remarkable changes were observed. As in previous Danish studies of ESBL-
producing E. coli from bloodstream infections, most of the isolates produced a CTX-M enzyme, with CTX-M-15 being the most 
predominant enzyme [DANMAP 2009, DANMAP 2011, DANMAP 2014, Hansen et al. Microb. Drug Res. 2014]. Only a minor part 
of the isolates carried plasmid mediated AmpC (CMY variants). 
As observed in DANMAP 2014 and in Hansen et al. the worldwide disseminated CTX-M-15 ST131 was strongly represented in 
this study, but the Danish E. coli isolates also belonged to other international STs (e.g., ST38, ST405, ST410, ST69 and ST648) 
related to spread of ESBLs. The finding of three E. coli isolates with OXA-48 group enzymes (OXA-48 and OXA-181) from blood-
stream infection is of concern.
Louise Roer, Frank Hansen, Anette M. Hammerum and Henrik Hasman 
For further information: Henrik Hasman (Henh@ssi.dk)
Table 1. Distribution of ESBL and Carbapenemase producing E. 
coli from bloodstream infections, Denmark 2015
 2014 2015
Region Numbers Numbers
The Capital Region of Denmark 110 116
The Zealand Region 27 14
Region of Southern Denmark 43 45
Central Denmark Region 43 59
North Denmark Region 22 41
Total Numbers 245 275
 2014 2015
Enzyme Number % Number %
CTX-M-1 10 4% 7 3%
CTX-M-141 38 16% 33 12%
CTX-M-14b 5 2% 5 2%
CTX-M-151 121 49% 139 51%
CTX-M-241 1 < 1% 5 2%
CTX-M-271 25 10% 33 12%
CTX-M-551 8 3% 14 5%
CTX-M-101 12 5% 15 5%
CMY-21 10 4% 6 2%
Other CMY variants1 4 2% 10 4%
Other ESBL enzymes 17 7% 15 5%
OXA-48-group1 3 1% 3 1%
 2014 2015
MLST Numbers % Numbers %
ST131 124 51% 135 49%
ST38 18 7% 23 8%
ST405 13 5% 12 4%
ST410 4 2% 11 4%
ST69 10 4% 10 4%
ST648 7 3% 10 4%
ST12 5 2% 9 3%
ST10 0 0% 6 2%
ST1193 2 1% 5 2%
Other STs1 62 25% 54 20%
Table 2. ESBL enzymes and carbapenemases detected  
in E. coli from bloodstream infections
1In some isolates more than one enzyme was detected in 2015
Table 3. Distribution of MLSTs in E. coli from  
bloodstream infections
1 less than 5 isolates per ST in 2015
DANMAP 2015
DANMAP 2015 DANMAP 2015
DANMAP 2015114
RESISTANCE IN HUMAN CLINICAL BACTERIA8.
Textbox 8.2 
Carbapenemase producing bacteria in Denmark, 2015
 
Background: Carbapenems comprise one of the only classes of antimicrobial agents that can be used for treatment of infec-
tions with multi-resistant Gram-negatives like Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa and Acineto-
bacter baumannii. Treatment options for infections with carbapenem resistant bacteria are often none or suboptimal. Resistance 
can be caused by the presence of various carbapenemases of which the most frequently occurring are K. pneumoniae car-
bapenemase (KPC), Oxacillinase (OXA), Verona integron-encoded metallo-ß-lactamase (VIM), and New Delhi metallo-β-lactamase 
(NDM), and Imipenemase (IMP).
In recent years, Danish Departments of Clinical Microbiology (DCM) have on a voluntary basis submitted carbapenem resistant 
isolates for verification and genotyping to the Antimicrobial Resistance Reference Laboratory at Statens Serum Institut. The 
present textbox describes carbapenemase-producing Enterobacteriaceae (CPE), carbapenemase-producing P. aeruginosa and 
Acinetobacter spp. 
During 2015, 91 carbapenemase producing bacteria were detected from 85 patients. More than one isolate from the same 
patient were included, if the isolates belonged to different bacterial species and/or if the isolates harboured different carbapen-
emases. In 2015, eight of the carbapenemase isolates were from bloodstream infections (four CPE, three P. aeruginosa and 
one A. baumannii) compared with seven carbapenemase-producing bacteria (all CPE) in 2014. In many cases, the sources of 
the carbapenemase producing bacteria were unknown or related to spread between patients in Denmark, which was different 
compared to the previous years, where most of the cases were related to travel abroad. 
Enterobacteriaceae: In 2015, 63 CPE (from 59 patients) were detected compared to 36 CPE in 2014 and 31 CPE during 2008–
2013 (Figure 1). Thirty-eight of the 63 CPE isolates harboured OXA-48-like genes. Twenty-one of the 63 CPE isolates were 
NDM-producing and one isolate produced both NDM and OXA-181. Furthermore, three KPC-producing isolates were detected. 
The NDM-1 producing C. freundii outbreak, which started in 2012 in the North Denmark Region, continued in 2015. Until the 
end of 2015, ten patients were involved in this outbreak. None of these patients had a prior history of travel noted in their 
hospital records. The origin of the NDM-1 producing C. freundii was unknown [Hammerum et al. J. Antimicrob. Agents (2016); 
published online].  
 
During 2015, NDM-1 producing K. pneumoniae were detected from three patients at a hospital in the Region of Southern Den-
mark. The isolates had highly similar SNP-profiles, indicating a possible spread between the patients or a common origin. None 
of the patients had travelled recently, and the origin of the NDM-1 producing K. pneumoniae was unknown.
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Acinetobacter spp.: In 2015, 17 OXA-23 producing A. baumannii isolates were detected. Furthermore, two NDM-1 producing A. 
baumannii were detected. 
P. aeruginosa: In 2015, seven VIM-producing P. aeruginosa isolates were detected. Furthermore, one IMP-producing P. aerugi-
nosa and one IMP-producing Pseudomonas putida were detected. 
Conclusion: The occurrence of carbapenemase-producing bacteria in Denmark is increasing, a trend worrisome to patients and 
clinicians. Especially the spread of CPE is of concern, since Enterobacteriaceae can be carried in the intestine for a long time 
without any symptoms of infections, which makes outbreak control difficult.    
Anette M. Hammerum, Frank Hansen and Henrik Hasman 
For further information: Anette M. Hammerum (ama@ssi.dk)
Figure 1. Numbers of carbapenemase-producing 
Enterobacteriaceae (CPE)
More than one isolate from the same patient were included, if the isolates belonged to different bacterial 
species and/or if the isolates harboured different carbapenemases
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8.3 Pseudomonas aeruginosa
Pseudomonas aeruginosa is an opportunistic pathogen of im-
munocompromised individuals. P. aeruginosa typically infects 
the pulmonary tract, urinary tract, burns, wounds, and also 
causes bloodstream infections. It is the most frequent colo-
nizer of medical devices (e.g. indwelling catheters). P. aeru-
ginosa infection is a serious problem in patients hospitalised 
with cancer, cystic fibrosis and burns. The case fatality rate in 
these patients is high. P. aeruginosa is intrinsically resistant to 
the majority of antimicrobial agents. The antimicrobial classes 
which can be used for treatment include some fluoroquino-
lones (e.g. ciprofloxacin and levofloxacin), aminoglycosides 
(e.g. gentamicin, tobramycin and amikacin), some beta-lactams 
(piperacillin-tazobactam, ceftazidime, and carbapenems) and 
colistin.
P. aeruginosa blood isolates obtained from hospitalised 
patients 
For P. aeruginosa, DANMAP 2015 includes data from 11 out of 
11 Departments of Clinical Microbiology (DCM), covering the 
total Danish population. DANMAP received data of 443 P. aeru-
ginosa isolates from blood. Resistance levels to all the tested 
antimicrobial agents were not significantly different from 
the levels in 2014 (Figure 8.10). Gentamycin stayed at the 
same level as in 2014 and the increasing trend in resistance 
from 2009 to 2013 did not seem to be sustained. Overall the 
resistance profile of the P. aeruginosa isolates from blood 
has been highly variable both when combining results from 
all reporting DCM, and when looking at each DCM individually 
from year to year. This might be explained by natural fluctua-
tion in the numbers of isolates. The occurrence of resistance to 
fluoroquinolones, carbapenems, ceftazidime and piperacillin/
tazobactam remained at the same level or lower as reported to 
EARS-Net 2014 by the Nordic countries [EARS-Net 2014].
Meropenem resistance was observed for 4,6% (n =20) of the 
P. aeruginosa isolates in 2015. A Danish study of P. aeruginosa 
carbapenem non-susceptible isolates from 2011 showed that 
carbapenemases were present in a minority of the isolates 
(7%) [Hansen et al. 2014 Microb. Drug Res. 20: 22-9]. As in 
previous years, putative carbapenemase producing  P. aerugi-
nosa isolates were sent  on  a voluntary basis from the DCM 
to SSI for national surveillance on carbapenemase producing 
bacteria, including not only isolates from bloodstream infec-
tions but also from other origins. In 2015, six VIM-producing P. 
aeruginosa isolates were detected from six different patients. 
Furthermore, two NDM-producing P. aeruginosa were detected 
from two patients. [Textbox 8.2].
Sissel Skovgaard and Stefan S. Olsen
Figure 8.10. Resistance (%) in Pseudomonas aeruginosa 
blood isolates from humans, Denmark
Note: The number (n) in parentheses represents the number of isolates 
tested for susceptibility in 2015
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8.4 Enterococci
Enterococci are part of the normal intestinal flora of both 
humans and animals but might also cause infections. Impor-
tant clinical infections caused by Enterococcus species include 
urinary tract infections, bacteraemia and bacterial endocarditis. 
E. faecalis and E. faecium can cause life-threatening infections 
in humans, especially in the hospital environment. The natu-
rally high level of antimicrobial resistance found in enterococci 
makes infections difficult to treat. Antimicrobial therapy for 
serious enterococcal infections requires the use of synergistic 
combinations of a cell-wall-active agent such as penicillin (am-
picillin) with an aminoglycoside (gentamicin) or a glycopeptide 
(vancomycin).
For E. faecalis and E. faecium, data from 11 of the 11 DCM 
were obtained, representing the total Danish population.
Enterococcus faecium and Enterococcus faecalis blood 
isolates obtained from hospitalised patients 
DANMAP received data on the antimicrobial susceptibility 
of 711 E. faecium isolates and 617 E. faecalis isolates from 
blood. Not all laboratories tested for susceptibility to the same 
antimicrobial agents. 
As for the last 10 years, most of the E. faecium isolates from 
bloodstream infections were ampicillin resistant. In 2015, 95% 
of the E. faecium isolates were resistant to ampicillin compared 
to 94% in 2014. Figure 8.11 shows the trend for ampicillin re-
sistance in E. faecium from 2002 through 2015. In 2002, 65% 
of the reported E. faecium isolates were resistant to ampicillin 
followed by an increase to around 87% in the period 2005-
2009. The increase observed for ampicillin resistant E. faecium 
in Danish hospital has been attributed to the clonal spread of 
Clonal Complex 17 E. faecium isolates [Lester et al J. Antimi-
crob. Chemother, 2008, 1203-1206]. The increase in ampicillin 
resistant E. faecium has continued and has been above 90% 
since 2010. Also the proportion of E. faecium to E. faecalis 
from Danish Hospital blood isolates has continued its increase 
with the numbers of E. faecium blood isolates exceeding the 
number of E. faecalis blood isolates since 2011. Figure 8.11 
shows both trends. The increase in vancomycin resistant E. 
faecium, (described in textbox 8.3), still constitutes only a 
minor fraction, 3.7% in 2015 of the E. faecium isolates from 
bloodstream infections. In 2015, 0.2% of the E. faecalis blood 
isolates were vancomycin resistant. The level of vancomycin 
resistant E. faecium was above the level reported to EARS-Net 
2014 by the other Nordic countries [EARS-Net 2014].
Treatment with fluoroquinolones, cephalosporins or carbapen-
ems has been described as a risk factor for development of an 
E. faecium infection. An increasing consumption of these an-
timicrobial agents has been observed in hospitals in Denmark 
during the last decade. The antimicrobial selection pressure 
in a hospital environment might be a reason for the high level 
of ampicillin resistant E. faecium as a cause of bloodstream 
infections.
Only one of the DCMs (Aalborg) tested all enterococcal blood 
isolates for high-level gentamicin resistance (HLGR). Among 
the tested E. faecalis isolates in 2015, 25% were HLGR, 
whereas 75% of the tested E. faecium isolates were HLGR. 
This is a insignificant change compared to 2014 with respec-
tively 30% and 68% HLGR.
Sissel Skovgaard and Stefan S. Olsen
Figure 8.11. Ampicillin resistance (%) in E. faecium blood isolates from humans, Denmark and the proportion of E. faecium/E. faecalis 
isolates. From 2002 until 2009 the figure presents data reported from DCM covering 75% of the Danish population. From 2010 till 
2014 data covers 95% of the Danish population and in 2015 the total Danish population is covered.
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Textbox 8.3 
Further increase in occurrence of clinical vancomycin-resistant 
enterococci in Danish hospitals in 2015
 
Background: Enterococcus faecalis and Enterococcus faecium are commensal bacteria in the intestine of humans. E. fae-
calis and E. faecium can also cause urinary tract infections (UTI) and fatal infections like sepsis and endocarditis, especially 
among older and/or chronically ill patients. Enterococci are intrinsically resistant to a number of first-line antimicrobial agents 
including cephalosporins. Therefore, therapy of enterococcal infections may be difficult. Severe enterococcal infections with 
penicillin-resistant enterococci are primarily treated with vancomycin, but recently an increase in the occurrence of vanco-
mycin-resistant enterococci (VRE) has been observed in Denmark and internationally. Many of the VRE are also resistant to 
ampicillin and gentamicin thus limiting the treatment possibilities. Newer antibiotics such as linezolid and daptomycin can be 
used for treatment of VRE, but both antimicrobial agents are associated with severe side effects. 
Surveillance of VRE: Since 2005, Danish Departments of Clinical Microbiology (DCM) have on a voluntary basis, submitted 
VRE for species identification, genotyping (vanA, vanB and vanC) and surveillance to the Antimicrobial Resistance Reference 
Laboratory at Statens Serum Institut. From 2015, all clinical VRE isolates have been whole-genome sequenced.
In 2012 and 2013, an increase in clinical vanA E. faecium isolates were observed (Figure 1). They were primarily detected at 
hospitals in the Capital Region, but also from The Zealand Region and the Central Denmark Region. VRE was detected in the 
two remaning regions of Denmark too, but to a much lower extent. Typing of VRE isolates from 2012 and 2013 showed spread 
of several vanA E. faecium clones both within hospitals and between hospitals [Pinholt et al. 2015, J. Antimicrobial. Chemother, 
70:2474-82]. This trend continued in 2014 and 2015, to a total of 372 clinical VRE isolates in 2015. Most of the clinical VRE 
were vanA E. faecium, which increased from 294 in 2014 to 368 in 2015 (Figure 1). In total, 89% of the vanA E. faecium iso-
lates were from hospitals located in The Zealand Region and The Capital Region. The majority of the vanA E. faecium isolates 
belonged to three sequence types; ST80 (33%), ST117 (10%) and ST203 (51%). Whereas the rest of the isolates belonged to 
ST18, ST192 and novel STs (1-6 isolates per STs). The STs were all part of the CC17 complex, which are commonly detected in 
hospitals outside of Denmark. None of the vanA E. faecium isolates belonged to STs linked to animal production (e.g. CC6).
The number of VREs detected from bloodstream infections in 2015 (n=30) was at the same level as in 2014 with one vanA E. 
faecalis, one vanB E. faecium and 28 vanA E. faecium reported.
Conclusion: The continued increase in vanA E. faecium cases in 2015 in Denmark is worrying. VRE can be carried in the intestine 
for a long period without any symptoms of infection and likewise persist in the hospital environment, which makes infection 
control difficult but should include proper cleaning, good hand hygiene, screening for VRE and subsequent isolation of patients.
Anette M. Hammerum, Sharmin Baig, Yasmin Kamel, Marc Stegger and Henrik Hasman 
For further information: Anette M. Hammerum (ama@ssi.dk) 
0
50
100
150
200
250
300
350
400
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
N
o.
 o
f 
is
ol
at
es E. faecalis vanB
E. faecalis vanA
E. faecium vanB
E. faecium vanA
Figure 1. Numbers of vancomycin resistant Enterococcus faecium and Enterococcus 
faecalis isolates from clinical samples and van genes, Denmark DANMAP 2015
119DANMAP 2015
8.RESISTANCE IN HUMAN CLINICAL BACTERIA
8.5  Streptococci
Streptococci include Streptococcus pneumoniae (pneumococci), 
beta-haemolytic streptococci (BHS), and non-haemolytic strep-
tococci (NHS). The prevalence of asymptomatic carriership with 
pneumococci in the nasopharynx varies with age. NHS are part 
of the normal commensal flora of the mouth and upper respira-
tory tract, skin and intestine in humans. 
Pneumococci may cause common and less severe infections 
such as otitis media and sinusitis, and more severe and inva-
sive infections such as pneumonia, bacteraemia, endocarditis 
and meningitis.
BHS of group A cause tonsillitis, otitis media, wound infections, 
but also more severe infections: e.g., bacteraemia, necrotiz-
ing myofasciitis, and rarely meningitis. BHS of group B may 
be present in the vaginal flora of 20-25% of women in the 
childbearing age and may therefore cause meningitis and 
septicaemia in the newborn. These infections also occur in 
elderly or immuno-compromised patients. BHS of groups C and 
G predominantly cause soft-tissue infections and sometimes 
bacteraemia. Approximately 10% of humans are asymptomatic 
throat carriers of BHS of any group. NHS may cause invasive 
infections, the most severe being endocarditis and cerebral 
abscesses – in risk of these are fx persons who undergo dental 
treatment. 
This report presents data on resistance in non-duplicate 
invasive isolates (i.e. from blood or cerebrospinal fluid) of 
pneumococci and BHS submitted in 2015 to the Neisseria 
and Streptococcus Reference laboratory. Isolates are received 
from all DCMs in Denmark. It is mandatory to submit invasive 
isolates of pneumococci in order to enable surveillance of vac-
cine coverage and the prevalent type distribution, while it is 
voluntary to submit isolates of BHS. Non-invasive isolates are 
infrequently received but are not included in this report. There 
is no surveillance of NHS.
Infections with pneumococci and BHS are usually treated with 
penicillins or macrolides. All submitted pneumococci and group 
A, B, C and G BHS were therefore tested for susceptibility to 
penicillin and erythromycin. Moreover, all BHS were tested 
for susceptibility to clindamycin and for inducible clindamycin 
resistance (Table 8.3).
Streptococcus pneumoniae 
Susceptibility testing was performed on 750 isolates of S. 
pneumoniae found in either blood (706 isolates) or cerebro-
spinal fluids (44 isolates) from Danish patients. The isolates 
belonged to 42 different serotypes, of which isolates belong-
ing to 18 serotypes showed non-susceptibility (resistant or 
intermediary resistant) to either penicillin or erythromycin or 
both (54 isolates, 7.2%).
For penicillin, 37 isolates (4.9%) were non-susceptible of which 
2 isolates (0.3%) were resistant. For erythromycin, 39 isolates 
(5.2%) were resistant.
For pneumococci, antibiotic susceptibility is closely connected 
to serotypes. For example, all three of the received invasive 
isolates of serotype 14 were non-susceptible to penicillin, and 
similarly all three of the received invasive isolates of serotype 
9V were resistant to erythromycin. Conversely, all of the 23 
received isolates of serotype 1 were fully susceptible to both 
penicillin and erythromycin. 
With the introduction of pneumococcal vaccines in 2007 
(PCV7) and 2010 (PCV13) in Denmark, the serotype-distribu-
tion was influenced. The total susceptibility-profile of Danish 
invasive pneumococcal isolates have therefore been influ-
enced as well. Serotypes covered by the PCV7 vaccine has di-
minished dramatically, and while 41% of the isolates reported 
to DANMAP were PCV7 serotypes in 2006, in 2015 this had 
decreased to 3%. Some serotypes not included in the vaccines 
are increasing in incidence, while others fluctuate through the 
years. In 2015, the predominant serotype found was serotype 
8 (164 isolates), of which 3 isolates were non-susceptible to 
penicillin, erythromycin or both. Serotype 8 was dominant in 
2014 as well, while in 2013 serotype 1 was dominant with 
100% susceptible isolates (more information on vaccine-cover-
age and serotypes can be found in the EPI-NEWS newsletters 
at www.ssi.dk). 
The levels of penicillin and erythromycin non-susceptibility 
in Denmark were similar to the levels reported in 2014 to 
EARSNet by the neighbouring countries Norway, Sweden, 
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blood and spinal fluid isolates from humans, Denmark 
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Germany, and the United Kingdom. Many other European coun-
tries reported considerably higher levels of resistance in 2014 
[EARS-Net 2014].
The numbers of submitted isolates of BHS of group A, B and 
G were virtually unchanged in 2015 compared to 2014, while 
the number of group C had increased from 80 to 103, thus 
continuing the tendency from 20013 to 2014. 
All BHS isolates were fully susceptible to penicillin. 
The prevalence of resistance to erythromycin and clindamy-
cin showed only minor variation compared to previous years. 
Susceptibility findings for erythromycin and clindamycin are 
shown in Table 8.3.
PneumococcI: TIne Dalby 
Streptococci: Steen Hoffmann 
For further information: TID@ssi.dk
BHS group Susceptibiity testing results 2013 2014 2015
A Number of isolates 177 149 154
Erythromycin resistant, number (%) 5 (2.8%) 1 (0.7%) 3 (1.9%)
Clindamycin resistant, number (%) 3 (1.7%) 1 (0.7%) 0 (0%)
Additionally, inducible clindamycin resistance, number (%) 1 (0.6%) 0 (0%) 2 (1.3%)
Susceptible to penicillin, erythromycin and clindamycin, % 172 (97%) 99% 151 (98%)
B Number of isolates 113 139 140
Erythromycin resistant, number (%) 20 (18%) 31 (22%) 30 (21%)
Clindamycin resistant, number (%) 14 (12.3%) 16 (11%) 14 (10%)
Additionally, inducible clindamycin resistance, number (%) 1 (0.9%) 4 (2.9%) 7 (5.0%)
Susceptible to penicillin, erythromycin and clindamycin, % 92 (81%) 77% 111 (79%)
C Number of isolates 68 80 103
Erythromycin resistant, number (%) 3 (4.4%) 3 (3.8%) 8 (7.8%)
Clindamycin resistant, number (%) 2 (2.9% 3 (3.8%) 2 (1.9%)
Additionally, inducible clindamycin resistance, number (%) 1 (1.4%) 1 (1.3%) 4 (3.9%)
Susceptible to penicillin, erythromycin and clindamycin, %  65 (96%) 95% 95 (92%)
G Number of isolates 145 183 183
Erythromycin resistant, number (%) 17 (11.7%) 19 (10.1%) 18 (9.8%)
Clindamycin resistant, number (%) 6 (4.1%) 3 (1.6%) 5 (2.7%)
Additionally, inducible clindamycin resistance, number (%) 6 (4.1%) 13 (6.9%) 9 (4.9%)
Susceptible to penicillin, erythromycin and clindamycin, % 128 (88%) 90% 167 (91)%
Table 8.3 Beta-haemolytic streptococci: Susceptibility testing results DANMAP 2015
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8.6 Staphylococcus aureus
Staphylococcus aureus is part of the normal flora of the skin 
and mucosa in approximately 50% of humans. Some people 
only carry S. aureus intermittently whereas others carry S. au-
reus for longer time. However, in addition S. aureus also causes 
infections ranging from superficial skin infections i.e. impetigo 
and boils to invasive infections such as post-operative wound 
infections, infections related to intravenous catheters and 
prosthetic devices, bacteremia, osteomyelitis, endocarditis and 
septic arthritis.
In Denmark, a voluntary surveillance programme of all S. aure-
us bacteremia cases was established in 1957. Laboratory and 
clinical notification of Methicillin-resistant S. aureus (MRSA) 
has existed since November 2006. At SSI, all isolates are 
typed by spa typing, susceptibility testing is performed for 17 
antimicrobials and the presence of the gene lukF-PV is deter-
mined.  LukF-PV codes for a cytotoxin (Panton-Valentine leu-
cocidin, PVL), which has been closely linked to skin abscesses 
and the very rare condition of severe necrotizing pneumonia. 
PVL is found both in MSSA and MRSA, for MRSA PVL has been 
closely associated with community acquired MRSA strains. In 
addition demographic and epidemiological information is reg-
istered. Based on the epidemiological information each case is 
classified with respect to possible place of acquisition: hospital 
(HA), community (CA), healthcare-associated with a community 
onset (HACO), import (IMP) and livestock-associated MRSA 
(CC398). For CA and HACO classification is separated into 
known and not known exposure.
Surveillance of bacteraemia 
In 2015, 1,973 S. aureus bacteremia cases corresponding to 
36.71 cases per 100,000 inhabitants were reported from the 
Departments of Clinical Microbiology (DCM) in Denmark. For 
the third year in a row, the number of cases was higher than 
in the previous year (ca. 1,500 annual cases). By compari-
son with the numbers of bacteremia cases registered in the 
Danish Microbiology Database (MiBa) since 2010, the number 
of cases reported to SSI has been almost complete (94-97%). 
The increasing number of cases the last 3 years may therefore 
reflect a change in practice in the hospitals, with either more 
samples taken, improved diagnostics or both as well as a real 
increase in occurence. Twenty-nine (1.5%) of the bacteremia 
cases were caused by MRSA. This is a decline compared to 
2014 but at the same level as in previous years, and still very 
low compared to most other countries participating in EARS-
Net [EARS-Net 2014]. Three of the 29 MRSA cases were 
caused by CC398 (8 MRSA CC398 in 2014). Four hundred and 
fifty two (23%) patients died within thirty days of the onset 
of bacteremia. The mortality for the MRSA bacteremia cases 
was 24% (n=7). Antimicrobial resistance in S. aureus bactere-
mia isolates from 2005–2015 is presented in Table 8.4. The 
highest frequency of resistance to other antimicrobials than 
penicillin was observed for fusidic acid (16%), erythromycin 
(7%), clindamycin (7%) and norfloxacin (6%). Susceptibility 
to all tested antimicrobial agents was at the same level as in 
2014, but resistance to erythromycin, clindamycin, fusidic acid 
and norfloxacin has increased steadily since 2005 (Table 8.4). 
Typing identified 567 different spa types distributed in 25 
different CC groups (the ten most prevalent spa types repre-
senting 33% of the total are presented in Table 8.5). The PVL 
toxin was demonstrated in 25 (1.3%) cases of which five were 
MRSA. The 25 PVL containing isolates were distributed over 
22 different spa types and 10 different CC groups.
Antimicrobial agent 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
% % % % % % % % % %
Methicillin 1.4 0.6 1.3 1.6 1.4 1.4 1.2 1.7 2.9 1.5
Penicillin 80 78 77 77 75 77 74 76 77 71
Erythromycin 5 4 5 7 5 7 6 7 8 7
Clindamycin 4 3 4 6 4 6 6 6 8 7
Tetracycline 3 2 3 2 3 2 2 3 5 4
Fusidic acid 10 9 9 9 13 13 14 15 15 16
Rifampicin <1 <1 <1 <1 <1 <1 <1 0 <1 <1
Norfloxacin 2 1 2 2 3 4 4 5 6 6
Kanamycin 1 <1 1 1 1 <1 1 2 2 3
Linezolid nt nt 0 0 0 0 0 0 0 0
Mupirocin 0 <1 <1 <1 <1 <1 <1 <1 <1 <1
Trimethoprim-sulfamethoxazole nt nt nt nt nt <1 1 1 1 <1
Notes: nt = not tested. In web annex table A8.1 the distribution of MICs and resistance for all tested antimicrobial agents are shown.
Table 8.4. Resistance (%) in isolates from S. aureus bacteraemia cases, Denmark DANMAP 2015
DANMAP 2015122
RESISTANCE IN HUMAN CLINICAL BACTERIA8.
Surveillance of methicillin-resistant S. aureus 
In 2015, 2,972 new MRSA cases were detected (52.1 per 
100,000 inhabitants). This was at the same high level as ob-
served in 2014 in Denmark (Figure 8.13). A case was defined 
as a person found positive for the first time with a specific 
MRSA strain regardless whether the patient was infected or 
colonized only. MRSA isolates were confirmed by detection of 
either the mecA or more uncommonly, the mecC gene.
In 2015, the number of new MRSA cases stabilized for the first 
time since 2009. CC398 cases constituted 39% (n=1,173) of 
new MRSA cases in 2015, which is a slight decrease compared 
to 2014 (Table 8.6). This decrease was expected to occur 
at some point, since the intensive screening of people with 
contact to livestock introduced in the MRSA guidelines in 2012 
has detected many CC398 cases in previous years, thus reach-
ing a saturation in this sub-population. 
MRSA isolates carrying mecC were demonstrated in 61 cases 
(2.1%) in 2015 (9 in 2009, 21 in 2010, 37 in 2011, 24 in 
2012, 41 in 2013 and 53 in 2014). Thirty-nine of the cases 
(64%) had infections at the time of diagnosis. Only two pos-
sible livestock contacts were registered for the 61 mecC cases.
The total number of cases and the number of cases presenting 
with infection according to epidemiological classification are 
DANMAP 2015
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Figure 8.13. Number of methicillin-resistant Staphylococcus aureus cases, with a three years moving average, Denmark
DANMAP 2015
SAB MRSA
spa type CC group(a) No. of cases spa type CC group(a) No. of cases No. causing 
infections (%)
t127 CC1 96 t002 CC5 173 94 (54)
t084 CC15 89 t127 CC1 148 75 (51)
t002 CC5 84 t008 CC8 122 79 (65)
t230 CC45 82 t304 CC8 112 46 (41)
t091 CC7 60 t019 CC30 90 60 (67)
t012 CC30 57 t223 CC22 87 37 (43)
t015 CC45 53 t044 CC80 48 22 (46)
t021 CC30 46 t437 CC59 44 31 (70)
t701 CC8 45 t032 CC22 40 21 (53)
t008 CC8 36 t843 CC130 38 21 (55)
Table 8.5. The ten most prevalent spa types demonstrated in SAB and in non- CC398 MRSA cases, Denmark 2015
a) CC = Clonal complex
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shown in Table 8.6. Most of the cases (83%) were acquired in 
Denmark. At the time of diagnosis, 39% (n=1,147) of cases 
had infection, which was similar to 2014 but lower than in pre-
vious years due to a much lower fraction of infections among 
CC398 cases (n=208, 18%). 
The epidemiological classification of MRSA infections 2007–
2015 is shown in Figure 8.14. Despite the overall increasing 
total number of cases, the number of hospital acquired infec-
tions (n=25) and the number of healthcare-associated with 
community onset (HACO) infections (n=141) were at stable 
very low levels. The number of CA and imported infections 
continued the increasing trend in 2015 and were by far the 
two largest groups (n = 500 and n= 273, respectively) while 
infections caused by CC398 decreased in 2015 (n=208) from 
240 cases in 2014 (Figure 8.14).
Molecular typing of the MRSA strains 
In total, spa typing revealed 293 different strain types not 
including isolate belonging to CC398 of which 204 types were 
associated with clinical infections. The single most abundant 
spa type detected was t034 (n=237). The 10 dominating 
non-CC398 spa types isolated in 2015 are shown in Table 
8.5. They constituted 50% of the total number of non-CC398 
Table 8.6. Epidemiological classification of new MRSA cases, Denmark
Epidemiologic 
classification
Exposure No. of cases (% 
of total)
No. (%) of cases 
with infections 
Imported (IMP) 500 (17) 273 (55)
Hospital-acquired (HA) 40 (1) 25 (63)
Health-care associated,  
community onset (HACO)
171 (6)
with known exposure 16 5 (31)
without known exposure 155 128 (83)
Health care worker 31 (1) 8 (26)
Community-acquired (CA) 1057 (36)
with known exposure 516 79 (15)
without known exposure 541 421 (78)
CC398 1173 (39)
with known exposure 982 131 (13)
without known exposure 140 77 (55)
project sampling 51 0 (0)
Note: Numbers shown in bold are totals
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Figure 8.14. Number of MRSA infections according to epidemiological classification, Denmark DANMAP 2015
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Staphylococcus aureus has been surveyed in Denmark since 
1957 and has thus been included in DANMAP since its initia-
tion. From its very beginning S. aureus bacteremia (SAB) 
surveillance has been based on a voluntary submission of 
all S. aureus bacteremia isolates from the Clinical Microbiol-
ogy Departments and registration of clinical epidemiological 
data. This information together with antimicrobial susceptibil-
ity testing, typing results and isolates has been curated by 
Statens Serum Institut. A comparison of submitted isolates 
to SSI in the period 2010-15 with SAB cases registered in 
the National Microbiology Database (MiBa) showed 95-97% 
concordance in the period.
The number of SAB cases has increased throughout the period 
and has now reached almost 2,000 annual cases. Most of 
these cases are in elderly people who often suffer from one or 
more comorbidities. The mortality rate decreased steadily from 
almost 50 % in the 1960s to around 20% in 1990 but has 
since remained stable. 
During the surveillance period, the methodology has changed 
due to technical developments. Unil the late 1990s strains 
were typed using phage typing, this was followed by a DNA 
restriction analysis  pulse field gel electrophoresis, which 
again was replaced by sequencing of the spa gene in 2006. 
This method has the great advantage that it easily can be 
compared to what is done in other laboratories. Tablet and disk 
diffusion has been used until 2013, were it was replaced by 
microbroth dilution to determine the MIC values for differ-
ent panels of antimicrobials. MRSA was common among SAB 
isolates in the period 1965- 75 with frequencies of 15-25%. 
In 1967, MRSA accounted for 46% of SAB cases in hospital-
ized patients. This was primarily due to the success of isolates 
belonging to phage type 83A complex, which were often 
also resistant to tetracycline, streptomycin and erythromycin. 
These clones were replaced by other less resistant types of 
S. aureus and from the mid- 1970s the frequency of MRSA 
among SAB isolates decreased and has remained below 2% 
among SAB cases, except in 2014 were it reached 2.9%. 
Staphylococcus aureus  
surveillance, 1996-2015
MRSA isolates. Ten spa types constituted 45% of the 1,147 
clinical infections with MRSA. These most prevalent spa types 
causing clinical infections at time of presentation were t002/
CC5 (n=94), t008/CC8 (n=79), t127/CC1 (n=75), t019/CC30 
(n=60), t304/CC8 (n=46), t034/CC398 (n=46), t223/CC22 
(n=37), t437/CC59 (n=31), t657/CC1 (n=25) and t044/CC80 
(n=22). The PVL encoding gene lukF-PV was demonstrated 
in 34.6% of the infections and in 12.5% of the asymptomatic 
carriers and most often in relation to isolates with spa types 
t008 (n=98), t019 (n=88), t002 (n=60), t044 (n=47) and t127 
(n=39).
Resistance among MRSA isolates 
Resistance data is presented in Table 8.7 and is divided into 
two categories: CC398 and other. CC398 isolates were typi-
cally resistant to tetracycline (100%) and clindamycin (87%) 
with high levels of resistance to erythromycin and norfloxacin 
(43% and 29%, respectively). Resistance to fusidic acid and ka-
namycin was higher among non-CC398 (19% vs 1% and 32% 
and 7%, respectively). Resistance to at least 1, 2 or 3 other 
antimicrobials in addition to β-lactam antibiotics (cefoxitin/
penicillin) was demonstrated in 64%, 45% and 31% of non-
CC398 the cases, respectively.
Andreas Petersen, Robert L. Skov and Anders Rhod Larsen
%
non-CC398 CC398
Erythromycin 37 43
Clindamycin 29 87
Tetracycline 24 100
Fusidic acid 19 1
Rifampicin <1 0
Norfloxacin 21 29
Kanamycin 32 7
Linezolid 0 0
Mupirocin <1 0
Trimethoprim-sulfamethoxazole 4 1
Number of tested isolates 1242 68
Table 8.7. Resistance (%) in MRSA isolates,  
Denmark 2015   
In web annex table A8.2 the distribution of MICs and resistance for all 
tested antimicrobials are shown.
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A complete MRSA surveillance was established on a voluntary 
basis in 1988, improved with a systematic collection of clinical 
information since 1999, and ultimately became notifiable in 
November 2006. Figure 8.13 shows the number of new MRSA 
cases registered in the period 1994-2015. Until 2001, less 
than 100 new cases were registered annually. The following 
increase has mostly been driven by the emergence of com-
munity associated (CA-) MRSA, which depicted a completely 
new era in MRSA evolution and epidemiology since MRSA had 
previously been restricted to hospital settings. 
The first Danish CA-MRSA (European CA-MRSA CC80-IV) cases 
were reported in 1997. These were followed by emergence of 
other CA-MRSA clones, most notably the South West Pacific 
(ST30-IV) and USA300 (ST8-IV), named after the geographic 
epicenters of their emergence. Import of these clones has 
occurred with travelers, migrants and refugees and has sub-
sequently led to secondary transmissions in the local com-
munities. The CA-MRSA clones share molecular characteristics, 
which may be of  
 
Of importance for the success of these clones outside hospital 
settings were: Smaller SCCmec elements (carrying the mecA 
gene, responsible for the MRSA phenotype) type IV and V 
compared to the SCCmec II and III found in the older hospital 
clones; and carriage of the Panton-Valentine leukocidine (PVL) 
genes. The smaller SCCmec elements IV and V in CA-MRSA may 
be an adaptation to the environment outside hospitals with 
less need for additional resistance genes and the PVL genes 
may increase infectivity in the skin and thereby transmission. 
Despite of the increasing number of CA-MRSA in Denmark, in-
fection control procedures has ensured a low level in hospitals. 
The annual number of patients acquiring MRSA infections in 
hospital has remained below 50 cases since 2006. 
Very few larger hospital outbreaks have been noted with the 
exception of the ST22-IV outbreak in Vejle County that went 
on for more than 4 years between 2002-2006. This outbreak 
peaked in 2005 and accounted a total of 514 cases during the 
4 years. 
However, as seen in Figure 8.13 the decline in MRSA following 
the “Vejle outbreak” was only temporary, since the numbers 
of imported cases, CA-MRSA as well as spread into health care 
facilities has continued. 
A new wave in the evolution of MRSA appeared with the 
emergence of MRSA in livestock (LA-MRSA). The spread of this 
clone among livestock was very fast with 3% of pig herds be-
ing positive in 2008, 15 % in 2011 and 68% in 2014. The first 
human cases with LA-MRSA (CC398) occurred in 2004 and the 
incidence has increased dramatically in the years after, peak-
ing in 2014 with 1,277 new cases. In 2012, a revision of the 
MRSA guidelines from the Danish Health Authorities, depicted 
screening of people with livestock contact at hospital admis-
sions. Consequently, CC398 cases are more often found by 
active screening than from clinical samples (20%) compared to 
other MRSA types (40-50%). The cases most often have docu-
mented contact to pigs (85-89%). The human to human trans-
mission appears to be less effective for this clone compared 
to others, which may be due to its adaptation to livestock as 
host, a feature that may be linked to the absence of the human 
immune modulatory genes (scn, sak and chp). Furthermore, the 
predominant SCCmec element found in CC398 is a type IV vari-
ant (5C2&5) that is comparable large to the old hospital type 
II and III elements probably making CC398 less fit to survive in 
the community. 
Despite the steady increase in MRSA in the surveillance period, 
the frequency has remained low compared to other European 
countries (EARSSnet.org) and most importantly the number of 
infections in hospitalized patients low. This success in keep-
ing a low frequency of MRSA in Denmark, the other Nordic 
countries (www.nordicmrsa.org) and in the Netherlands is most 
likely a result of the “search and destroy” policy in the hospi-
tals in combination with a general rational antibiotic policy. 
For further information: Anders Rhod Larsen (ARL@ssi.dk), Andreas 
Petersen, Robert Skov, (RSK@ssi.dk)
Staphylococcus aureus  
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Textbox 8.4 
LA-MRSA CC398 in people with no livestock contact and  
in various animal populations
LA-MRSA CC398 in people with no livestock contact
Danish pigs constitute a rapidly expanding reservoir of LA-MRSA CC398 and occupational contact to pigs is known to be a 
major source of MRSA in livestock workers where they may also cause infections (Textbox 8.5, DANMAP 2014). In a recent 
Danish study, Statens Serum Institut analyzed patient information and MRSA strain typing results collected between 1999 and 
2011 to investigate the emergence and early epidemiology of LA-MRSA CC398 in humans [Larsen et al. 2015. Euro. Surveill. 
20:pii=30021]. The study included 148 LA-MRSA CC398 cases were infections were registered. The incidence increased by ca. 
66% per year from the first cases in 2004 to 2011 (from 0.093 to 1.1 per 100,000 person-years). Approximately one-third of 
the new infections per year were observed in people with no livestock contact, of whom the vast majority lived in rural areas 
with livestock production. Figure X shows that this proportion of LA-MRSA CC398 infections in people with no livestock contact 
has remained stable when analyzing data from 2012 to 2015 (Statens Serum Institut, unpublished data). Only seven of the 
148 documented LA-MRSA CC398 infections during 2004-2011 occurred in Copenhagen. Thus, the risk of acquiring a LA-MRSA 
CC398 infection was higher in rural areas compared to other areas of Denmark, including Copenhagen. However, LA- MRSA 
CC398 only accounted for a small proportion of all MRSA infections in the period, and the overall incidence in people without 
direct or indirect exposure to animals was not statistically different between urban and rural municipalities. These findings sup-
port that LA-MRSA CC398 is able to spread from animal farms into the surrounding community most likely via livestock workers, 
whereas the low number of LA-MRSA CC398 infections in urban areas of Denmark suggests that foodborne transmission does 
not play a major role in the LA-MRSA CC398 epidemiology. In 2012, screening of livestock workers at hospital admissions was 
amended to the MRSA guidelines from The Danish Health Authority. Consequently, many livestock workers have been tested 
and found LA- MRSA CC398 positive in the years after and non-tested persons in this subpopulation has diminished. This may 
explain the decrease in incidence observed in 2015, as only new MRSA cases are reported. Since asymptomatic carriage of 
CC398 MRSA in livestock workers is not treated, the accumulated numbers of MRSA positive livestock workers has most likely 
increased during the years and thereby the potential source for secondary transmissions. Despite of that, the incidence of 
CC398 MRSA among the general population has not increased in 2015, which indicates that secondary transmissions are lim-
ited. This limitation could be due to constraints of the CC398 MRSA in the competition with other S. aureus in the environment 
outside the stables or in the human host, which needs to be investigated in more details.
Figure 1. Number of new patients with LA-MRSA CC398 infection per year.
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LA-MRSA CC398 in various animal populations
During 2015 the Danish Veterinary and Food Administration conducted a series of screenings for LA-MRSA in different produc-
tion animal populations, poultry, veal calves, mink, and organic pigs. In the poultry herds, which comprised broilers, layers, and 
turkeys, all in all 54 herds, 25 choanal swab samples were collected and analyzed in pools of 5. In veal calves, 25 animals were 
sampled in each of 50 herds by nasal swab samples, which also were analyzed in pools of 5. A total of 64 organic pig herds were 
also sampled, 5 pools of 5 nasal swabs from each herd. Finally, an investigation of 50 mink farms was conducted. These farms 
were all samples during the pelting season so that the animals could be sampled immediately after euthanasia. On each farm, 
25 animals were sampled by pharyngeal swabs. Findings are shown in Table 1.
Table 1. LA-MRSA in various production animals
Production animal Number of herds sampled Number (%) LA-MRSA positive herds
Poultry 54 1 (2%)
Organic pigs 64 4 (6%)
Veal calves 50 5 (10%)
Mink 50 8 (16%)
 
The single poultry herd that was found positive was a turkey flock. The finding indicates that LA-MRSA is not common in Dan-
ish poultry production. Among the organic pig herds, only 6 % were positive for LA-MRSA, as opposed to the 63-68 % positive 
conventional herds that was found in a screening in 2014. The reasons for this marked difference are essentially unknown but 
presently under investigation, as it may provide important knowledge about the epidemiology of LA-MRSA in pigs.
Sixteen percent of the mink farms were found positive for LA-MRSA. However, there are indications from other investigations 
that the proportion of positive farms is in fact higher, and that LA-MRSA may also be found in the mink feed (Hansen et al., un-
published). LA-MRSA was detected in 5 of the 50 veal calf farms, corresponding to 10 %. In another investigation in Danish veal 
production carried out by DTU and SEGES in 2015, 2 out of 17 herds were found positive, but out of 697 sampled animals, only 
4 were found positive, suggesting a low within-herd prevalence. LA-MRSA is therefore concluded to be a minor issue in Danish 
veal production.
Jesper Larsen, Andreas Petersen, Anders Rhod Larsen, Robert Skov, Karl Pedersen 
For further information: Anders Rhod Larsen (arl@ssi.dk), Karl Pedersen (kapes@vet.dtu.dk) 
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8.7 Neisseria gonorrhoeae
Background: Neisseria gonorrhoeae is the causative agent 
of the sexually transmitted infection gonorrhoea, which is 
usually located in the urethra in males and cervix in females. 
N. gonorrhoeae (gonococci) may sometimes be demonstrated 
in specimens from the pharynx or rectum in either gender. In 
females, the finding of gonococci in rectal specimens is usually 
due to colonization after contamination with vaginal secre-
tion, while in men who have sex with men (MSM) it is due to 
unprotected anal sex leading to infection. In both genders the 
condition is generally asymptomatic. Pharyngeal gonorrhoea is 
virtually always asymptomatic. 
Complications of gonorrhoea include e.g. salpingitis, epididymi-
tis, orchitis, and prostatitis. Further, conjunctivitis may occur in 
newborns after transmission from an infected mother during 
labour and rarely in adults following direct inoculation.
Methods: Through decades, all Departments of Clinical Micro-
biology in Denmark have submitted their isolates of gonococci 
to the Neisseria and Streptococcus Reference (NSR) laboratory 
at Statens Serum Institut for national surveillance of antimicro-
bial resistance. 
At the NSR laboratory ceftriaxone, ciprofloxacin and azithromy-
cin MICs were determined using the Etest® on chocolate agar 
incubated at 35°C in 5% CO2. The breakpoints used were those 
defined by the EUCAST. Both fully and intermediary resistant 
isolates are categorized as resistant in this report. Penicillinase 
production was tested for using the Nitrocephin assay.
As part of NSR’s participation in ECDC’s surveillance of sexu-
ally transmitted infections since 2009, approximately 110 
gonococcus isolates are investigated per year for susceptibility 
to an expanded panel of antimicrobial agents. In addition to 
ceftriaxone, ciprofloxacin and azithromycin, this panel includes 
cefixime and in selected years also spectinomycin, and gen-
tamicin. The latter two drugs were not included in the surveys 
in 2014 and 2015.
Results and discussion: Most of the received isolates were 
from urethra or cervix, while clinicians only rarely obtain speci-
mens from rectum and pharynx. Occasionally, the NSR labora-
tory receives strains isolated from other anatomical sites, such 
as conjunctivae, joint fluid, blood, Bartholin’s abscess, etc.
In 2015, isolates from 1127 unique cases of gonorrhoea were 
received. The annual number has increased considerably from 
2011 through 2015, presumably because the widespread use 
of combined PCR-testing for Chlamydia trachomatis and N. 
gonorrhoeae has identified unexpected cases of gonorrhoea 
(followed by culture), but possibly also due to an increasing 
incidence of gonorrhoeae.
The ciprofloxacin resistance rate was 46% in 2014 and 29% 
in 2015, thus showing a steady decline since the peak of 75% 
in 2009 (Figure 8.15). The percentage of strains producing 
penicillinase was 8% in 2015. It has fluctuated between 22% 
in 2005 and 11% in 2014 and 2013.
Ceftriaxone resistant gonococci (MIC > 0.125 mg/L) as well as 
ceftriaxone treatment failure in patients with gonorrhoea have 
occurred in several countries during recent years. No cases 
from Denmark have ever been reported. During 2003 through 
2009 the proportion of isolates with MIC ≥  0.008 mg/L 
gradually increased from 40% to nearly 75% (Figure 8.16), 
but  during recent years this shift has nearly reversed (44% in 
2014 and 17% in 2015). Thus, there is no evidence of emerg-
ing ceftriaxone resistance in Denmark.
In 2014, azithromycin resistance including intermediary resist-
ance (MIC > 0.5 mg/L) in gonococci was 36% while in 2015 
it was 11% (Table 8.8). The National Board of Health issued 
guidelines in 2015 for the diagnosis and treatment of sexually 
transmitted infections. A combination of high dose ceftriaxone 
(500 mg i.m.) and azithromycin (2 g) is recommended for the 
treatment of gonorrhoea. Ciprofloxacin 500 mg p.o. may be 
used for treatment if the strain is fully susceptible. 
Resistance against cefixime (MIC > 0.125 mg/L) was 6% in 
2014, i.e. a decrease compared to 2013, and further decreased 
to 0% in 2015. Cefixime is an oral cephalosporin that has 
never been used in Denmark. 
Conclusions: The incidence of gonorrhoea is increasing sub-
stantially. Although resistance problems are so far not present in 
Denmark, the emerging ceftriaxone treatment failures in other 
countries underlines the importance of maintaining the central-
ised national surveillance of antimicrobial resistance in gonococci. 
Steen Hoffmann 
For further information: Steen Hoffmann (hof@ssi.dk)
Antimicrobial agent 2009 2010 2011 2012 2013 2014 2015
Azithromycin 46 23 12 12 45 36 11
Cefixime 15 18 21 11 9 6 0
Spectinomycin 0 0 0 0 0 NT NT
Number of isolates 119 111 126 114 111 108 1127
Table 8.8. Resistance rates (%) against azithromycin, cefixime and spectinomycin in gonococci, Denmark 2009–2015 
NT = not tested
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Figure 8.15. Ciprofloxacin resistance and penicillinase production in gonococci, Denmark 2003–2015
Figure 8.16. Distribution of ceftriaxone MIC values in gonococci, Denmark 2003–2015
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Figure 1. Ciprofloxacin resistance and penicillinase production in gonococci, Denmark, 
2003 2015
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Figure 2. Distribution of ceftriaxon MIC values (mg/L) in gonococci, Denmark, 
2005-2015
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Textbox 8.5  
Increasing rates of drug-resistance in Mycobacterium tuberculosis 
isolates in Denmark
Background: In recent years, the global incidence of tuberculosis (TB) has declined. However, the emergence of drug-resistant 
Mycobacterium tuberculosis (Mtb) strains challenges TB control in many parts of the world, especially Eastern Europe, Asia and 
Southern Africa (https://extranet.who.int/sree/Reports?op=vs&path=/WHO_HQ_Reports/G2/PROD/EXT/MDRTB_Indicators_map). 
Multidrug-resistant (MDR) TB is caused by Mtb resistant to at least rifampin and isoniazid, the two most important drugs for 
TB treatment. Extensively-drug-resistant (XDR) TB is a form of MDR-TB with additional resistance to any of the fluoroquino-
lones (e.g. moxifloxacin) and to at least one of three injectable second-line drugs (amikacin, capreomycin or kanamycin). By 
now, XDR-TB has been reported in 105 countries worldwide [1]. Mtb drug resistance is caused by spontaneous mutations in 
genes during the bacterial multiplication, which confer resistance to the drugs at different frequencies. Exposure to a single 
drug, or suboptimal drug concentrations, provides a selective environment favouring drug-resistant bacteria and the develop-
ment of MDR/XDR-TB [2]. Previously, MDR-TB has only been identified in approx.0.5% of all culture-verified TB-cases in Den-
mark, corresponding to approx. two cases per year, and until recently in 2013, XDR-TB had not been seen. In comparison, in 
the WHO European Region, the prevalence of MDR-TB among 88,732 new pulmonary TB cases tested was 18.4% in 2014 [3]. 
Methods: In Denmark, all clinical samples from suspected TB patients have been cultured at the International Reference Labo-
ratory of Mycobacteriology, Statens Serum Institut (SSI). At first, stained using auramine-rhodamine followed by fluorescence 
microscopy. Then, cultured in liquid medium (BACTEC MGIT 960 System, BD) and solid medium (Löwenstein-Jensen). If culture 
positive, Mtb has been identified by MTBC TBc ID (BD) and GenoType MTBC (Hain Lifescience) and phenotypic susceptibility 
tests have been performed by the modified proportion method on liquid media in MGIT 320/960 Systems (BD) supplemented 
by genotypic susceptibility tests with GenoType MTBDRplus and GenoType MTBDRsl (Hain Lifescience).  
Results: Five MDR-TB cases and 1 XDR-TB case were detected in Denmark in 2015 among approx. 358 notified cases, corre-
sponding to 1.7% MDR/XDR-TB in total. The XDR-TB case was Russian-born and found to be resistant to 13 out of 15 tested 
antibiotics (!) In addition, 1 Somalian-born MDR-TB case was resistant to all fluoroquinolones, and 1 Syrian-born MDR-TB case 
was resistant to 2 out of 3 tested injectable second-line drugs. Thus, these two cases were “pre-XDR”. Two of the 3 other 
MDR-TB cases were from Somalia whereas one was from Denmark. Additionally 13 cases (3.6%) were isoniazid mono-resis-
tant.
Discussion: The 2015 drug-resistance figures for Mtb are the highest ever registered in Denmark with 5 MDR-TB-cases plus 
the only second XDR-TB case in the country; the first was registered in 2014. In addition, two of the MDR-TB cases were “pre-
XDR” with additional problematic resistance. Although the total figures are small, we have to be prepared for an increasing 
number of MDR/XDR-TB cases in Denmark in the future. It is important to remind clinicians to be aware of drug-resistant tu-
berculosis and remember to send all specimens for culturing, among others, to secure sensitive, fast and correct susceptibility 
testing, performed through a combination of phenotypic- and genotypic test methods. The sensitivity of genotypic tests only 
is low [4] as well as the positive predictive value [5] and genotypic tests are only available for a limited number of drugs [2]. 
Troels Lillebaek and Erik Svensson, International Reference Laboratory of Mycobacteriology, SSI. 
For furher information: Troels Lillebaek tll@ssi.dk 
[1]  http://who.int/mediacentre/factsheets/fs104/en/
[2]  Domínguez J, Boettger E, Cirillo D, Cobelens F, Eisenach K, Gagneux S, Hillemann D, Horsburgh R, Molina-Moya B, Niemann S, Tortoli E, 
Whitelaw A, Lange C, TBNET and RESIST-TB networks. Clinical implications of molecular drug resistance testing for Mycobacterium 
tuberculosis: a TBNET/RESIST-TB consensus statement. Int J Tuberc Lung Dis 2016;20(1):24-42.
[3]  European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 
2016. Stockholm: European Centre for Disease Prevention and Control, 2016.
[4]  Arentz M, Sorensen B, Horne DJ, Walson JL. Systematic review of the performance of rapid rifampicin resistance testing for drug-resistant 
tuberculosis. PLoS One 2013; 8(10): e76533
[5]  Tomasicchio M, Theron G, Pietersen E, Streicher E, Stanley-Josephs D, van Helden P, Warren R, Dheda K. The diagnostic accuracy of the 
MTBDRplus and MTBDRsl assays for drug-resistant TB detection when performed on sputum and culture isolates. Scientific Reports 2016. 
6:doi:10.1038/srep17850
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9. Materials and methods
9.1 General information
For the DANMAP 2015 report, population sizes and geographi-
cal data were obtained from Statistics Denmark [www.dst.
dk] and data on general practitioners from the Danish Medical 
Association [www.laeger.dk].
The epidemiological unit for pigs and cattle was defined as 
the individual farm level, meaning that only one isolate per 
bacterial species per farm was included in the report. The 
same epidemiological unit was applied for broilers, except for 
Salmonella where the individual flock of broilers was defined 
as the epidemiological unit. For food, the epidemiological unit 
was defined as the individual meat sample. For humans, the 
epidemiological unit was defined as the individual patient and 
the first isolate per patient per year was included.
Unless stated otherwise, all differences and temporal trends 
were tested for statistical significance (p<0.05) using Chi-
square tests (see Section 9.6.3).
9.2 Data on antimicrobial consumption
An overview of all antimicrobial agents used for humans and 
animals in Denmark is presented in Table 3.2.
Antimicrobial usage for animals in Denmark
In Denmark, all antimicrobial agents used for treatment were 
available on prescription only. Antimicrobial agents were only 
sold by pharmacies or as medicated feed from the feed mills 
until 2007. From April 2007, the monopoly was suspended 
and private companies (four in 2015) were given license to 
sell prescribed veterinary medical products for animals, when 
following strict guidelines, identical to pharmacies. Further-
more in 2007, price setting of antibiotic was liberalised, which 
allowed for discounts e.g. to veterinarians, when buying larger 
quantities.
The pharmacy or company either sells the medicines to veteri-
narians for use in the practice or for re-sale to farmers, or sells 
the medicines directly to the animal holder on presentation 
of a prescription. By law, veterinarians are allowed only very 
small profits on sale of medicine (5%), to limit the economic 
incentive to overprescribe.
In 2015, 98% of antimicrobial agents were purchased through 
pharmacies and the drug trading companies, while 2% were 
purchased from the feed mills. These numbers did not include 
prescribed zinc oxide from the feeding mills for the pigs. For 
cattle, the majority of antimicrobial agents were purchased 
from pharmacies, whereas 10 years ago where more than 
80% of the antimicrobial agents used in cattle was purchased 
through the veterinarian. In aquaculture, more than 80% is 
purchased through the feed mills.
Data registration
In addition, data on coccidiostatics as feed additives (non-pre-
scription) and antimicrobial growth promoters (not in use since 
2000) were also collected by VetStat, providing an almost com-
plete register of all antimicrobials used for animal in Denmark 
each year. In very rare instances medicines are prescribed on 
special license and will not be included in VetStat (i.e. medi-
cines not approved for marketing in Denmark).
Data on all sales of veterinary prescription medicine from the 
pharmacies, private companies, feed mills and veterinarians are 
sent electronically to a central database called VetStat, which 
is hosted by the Danish Veterinary and Food Administration. 
Prior to 2001, all data on antimicrobial sales were derived from 
pharmaceutical companies. Veterinarians are required by law 
to report all use of antibiotics and prescriptions for produc-
tion animals to VetStat monthly. For most veterinarians, the 
registration of data is linked to the writing of invoices. The 
electronic registration of the sales at the pharmacies is linked 
to the billing process and stock accounts at the pharmacy, 
which ensures a very high data quality regarding amounts and 
identity of drugs. Data are transferred daily from pharmacies 
to The Register of Medicinal Product Statistics at SSI and on to 
VetStat also daily. However, VetStat does not have any valida-
tion on data entry and slight typing errors from vets may occur. 
The VetStat database contains detailed information about 
source and consumption for each prescription item: date of 
sale, identity of prescribing veterinarian, source ID (identity 
of the pharmacy, feed mill, or veterinarian practice reporting), 
package identity code and amount, animal species, age-group, 
disease category and code for farm-identity (CHR Danish 
Central Husbandry Register). The package code is a unique 
identifier, relating to all information on the medicinal product, 
such as active ingredient, content as number of unit doses (e.g. 
number of tablets), package size, and code of the antimicro-
bial agent in the Veterinary Anatomical Therapeutic Chemical 
(ATCvet) classification system.
Knowledge of the target animal species enables the presentation 
of consumption data in “defined animal daily doses” a national 
veterinary equivalent to the international defined daily doses 
(DDDs) system applied in the human field [www.whocc.no].
Methods
DANMAP reports consumption of antimicrobials in different 
animal populations and in veterinary and human sectors. To 
allow for quantitative comparison in the different population, 
the quantity of antimicrobials used, their potency, their for-
mulation, the route of administration, the age of the animals 
(where relevant) and the population sizes are accounted for by 
generating DADDs. 
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The basic principles for the DADD are similar to the principles 
previously described for the ADD [DANMAP 2011, DANMAP 
2012]. The DADD is based on the VetStat ADDs, but re-defined 
for each group of antimicrobial agents, adding adjustments for 
each combination of active compound, administration route, 
formulation, according to following principles:
1. A DADD group is defined for each antimicrobial agent by 
administration route and animal species; and when appro-
priate also age group.
2. Minor inconsistencies have been corrected e.g. due to 
rounding of numbers,;
3. Approved dosage for the most widely used antimicrobial 
products were given priority above dosage for products that 
are rarely used;
4. Approved dosage for older products within the group were 
maintained as the common DADD even if a new product is 
approved with a higher dosage;
5. If the dosage for a group with large variation in approved 
dosages of the products, the dosages provided by ”The 
Veterinary Formulary” [British Veterinary Association, 2005, 
6th edition] were applied;
6. Dosages may vary within active compound and administra-
tion route, if different dosages have been approved for 
different age group/indication or formulation.
When principle 3 and 4 are conflicting, principle 5 is applied. 
Denominator
Trends in antimicrobial consumption in pigs are presented in 
DADD per 1,000 animals per day – DAPD. The number of ani-
mals in a population (in epidemiological terms: the population 
at risk) is represented by their live biomass. The biomass of a 
species is calculated, taking into account average live body-
weight and the average life-span in each age group. In 2015, 
DAPD calculations were carried out for pigs only.
Due to a relative high number of pigs exported around 30 kg, 
an adjusted measure of consumption per pig was calculated. 
The adjustment is based on the assumption that pigs exported 
at 30 kg, on average, received the same amount of antimicrobi-
al agents before export, as other pigs from farrowing to 30 kg. 
Antimicrobial use per pig produced (adjusted) is calculated as: 
[DADDs + DADDw + (1+Q)*DADDf] / (biomass-days-total + 
Nw*5,800(kg*days)), where DADDs = amount of antimicro-
bial agents used in sows; DADDw = amount of antimicrobial 
agents used in weaners; DADDf = amount of antimicrobial 
agents used in finishers; Q is the proportion of weaning pigs 
exported around 30 kg. Nw = number of pigs exported at 30 
kg bodyweight, and Nw*5,800 is the number of biomass days 
the exported pigs would have contributed to the live biomass 
if not exported. 
9.2.2 Estimation of live biomass of animals
The estimation of live biomass and thus the number of stan-
dard animals at risk per day depends on the available data 
sources for each species.
Pig production. The estimation was based on the number of 
pigs produced, including exports at different ages [Statistics 
Denmark; Danish Agriculture and Food Council], productivity 
data for each year [Danish Agriculture and Food Council] and 
census data for breeding animals [Statistics Denmark]. The 
average weight and life span for the growing animals (piglets, 
weaners and finishers) were estimated from the productivity 
number. The estimation methods were developed in coopera-
tion with Danish Agriculture and Food Council. There are no 
statistics on average weight of breeding animals available, so 
DAPD - DADD per 1,000 animals per day  
The number of DADDs administered to an animal species during a year (in thousands) divided by the number of stan-
dard animals at risk per day. The number of standard animals at risk per day takes into account species differences in 
average body-mass and life-span. When relevant, the numbers of DADDs and standard animals at risk are estimated 
for specific age groups, or simply as number of doses (DADDs) used to treat one kg of animal divided with the total 
estimated biomass (in tonnes). 
DAPD is a statistical measure, providing a rough estimate of the proportion of animals treated daily with an average 
maintenance dose of a particular antimicrobial agent. For example, 10 DAPDs indicate that an estimated 1% of the 
population, on average, receives a certain treatment on a given day. The DAPD is also referred to as the treatment 
proportion. In principle, the metric DAPD is parallel to the metric used in pharmaco-epidemiology for the human sec-
tor, Defined daily dose per 1,000 inhabitants per day (DID), see Section 9.2.3
DADD Defined animal daily dose 
DADD is the average maintenance dose per day for 
a drug used for its main indication in the appropriate 
animal species. The DADD is not defined at product 
level but for each antimicrobial agent, administration 
route and animal species and when appropriate, also 
age group. DADD has been specifically defined for use 
in DANMAP and does not always completely match the 
“prescribed daily dose” or the recommended dosage in 
the Summaries of Product Characteristics (SPC).
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an estimated average weight had to be assumed. However, the 
size of the breeding animals has probably increased over the 
last decade, but this could not be accounted for.
Cattle production. The live biomass of the cattle population is 
estimated from census data [Statistics Denmark] and the aver-
age live weight of the different age groups. The Danish cattle 
population is mainly dairy, particularly Holstein Friesian, but 
also other breeds such as Jersey and a small population of beef 
cattle. Most of the cattle slaughtered are dairy cows and bull 
calves of dairy origin. The average live weight was estimated 
for 10 different age and gender categories.
Turkey production. The live biomass is estimated based on 
the number of turkeys produced [Statistics Denmark; Danish 
Agriculture and Food Council] and an average live weight at 
slaughter of 21 kg for male turkeys and 11 kg for hens after 
an estimated average life span of 20 weeks and 15.5 weeks, 
respectively [Danish Agro; S. Astrup, personal communication]. 
The estimated mean live biomass per turkey is assumed to be 
half of the weight at slaughter.
Fur animals. The live biomass of mink is estimated from 
production data [Statistics Denmark, Kopenhagen Fur] and the 
average weight at pelting was 2.45 kg [Kopenhagen Fur]. The 
progeny live for approximately 7 months. The biomass for the 
breeding animals (female) was estimated based on census 
data and an assumed average live weight of 2 kg.
Pet animals. Only dogs and cats are taken into account, as the 
other population sizes are negligible in Denmark, and relatively 
rare in veterinary practice. The population is based on census 
data [Statistics Denmark, 2000] estimating 650,000 cats 
and 550,000 dogs. The number of dogs in Denmark has been 
relatively stable during the last ten years [Danish Dog regis-
ter, 2012]. The average live weight for cats and dogs were 
estimated to 4 kg and 20 kg, respectively (based on pedigree 
registration data).
Aquaculture. The estimation is based on data from the Danish 
AgriFish Agency (NaturErhvervstyrelsen) on produced amounts 
in each subtype of production, and information on the typical 
lifespan and entrance and exit body weights, and were calcu-
lated in cooperation with Danish Aquaculture [NH Henriksen, 
Danish Aquaculture].
9.2.3 Antimicrobial consumption in humans
Data on consumption of antibacterial agents in humans were 
obtained from The Register of Medical the Department of Data 
Delivery and Medicinal Product Statistics, at Statens Serum In-
stitut. The Register receives monthly reporting of consumption 
from all pharmacies in Denmark, including hospital pharmacies. 
Data from the primary health care sector have been collected 
since 1994, whereas data on consumption in hospitals are 
available from 1997.
Only somatic hospitals were included, when the consumption 
was measured by occupied bed-days and admissions. Data 
from private hospitals and clinics, psychiatric hospitals, special-
ised non-acute care clinics, rehabilitation centres and hospices 
were excluded from DANMAP (representing approximately 
3% of the antimicrobial consumption at hospitals and of the 
number of bed-days).
In the primary health care in Denmark, all antibacterial agents 
for human use are prescription-only medicines and are sold by 
pharmacies in defined packages. Each package is uniquely iden-
tified by a code, which can be related to package size, content 
as number of unit doses (e.g. number of tablets), content as 
number of Defined Daily Doses (DDDs), code of the antimicrobi-
al agent in the Anatomical Therapeutic Chemical (ATC) classifi-
cation system, and producer. In addition, the following informa-
tion is collected for each transaction: social security number 
(CPR number) of the patient, code identifying the prescribing 
physician, date and pharmacy of the transaction, and informa-
tion regarding reimbursement of cost, if applicable. For hospital 
data we have information of the type of department and hospi-
tal but no information on the individual consumption level.
Before 2012 data from hospitals on certain infusion substanc-
es was obtained directly from the hospital pharmacies. From 
2013 onwards all data from hospitals are reported to and de-
livered by The Register of Medicinal Product Statistics at SSI.
The present report includes data on the consumption of “anti-
infectives for systemic use”, or group J01, of the 2014 update 
of the ATC classification, in primary health care and in hospitals 
as well as consumption of per oral and rectal preparations of 
metronidazole (P01AB01) and oral preparations of vancomycin 
(A07AA09). As recommended by the World Health Organiza-
tion (WHO), consumption of antibacterial agents in primary 
health care is expressed as DIDs, i.e. the number of DDDs per 
1,000 inhabitants per day (DDD/1,000 inhabitant-days). Con-
sumption in primary health care is also reported as a number 
of packages per 1,000 inhabitants. Consumption of antibac-
terial agents in hospitals is expressed as DIDs, for comparison 
with primary health care, and DBDs, the number of DDDs per 
100 occupied beds per day (DDD/100 occupied bed-days).
Since antimicrobial consumption expressed as DDD/100 
occupied bed-days does not necessarily reflect changes in 
hospital activity and production, consumption in hospitals is 
also presented as DAD (the number of DDDs per 100 admitted 
patients).
The number of occupied bed-days is calculated as the date 
of discharge minus the date of admission (minimum one day), 
and the number of admissions is calculated as one admission 
whenever a patient is admitted to one specific ward (one 
patient can be registered as admitted multiple times if trans-
ferred between wards during one hospital stay). Data on the 
number of occupied bed-days (or patient-days) and number of 
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admissions in each hospital were obtained from the National 
Patient Registry at the National Board of Health [www.sst.dk].
9.3 Collection of bacterial isolates 
9.3.1 Animals
Meat inspection staff or abattoir personnel at the slaughter 
houses collected caecal samples from healthy pigs, cattle (< 1 
year) and broilers according to sampling framework laid down 
by Decision 2013/652/EU. The samples were collected once 
a month throughout 2015, and the sampling was stratified 
per slaughterhouse by allocating the number of samples from 
domestically produced animals collected per slaughterhouse 
proportionally to the annual throughput of the slaughterhouse.
For broilers, four intact caeca from each flock were pooled into 
one sample. For pigs and cattle, samples contained 30-100 g 
caecum material from a single animal. All samples were sent 
to the Food Administrations (DVFA) laboratory in Ringsted and 
examined for indicator E. coli and ESBL, AmpC and carbapene-
mase-producing E. coli. In addition, samples from broilers and 
cattle were examined for Campylobacter, and samples from 
pig were examined for Salmonella and Enterococcus faecalis. 
Salmonella serotyping was performed at DTU National Food 
Institute.
Prior to 2014, DANMAP data also included isolates from the 
national Salmonella surveillance programme in pigs, where se-
rological surveillance at slaughter identified high risk herds for 
on-farm sampling. Salmonella from layers, broilers, turkeys and 
cattle are not included in DANMAP 2015 due to low numbers 
of isolates available from the national surveillance [Annual 
Report on Zoonoses in Denmark, 2015].
9.3.2 Meat
The regional DVFA officers collected packages of chilled or 
frozen broiler meat, pork and beef in Danish wholesale and 
retail outlets according to sampling framework laid down by 
Decision 2013/652/EU. The samples were collected two to 
four times a month throughout the year. (No samples were 
collected in January and July). Products with added saltwater or 
other types of marinade were excluded and the packages were 
selected without pre-selecting based on the country of origin. 
The number of establishment and samples selected by each 
Regional DVFA control unit was proportional to the number of 
establishments in the region in relation to the total number of 
establishments in the country. One unit of product (minimum 
of 200 g) was collected and examined for indicator E. coli, 
Enterococcus faecalis, Enterococcus faecium and ESBL, 
AmpC and carbapenemase-producing E. coli at the DVFA 
laboratory.
The Salmonella isolates originate from the national pro-
gramme at the slaughterhouses, where the carcass are 
swabbed in four designated areas (the jaw, breast, back and 
ham) after min. 12 hours of chilling (covering 10x10cm). The 
numbers of swabs collected depend on the slaughterhouse 
capacity. If > 30.000 animals are slaughtered/year, 5 animals/
day are pooled to one sample. If between 30.000 and 10.000 
animals are slaughtered/year, 5 animals are sampled every 
second months (single samples). If between 10.000 and 1.000 
animals are slaughtered/year, 5 animals are sampled every six 
months (single samples). If less than 1.000 animals are slaugh-
tered/year, no samples are taken. All samples were processed 
at Industry laboratories. Isolates from all Salmonella positive 
samples were send to DTU National Food Institute, where one 
isolate per sample were serotyped. Salmonella from broiler 
meat and beef, as well as imported meat are not included in 
DANMAP 2015 due to low numbers of isolates available from 
the national surveillance [Annual Report on Zoonoses in Den-
mark, 2015].
The Campylobacter jejuni isolates originated from the 
national control programme: Intensified control of Salmonella 
and Campylobacter in fresh meat based on a case-by-case 
risk assessment. Sampling was carried out every week by 
the regional DVFA officers, and included Danish and imported 
fresh broiler meat ready for retail, e.g. located in cold stores, 
slaughterhouses, cutting and processing facilities, but also 
at catering companies or at border control posts. Sampling 
includes products with added saltwater but excludes products 
with other types of marinade. The number of batches to be 
controlled by each Regional DVFA control unit is proportional to 
the number of establishments in the Region and the country. 
Establishments where DVFA recently have deemed controlled 
batches of meat unsafe may receive additional control visits. 
The Samples were examined for Campylobacter at the DVFA 
laboratory. 
9.3.3 Humans
S. Typhimurium and C. jejuni. Antimicrobial susceptibility 
was performed on human faecal isolates submitted to Statens 
Serum Institut (SSI). Salmonella isolates were submitted from 
all DCM in Denmark and Campylobacter isolates were submit-
ted from Departments of Clinical Microbiology (DCM) covering 
three geographical regions: Northern Jutland, Funen and Zea-
land. Exact figures of the proportion tested and the sampling 
strategy for the different species can be found in Sections 
6.1 and 6.2. As in previous years, SSI collected information 
on travel history through phone interviews. Patients were 
asked about the date of disease onset and whether they had 
travelled abroad within a seven-day period prior to the onset 
of disease. Furthermore, patients who had been abroad were 
asked about their destinations. Cases were categorised as 
“domestically acquired” if the patients had not travelled within 
the week prior to the onset of disease.
Staphylococcus aureus. All blood isolates were referred to the 
Staphylococcus reference laboratory at SSI on a voluntary basis. 
In November 2006, methicillin-resistant S. aureus (MRSA) be-
came a notifiable disease in Denmark and it became mandatory 
to submit all MRSA isolates to the reference laboratory.
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Invasive Streptococcus pneumoniae, Streptococcus 
pyogenes (group A streptococci), group B, C and G strep-
tococci. Invasive pneumococcal disease is a notifiable disease 
in Denmark, and therefore all invasive isolates nationwide 
are sent to SSI for identification or confirmation as well as 
susceptibility testing and typing. Invasive group A, B, C and G 
streptococcal isolates are referred to SSI on a voluntary basis. 
Traditionally, only isolates from blood and spinal fluid are 
included in the DANMAP report.
E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, 
E. faecium and E. faecalis. Data were provided on all clinical 
isolates recorded from either blood samples (E. coli, K. pneu-
moniae, P. aeruginosa, E. faecium and E. faecalis) or urine 
samples (E. coli and K. pneumoniae) submitted for susceptibil-
ity testing to the DCM at the following hospitals: Rigshospi-
talet, Hvidovre, Herlev, Region Zealand, Odense, Sønderborg, 
Esbjerg, Vejle, Herning/Viborg, Aarhus and Aalborg. 
No samples were collected from healthy humans.
9.4 Microbiological methods
9.4.1 Animals and meat
Salmonella from pigs and meat was isolated according to the 
methods issued by the NMKL [NMKL No. 187, 2007] or Annex 
D, ISO 6579 [ISO6579:2002/Amd 1:2007]. Serotyping of 
suspect colonies by slide agglutination according to the White-
Kauffmann-Le Minor Scheme in combination with “The mo-
lecular approach” developed by CD [Fitzgerald et al, 2007;J Clin 
Microbiol. 45:3323-34] [McQuiston et al, 2011; J Clin Microbiol. 
49: 565–573]. Only one isolate per serotype was selected from 
each herd or type of meat.
Campylobacter from broilers, cattle and meat was isolated 
according to the methods issued by the NMKL [NMKL No. 119, 
2007]. Identification was performed by microscopy and rtPCR 
assay. [Mayr et al. 2010. J Food Prot. 72(2):241-50]. Only one 
C. jejuni isolate per broiler flock, cattle herd or per batch of 
fresh meat was selected.
Indicator E. coli from broilers, pigs and cattle was isolated from 
a 5 gram of sample added to 45 ml of MacConkey broth and 
incubated o/n at 44°C. The suspension was streaked onto violet 
red bile agar and incubated for 24 h at 44C. Presumptive E. coli 
was identified using TBX agar incubated o/n at 44°C. For Isolation 
of ESBL-, AmpC- and carbapenemase-producing E. coli, the 
EURL-AR laboratory protocol was applied [October 2015, see 
also Textbox 7.1]. Only one indicator E. coli, ESBL-, AmpC- and 
carbapenemase-producing E. coli isolate per broiler flock, pig herd, 
cattle herd or meat sample was selected.
Enterococcus from pigs was isolate from an adequate amount 
of caecal material suspended in 2 ml BPW. The suspension was 
streaked onto Slanetz Bartley agar and incubated 48 h at 44°C. 
Two colonies resembling typical E. faecalis were sub-cultivated 
on blood agar. Species identification was done by rtPCR-assay. 
Only one isolate of E. faecium and E. faecalis was selected 
per meat sample and one E. faecalis isolate per pig herd was 
selected.
9.4.2 Humans
Salmonella isolates were serotyped by slide agglutination 
according to the Kauffman-White Scheme.
Campylobacter. Species identification was performed using a 
species-specific PCR assay [Klena et al. 2004. J Clin Microbiol. 
42: 5549–5557].
Staphylococcus aureus. Species confirmation and typing was 
performed by sequencing of the S. aureus specific spa gene 
[Harmsen et al. 2003. J Clin Microbiol. 41: 5442–5448]. Spa 
-negative isolates were confirmed as S. aureus by MALDI-TOF. 
Based on the spa type and known association with MLST 
typing, each isolate was assigned to a clonal complex (CC). 
For MRSA isolates, presence of the mecA or mecC methicillin 
resistance genes was confirmed by PCR [Larsen et al. 2008. 
Clin Microbiol Infect. 14: 611–614; Stegger et al. 2012. Clin 
Microbiol Infect. 18: 395–400]. For all isolates, presence of 
lukF-PV gene (PVL) was demonstrated by PCR [Larsen et al. 
2008. Clin Microbiol Infect. 14: 611–614; Stegger et al. 2012. 
Clin Microbiol Infect.18: 395–400].
Invasive Streptococcus pneumoniae. Serotype identifica-
tion of invasive S. pneumoniae was performed by latex agglu-
tination (ImmuLex™ Pneumotest Kit, SSI Diagnostica, Hillerød, 
Denmark) and further with factor specific antisera by the 
Neufeld Quellung test (SSI Diagnostica, Hillerød, Denmark).
Invasive Streptococcus pyogenes (group A streptococci), 
group B, C and G streptococci. Identification of groups were 
performed by latex agglutination (Streptococcal Grouping 
Reagent, Oxoid, Roskilde, Denmark).
9.5 Susceptibility testing
Antimicrobial susceptibility testing of Salmonella, Campy-
lobacter, indicator E. coli, Enterococcus and Staphylococ-
cus aureus was performed as microbroth dilution MIC with 
Sensititre (Trek Diagnostic Systems Ltd., East Grinstead, UK). 
Inoculation and incubation procedures were in accordance with 
the CLSI guidelines [Clinical and Laboratory Standards Insti-
tute, USA] and the European standard ISO 20776-1:2006. The 
isolates are susceptibility tested in accordance with in Decision 
2013/652/EU.
The relevant quality control strains were used: Staphylococcus 
aureus ATCC 29213, Escherichia coli ATCC 25922, Pseudo-
monas aeruginosa ATCC 27853, Enterococcus faecalis ATCC 
29212 and Campylobacter jejuni ATCC 33560.
Most of the isolates from animals and meat were susceptibil-
ity tested at the DVFA laboratory. Only Salmonella from the 
surveillance of fresh meat were tested at DTU National Food 
Institute. Isolates were stored at -80°C until susceptibility 
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testing. Salmonella, Campylobacter and Staphylococcus aureus 
isolates of human origin were tested at SSI. MIC-testing at DTU 
National Food Institute and the DVFA laboratory in Ringsted is 
accredited by DANAK (the national body for accreditation).
Invasive Streptococcus pneumoniae from humans. 
Screening for penicillin- and erythromycin-resistant S. pneu-
moniae was performed with 1 μg oxacillin discs and 15 μg 
erythromycin discs (Oxoid, Roskilde, Denmark), respectively, 
on Müller-Hinton agar (Müller-Hinton plate, 5% blood, 20 
mg beta-NAD, SSI Diagnostica, Hillerød, Denmark). Penicillin 
and erythromycin MICs were determined using STP6F plate, 
Sensititre (Trek Diagnostic Systems Ltd., East Grinstead, UK) 
as recommended by the manufacturer. All breakpoints used 
were as defined by the EUCAST. Both fully and intermediary 
resistant isolates were defined as resistant. 
Invasive Streptococcus pyogenes (group A), group B, C 
and G streptococci from humans. Screening for penicillin-, 
erythromycin- and clindamycin-resistant streptococci was 
performed with 1 unit penicillin G discs, 15 μg erythromycin 
discs and 2µg clindamycin discs (Oxoid, Roskilde, Denmark), 
respectively, on Müller-Hinton agar (Müller-Hinton plate, 5% 
blood, 20 mg beta-NAD, SSI Diagnostica, Hillerød, Denmark). 
Isolates were simultaneously tested for inducible clindamycin 
resistance. Non-sensitive streptococci were tested further 
with the respective E-tests (Biomérieux), either benzylpenicil-
lin, erythromycin or clindamycin on Müller-Hinton agar. The 
breakpoints used were as defined by the EUCAST. Both fully 
and intermediary resistant isolates were defined as resistant.
E. coli, K. pneumoniae, invasive P. aeruginosa, invasive 
E. faecium and E. faecalis from humans. Since November 
2015, all Danish DCM used the EUCAST terminology with the 
EUCAST breakpoints and the EUCAST disk diffusion method for 
most species.
Data on antimicrobial resistance from private hospitals and 
clinics and from psychiatric hospitals were excluded. All sub-
mitting laboratories participate in national and international 
quality assurance collaborations such as the United Kingdom 
National External Quality Assessment Schemes (NEQAS).
9.6 Data handling
9.6.1 Animals and meat
For the samples examined at the DFVA laboratory, sampling 
details and laboratory results were stored in the DFVA Labora-
tory system. Following validation by DFVA, data were electron-
ically transferred to DTU National Food Institute. Sampling de-
tails and laboratory results for Salmonella in pork were stored 
in the DTU Laboratory system. At the DTU National Food 
Institute, data were harmonised and one isolate per epidemio-
logical unit was selected for reporting. All data were combined 
in one Oracle database at isolate level (9i Enterprise Edition®). 
The database contained all antimicrobial data reported in DAN-
MAP or to EFSA since 2007 (partial dataset from 2001-2006). 
Variables for animal samples include bacterial species, subtype 
where applicable date of sampling, species of animal and herd 
identifier. For each meat isolate, variables include food type, 
bacterial species, date and place of sampling, date of examina-
tion and country of origin whenever possible. MIC values were 
retained as continuous variables in the database, from which 
binary variables were created using the relevant ECOFF from 
2015 for all years. Calculations of multi-resistance are not 
included in DANMAP 2015. 
Table 9.1 presents the interpretation of MIC-values used for 
any combination of bacteria and antimicrobial agent. Since 
2007, data are interpreted by EUCAST epidemiological cut-off 
values (ECOFFs) with a few exceptions described in Table 
9.1. In general, if ECOFFs were re-validated and changed by 
EUCAST during the past year, all data presented from previous 
years were interpreted using the changed ECOFFs. 
All MIC-distributions are presented in the web annex at www.
danmap.org. Each of the tables provides information on the 
number of isolates, the applied interpretation of MIC-values 
and the estimated level of resistance and binomial proportion 
confidence intervals.
All handling, validation and analysis of results were carried 
out using Microsoft Excel and SAS®Software, SAS Enterprise 
Guide 6.1.
9.6.2 Human
Salmonella and Campylobacter. Data on Salmonella and 
Campylobacter infections are stored in the Danish Registry 
of Enteric Pathogens (SQL database) maintained by SSI. This 
register includes only one isolate per patient within a window 
of six months and includes data on susceptibility testing of 
gastrointestinal pathogens.
Staphylococcus aureus. For MRSA, data on the characteris-
tics of the isolates and the clinical/epidemiological information 
were obtained from the Danish MRSA register at SSI (manda-
tory reportable). Patients were registered, regardless of coloni-
sation or clinical infection, the first time they were diagnosed 
with MRSA or when a new subtype was demonstrated. Based 
on the reported information, MRSA cases were classified as 
colonization/active screening (i.e. surveillance samples to de-
tect nasal, throat, gut or skin colonization), imported infection 
(i.e. acquired outside Denmark), infection acquired in a Danish 
hospital, defined as diagnosed >48 hours after hospitalisation 
with no sign of infection at admittance (HA-MRSA) or infection 
diagnosed outside hospitals (community onset).
MRSA cases with community onset were further classified 
according to risk factors during the previous 12 months as 
either health-care associated with community onset (HACO) or 
community-acquired (CA). Health-care associated risk factors 
included prior hospitalizations, stay in long-term care facilities 
and being a health-care worker. Community risk factors includ-
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ed known MRSA-positive household members or other close 
contacts. Due to the increasing numbers of cases belonging to 
CC398, this type was treated separately as both epidemiology 
and relevant exposure are different from other CA cases.
Streptococcus pneumoniae, Streptococcus pyogenes 
(group A streptococci), group B, C and G streptococci. 
Data on susceptibility testing of isolates were stored as MICs 
in a Microsoft® Access database linked to a SQL server at SSI. 
Analysis including selection of isolates from blood and spinal 
fluid samples and removal of duplicate isolates was performed 
in Microsoft® Access.
E. coli, K. pneumoniae, invasive P. aeruginosa, invasive E. 
faecium and invasive E. faecalis. All eleven DCM in Denmark 
provided data on resistance levels in E. coli, K. pneumoniae, 
invasive P. aeruginosa, invasive E. faecium and invasive E. fae-
calis isolates. Data were extracted from the following labora-
tory information systems:
ADBakt (Autonik AB, Skoldinge, Sweden) for the DCM at Hvi-
dovre, Herlev and Aalborg Hospitals. 
MADS (DCM Skejby Hospital, Aarhus, Denmark) for the DCM at 
Rigshospitalet, Slagelse/Region Zealand, Odense, Sønderborg, 
Esbjerg, Vejle, Herning/Viborg, and Aarhus (Skejby) Hospitals. 
Resistance data on the first isolate per patient per year were 
included. Generally, resistance data were excluded if suscep-
tibility to a certain antimicrobial agent was tested on only a 
selected number of isolates.
9.6.3 Statistical tests
Significance tests of differences between proportions of 
resistant isolates were calculated using SAS®Software, SAS 
Enterprise Guide 6.1 using univariable Chi-square, or Fisher’s 
Exact Tests as appropriate
All changes and differences yielding p<0.05 were commented 
on in the text, whereas the remaining data was visualised in 
figures or tables only.
Annette Nygaard Jensen, Birgitte Borck Høg, 
Helle Korsgaard and Ute Wolff Sönksen
Table 9.1. Interpretation criteriae for MIC-testing by EUCAST epidemiological cut-off values (blue fields)  
and the corresponding EUCAST clinical breakpoints (white fields) 
Salmonella E. coli E. faecium E. faecalis C. jejuni  
Antimicrobial agent
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
Ampicillin >8* >8* >8* >8* >4* >8* >4* >8*
Azithromycin
Cefepime >0.125*
Cefotaxime >0.5* >2* >0.25* >2*
Cefoxitin >8* >8*
Ceftazidime >2* >4* >0.5* >4*
Chloramphenicol >16* >8* >16* >8* >32* >32*
Ciprofloxacin >0.064* >0.064* >0.064* >1* >4* >4* >0.5* >0.5*
Colistin >2*/8(a) >2* >2* >2*
Daptomycin >4* >4* >4* >4*
Ertapenem >0.064* >0.064*
Erythromycin >4* >4* >4* >8*
Imipenem >1* >0.5*
Gentamicin >2* >4* >2* >4* >32* >4* >32* >4* >2*
Linezolid >4* >4*
Meropenem >0.125* >8* >0.125* >8*
Nalidixic acid >16* >16* >16*
Quinupristin/dalfopristin >4(c) >4*
Streptomycin >4*
Sulfonamide >256(b) >64*
Teicoplanin >2* >2* >2* >2*
Tetracycline >8* >8* >4* >0.5* >4* >0.5* >1* >2*
Tigecycline >1* >2* >1* >2* >0.25* >0.25*
Trimethoprim >2* >4* >2* >4*
Vancomycin >4* >4* >4* >4*
Note: * indicates EUCAST epidemiological cut-off values (ECOFFs) and EUCAST clinical breakpoints.  
a) The EUCAST ECOFF (>2) for colistin was applied for S. Typhimurium and other serotypes, except for S. Enteritidis and S. Dublin where ECOFF >8 
was applied according to investigations presented in DANMAP 2011. 
b) No current EUCAST ECOFF is available for sulfamethoxazole, so the previous cutoff (>256) was maintained. 
c) The EUCAST ECOFF (>1) was not applied for quinupristin/dalfopristin (tradename synercid) according to investigations presented in DANMAP 2006.
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List of abbreviations
AGP Antimicrobial growth promoter
ATC Anatomical Therapeutic Chemical Classification System
ATCvet Anatomical Therapeutic Chemical Classification System for veterinary medicines 
CA Community-acquired
CC Clonal complex
CDI Clostridium difficile infections
CHR Central Husbandry Register
CI Confidence interval
CNS Central nervous system
COHA Community onset hospital-acquired
CPE Carbapenemase producing Enterobacteriaceae 
CPO Carbapenemase producing organisms
CPR Danish Civil Registry, register for social security numbers 
DAD Defined Daily Doses per 100 admissions
DADD Defined animal daily dose
DAPD Defined animal daily dose per 1,000 animals per day 
DBD Defined Daily Doses per 100 occupied bed-days 
DCM Department of Clinical Microbiology
DDD Defined Daily Dose
DID Defined Daily Doses per 1,000 inhabitants per day (DDD/1000 inhabitant days) 
DTU Technical University of Denmark
DVFA Danish Veterinary and Food Administration
EARS-Net The European Antimicrobial Resistance Surveillance Network 
ECDC European Centre for Disease Prevention and Control
EFSA European Food Safety Authority 
ESBL Extended spectrum beta-lactamase 
GI Gastrointestinal
GP General Practitioner
HAI Hospital-acquired infections
HAIBA Hospital-acquired infections database 
HLGR High-level gentamicin resistance 
HOHA Hospital onset hospital-acquired
MIC Minimum inhibitory concentration
MRSA Methicillin-resistant Staphylococcus aureus
N Number of samples
n Number of isolates tested for antimicrobial susceptibility
OIE World Organisation for Animal Health
RFCA Regional Veterinary and Food Control Authorities 
SEGES  Knowledge Centre for Agriculture
SSI Statens Serum Institut
VASC Veterinary advisory service contracts 
VMP Veterinary medicinal products
VetStat Danish Register of Veterinary Medicines 
VRE Vancomycin resistant enterococci
WGS Whole-genome sequencing 
WHO World Health Organization
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Glossary
Anatomical Therapeutic Chemical (ATC) classification. Inter-
national classification system for drug consumption studies. 
The ATC code identifies the therapeutic ingredient(s) of each 
drug for human use according to the organ or system on which it 
acts and its chemical, pharmacological and therapeutic proper-
ties. Antibacterials for systemic use are known as ATC group J01. 
The ATC classification is maintained by the WHO Collaborating 
Centre for Drug Statistics and Methodology (Oslo, Norway) 
(www.whocc.no/atcddd/indexdatabase/). The ATC classification 
for veterinary medicinal products, ATCvet, is based on the same 
main principles as the ATC classification system for medicines 
for human use and is also maintained by the WHO Collaborating 
Centre for Drug Statistics and Methodology (www.whocc.no/
atcvet/database/).
Antibacterial agents. Synthetic (chemotherapeutics) or natural 
(antibiotics) substances that destroy bacteria or suppress 
bacterial growth or reproduction [Source: Dorland’s Illustrated 
Medical Dictionary]. Antimycobacterial agents are not included. 
In the section of human consumption, ‘antibacterial agents’ are 
referred to as ‘antimicrobial agents’ (see below).
Antimicrobial agents. The term ‘antimicrobial agents’ covers 
antibacterial, antiviral, coccidiostatic and antimycotic agents. 
In the section on veterinary consumption, the broad term 
‘antimicrobial agents’ is usually used because coccidiostats are 
included. Antiviral substances are not used in veterinary medi-
cine, and antimycotics are only registered for topical veterinary 
use and used mainly in companion animals. Antimycobacterial 
agents are not included. The term ’antibacterial agents’ is only 
used in the veterinary section for precision, to distinguish 
from use of coccidiostats as feed additives (poultry only). In the 
section of human consumption, the term ‘antimicrobial agents’ 
refers to all antibacterial agents for systemic use (J01 in the 
ATC system).
Broiler. A type of chicken raised specifically for meat pro-
duction. In Denmark, the average weight after slaughter is 
1.51 kg.
Central Husbandry Register (CHR). This is a register of all 
Danish farms defined as geographical sites housing produc-
tion animals. It contains information concerning ownership, 
farm size, animal species, age groups, number of animals and 
production type. Each farm has a unique farm identity number 
(CHR-number).
Defined animal daily dose (DADD). DADD is the average 
maintenance dose per day for a drug used for its main indication 
in the appropriate animal species. DADD has been specifically 
defined for use in DANMAP and does not always completely 
match the “prescribed daily dose” or the recommended dosage 
in the Summaries of Product Characteristics (SPC). In contrast to 
the ADD previously used in DANMAP, the DADD not has been 
defined for each antimicrobial agent, administration route and 
animal species but at product level. In DANMAP 2012, the DADD 
replaces the ADD (as defined in VetStat), which has been used 
since DANMAP 2003. For more details, see Chapter 10, Materials 
and Methods. The DADDs used in DANMAP 2015 are presented 
the web annex.
DADD per 1,000 animals per day (DAPD). Trends in veterinary 
consumption, both within and across species, are presented 
in DAPD, allowing for comparison between sectors and adjust-
ing for changes in live biomass. The estimated live biomass is 
expressed as the number of standard animals with an estimated 
average weight and lifetime. This may also be referred to as 
the ‘standard-animals-at-risk’ and takes into account species 
differences in body-mass and life-span. DAPD is a statistical 
measure, providing an estimate of the proportion of animals (in 
thousands) treated daily with a particular antimicrobial agent. 
For example, 10 DAPDs indicate that an estimated 1% of the 
population, on average, receives a certain treatment on a given 
day (Section 4.3 and Chapter 9, Materials and Methods).
Defined Daily Dose (DDD). This is the assumed average main-
tenance dose per day for a drug used for its main indication in 
adults. It should be emphasised that the Defined Daily Dose is 
a unit of measurement and does not necessarily reflect the 
recommended or prescribed daily dose. DDDs provide a fixed 
unit of measurement independent of price and formulation, 
enabling the assessment of trends in drug consumption and to 
perform comparisons between population groups. The DDDs 
are defined and revised yearly by the WHO Collaborating Centre 
for Drug Statistics and Methodology (www.whocc.no/atcddd/
indexdatabase).
DDD per 1,000 inhabitants per day (DID). Consumption in 
both primary health care, hospital care and the overall total con-
sumption is presented in DID, allowing for comparison between 
sectors and for illustration of the consumption in hospital care 
without taking account of hospital activity (discharges). Data 
presented in DID provide a rough estimate of the proportion of 
the population within a defined area treated daily with certain 
drugs. For example, 10 DIDs indicates that 1% of the population 
on average gets a certain treatment daily. In figure presented as 
DDD/1,000 inhabitant-days.
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ESBL. In the DANMAP report, ‘ESBL’ describes the clinically 
important acquired beta-lactamases with activity against 
extended-spectrum cephalosporins; including the classical class 
A ESBLs (CTX-M, SHV, TEM), the plasmid-mediated AmpC and 
OXA-ESBLs [Giske et al. 2009. J. Antimicrob. Chemother. 63: 1-4].
Finishers. Pigs from 30-100 kg live weight from after the 
weaner stage to time of slaughter.
Fully sensitive. An isolate will be referred to as fully sensitive if 
susceptible to all antimicrobial agents included in the test panel 
for the specific bacteria.
Intramammaria. Antimicrobial agents for local application in 
the mammary gland (udder) to treat mastitis.
Layer. A hen raised to produce eggs for consumption.
Minimum inhibitory concentration (MIC). This is the lowest 
concentration of antimicrobial agent in a given culture medium, 
e.g. broth or agar, below which growth of the bacteria is not 
inhibited.
Multi-resistant. A Salmonella, Campylobacter, Enterococcus 
or E. coli isolate is assumed multi-resistant if it is resistant 
to three or more of the antimicrobial classes. The number of 
antimicrobial classes and antimicrobial agent included therein 
depend on the test panel for each bacterium.
Pet animals. Dogs, cats, birds, mice, guinea pigs and more exotic 
species kept at home for pleasure, rather than one kept for work 
or food. Horses are not included as pet animals. The live bio-
masses of Danish pets used for estimating veterinary consump-
tion only include dogs and cat.
Piglet. The newborn pig is called a piglet from birth till they are 
permanently separated from the sow at 3-4 weeks of age. The 
weight of the piglet at weaning is approximately 7 kg.
Poultry. The major production species are fowl Gallus gallus 
(broilers, layers, including breeding and rearing) and turkey. 
Regarding antimicrobial consumption, ‘poultry’ also includes 
domesticated ducks, geese, game birds and pigeons.
Sow. Any breeding female pig on the farm.
Weaner. Any pig of 7–30 kg live weight after it has been weaned
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